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ABSTRACT 
This cross-sectional study described antimicrobial resistance (AMR) in healthy 
pigs in 20 Alberta and Saskatchewan herds. All herds used antimicrobials; the daily 
probability of antimicrobial exposure was 0.8 for nursery pigs and 0.3 for grow-finish 
pigs. Salmonella spp. (n = 468) were isolated from nursery, grow-finish pigs and sows 
while Escherichia coli (n = 1439) and Campylobacter spp. (n = 405) were isolated from 
grow-finish pigs.  
  
Fifty-nine percent of the Salmonella were pansusceptible. Isolates from sows 
were more likely to be pansusceptible than those from other production phases, while 
Salmonella from nursery pigs were more likely to be multiresistant. All Salmonella and 
E. coli were susceptible to ceftriaxone and ciprofloxacin, drugs critically important to 
human medicine, while one E. coli was resistant to ceftiofur. Resistance was most 
common to tetracycline and sulfamethoxazole (Salmonella, 35% and 27%; E. coli, 68% 
and 46%). Although often considered an ‘indicator’ organism, E. coli AMR was a poor 
sentinel for Salmonella AMR at the herd-level.  
 
Antimicrobial resistance genes, described in 151 E. coli, were associated in two 
sets: aadA1 / sul1 / tetA and blaTEM / strA – strB / sul2 / tetB. Associations between genes 
consistently matched associations between phenotypes suggesting phenotype data may be 
useful for predicting co-selection. Demonstrating dose-response relationships between 
ii 
iii 
various antimicrobial exposures and resistance phenotypes in E. coli reiterated the 
importance of co-selection. Significant predictors included exposures in other production 
phases and to unrelated drugs. Four E. coli resistance-phenotypes were associated with 
macrolide exposure; the most commonly used antimicrobial class in study herds. 
Additionally, 70% of the Campylobacter were resistant to a macrolide and this resistance 
was associated with macrolide exposure in nursery pigs. Study herds did not use 
quinolones. Despite this, 15% of Campylobacter were resistant to a quinolone. Both 
Campylobacter and E. coli AMR clustered within herds, indicating on-farm interventions 
could mitigate AMR in pigs. 
 
This study described AMR in enteric bacteria from healthy pigs. Identifying dose-
response relationships between antimicrobial resistances and exposures to unrelated 
drugs, and exposures of pigs in different production phases, emphasize the importance of 
judicious antimicrobial use in pig production.  
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CHAPTER 1 
INTRODUCTION 
Antimicrobial resistant bacteria from livestock are a food safety hazard; bacteria can 
contaminate carcasses and persist through food-processing and handling to infect consumers (1-
5). Antimicrobial use selects for resistant bacteria (6-15). When pigs receive antimicrobials, 
susceptible bacteria die. While it is desirable to kill pathogens, the loss of susceptible normal 
microbiota creates an ecological niche into which resistant bacteria can propagate and spread 
(16). In North America, pigs commonly receive antimicrobials through feed to treat disease, 
prevent disease and improve growth, and less commonly through water and by injection to 
control or treat infections (17-21). Laboratory experiments, controlled trials and observational 
studies have found antimicrobial exposure can select for antimicrobial resistance (10-13,22,23). 
However, most available descriptions of antimicrobial use in North American swine are 
qualitative (17-21,24,25). Quantitative data are needed to better understand the relationship 
between antimicrobial exposures and resistant bacteria in healthy pigs. 
 
Twelve thousand cases of campylobacteriosis and six thousand cases of salmonellosis are 
reported in Canadians annually (26). These counts represent the ‘tip-of-the-iceberg’ as many 
cases go unrecognized and unreported (27). Antimicrobial resistant pathogens, including 
foodborne Salmonella and Campylobacter, cause greater morbidity than their susceptible 
counterparts; people taking antimicrobials are at increased risk of infection, and treatment failure 
and severe disease are more common with resistant infections (28-31). Pork is among the three 
most commonly consumed animal proteins in Canada (32). The rates of AMR in bacteria from 
1 
pigs at slaughter, and pork at retail, are intermediate between those reported in beef and chicken 
(33). So although the number of foodborne infections attributable to pork is unknown in Canada, 
there is undoubtedly some potential to decrease the burden of disease if on-farm interventions 
can minimize resistant meat contaminants. However, before measures to control AMR can be 
developed for swine farms, more data are needed describing the frequency and patterns of 
resistance in these zoonotic bacteria. These data will provide insight into the epidemiology of 
AMR on-farms, and will serve as a benchmark for future data comparisons. To date, the only 
published on-farm description of AMR in Salmonella from pigs on-farms described grow-finish 
pigs in Alberta (34). No on-farm studies are available describing AMR in Campylobacter from 
pigs.  
 
Describing AMR in commensals provides insight into the selective pressure for 
resistance in gastrointestinal bacteria (3). Resistant commensal bacteria, such as E. coli, do not 
typically cause disease. Rather, these bacteria serve as a reservoir of antimicrobial resistance 
genes that can be transferred to other bacteria in the gut, including zoonotic pathogens such as 
Salmonella (3,35-37). Antimicrobial resistance is the ability for bacteria to survive in the 
presence of normally inhibitory drug concentrations (38). Most resistance phenotypes can arise 
through the expression of a variety of AMR genes (39-43). Because E. coli serves as a reservoir 
of resistance genes, describing the resistance genes documents the diversity of resistance 
determinants available for dissemination to other bacteria (42,44). These data can also 
distinguish between apparently equivalent resistance-phenotypes in different populations of 
animals and generate hypotheses about gene linkages and co-selection (39,40,42,43). Such 
findings provide insight into the evolution of AMR (44). Targeted research projects have 
2 
described AMR in E. coli from swine farms in Ontario and British Columbia, and the AMR 
genes carried by porcine E. coli in Ontario (23,40,42,45). To date, AMR in E. coli from western 
Canadian swine farms has not been described in the published literature  
 
In response to growing concern about antimicrobial resistance, international authorities 
have recommended that countries monitor their agricultural antimicrobial use and AMR in 
bacteria from food animals (46-49). Canada has responded to these recommendations by 
conducting AMR surveillance in abattoirs and retail outlets (33). This pilot project was initiated 
in 2004, in part, to assist Canadian authorities in their efforts to develop the on-farm branch of 
their national surveillance program. The studies described in this thesis were part of a cross-
sectional study conducted in a convenience sample of 20 Alberta and Saskatchewan swine farms. 
The main objective of this project was to describe the AMR of gram negative enteric bacteria 
from healthy pigs, and investigate the relationship between resistance and antimicrobial 
exposures in swine herds.  
 
The initial chapter of this thesis provides a review of the pertinent literature (Chapter 2). 
Chapter 3 describes the antimicrobial use on study farms; these data were used in Chapters 7 and 
8 to conduct antimicrobial resistance and exposure risk-factor analyses. Chapter 4 presents the 
frequencies and patterns of resistance in Salmonella isolates. The majority of this thesis was 
devoted to AMR in E. coli; phenotypic (Chapter 5) and genotypic (Chapter 6) AMR were 
described, along with the associations between on-farm antimicrobial use and resistance (Chapter 
7). The final study describes the resistance of Campylobacter isolates (Chapter 8). In this 
chapter, antimicrobial use risk factors for resistance to the macrolides and quinolones are 
3 
described. The concluding chapter (Chapter 9) reviews and discusses the important findings of 
this thesis. It closes with identified research needs for future on-farm AMR studies.  
 
Each chapter of this thesis was written as an independent paper. While this makes the 
study findings more usable, it inevitably causes repetition between chapters, particularly in the 
materials and methods. For those who read this thesis as a complete unit, I apologize for this 
inconvenience and am impressed with your perseverance. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
Antimicrobial resistant bacteria from livestock are a food safety concern. The 
incidence of disease from resistant foodborne bacteria is higher in people taking 
antimicrobials than in people without antimicrobial exposure. Resistant Salmonella and 
Campylobacter infections are difficult to treat because of limited antimicrobial selection 
and increased disease severity (1-4). Commensal bacteria, such as Escherichia coli, can 
transfer resistance genes to other commensal and pathogenic bacteria while passing 
through the human gastrointestinal tract (5-9). Thus, AMR in food animals is a public 
health problem because it increases foodborne disease incidence and severity and 
potentially provides resistance genes to human enteric bacteria. 
 
Beef, chicken and pork are the most commonly consumed animal proteins in 
Canada, and pork is the most common worldwide (10,11). Antimicrobials are used 
extensively in pork production and resistant bacteria have been identified in pigs on-farm, 
at slaughter and in pork at retail (12-15). On-farm studies can evaluate antimicrobial use 
and management practices as risk factors for resistance in pigs (16,17). Ultimately, on-
farm studies may identify interventions that minimize AMR in pigs and consequently 
foodborne disease in people.   
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 2.2 Methods 
This literature review discusses antimicrobial resistance (AMR) in Salmonella 
spp., E. coli and Campylobacter spp. from pigs on North America farms. The review 
begins by describing antimicrobial use in pigs. Following this, the public health 
significance of AMR and extent of resistance on swine farms is considered for each 
bacterium. Supporting and refuting evidence that antimicrobial use causes resistance is 
also investigated. The objective of this review is to document consistent findings in North 
America, consider reasons for conflicting findings, and identify areas requiring further 
research. Therefore, data were restricted to North American studies conducted since 1990 
unless North American on-farm data were scarce or seminal studies occurred outside of 
these geographical and temporal restrictions.  
 
Standard search engines including AGRICOLA, CAB abstracts, and Ovid 
MEDLINE® as well as non-scientific search engines including GoogleTM were used for 
literature searches. Search terms included, but were not limited to, combinations of the 
following: antimicrobial, antibiotic, use, exposure, treatment, susceptibility, resistance, 
Campylobacter, Escherichia coli, Salmonella, swine, pig(s), herd and farm. Cited 
references were examined for additional resources. An English language restriction was 
used.  
 
2.3 Antimicrobial use in North American swine 
There is worldwide concern about AMR in human medicine. Though most 
resistance in human pathogens is presumably due to antimicrobial use in humans, 
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veterinary drug use also contributes to this problem (9,18,19). International agencies, 
including the World Health Organization (WHO) and the World Organisation for Animal 
Health (OIÉ), recommend countries monitor the amounts of antimicrobials used in food 
animals (20,21). These data are needed to evaluate judicious-use campaigns, make 
recommendations for appropriate antimicrobial use, and conduct AMR risk assessments 
(22,23). 
 
Numerous metrics for describing antimicrobial use have been proposed or used 
including total weight consumption, therapeutic costs, and treatment doses (24). In the 
last decade, many European Union (EU) countries have described their agricultural 
antimicrobial use  by weight consumption (25-28). Denmark has collected farm-level 
data, while other countries have estimated national consumption from sales data (25-29). 
In contrast to these EU countries, Canada and the United States have not reported 
agricultural antimicrobial sales numbers. Reasons for not reporting this information 
include confidentiality concerns and an inability to stratify use by species, production 
class, or indication (23,30). Stratified exposure estimates are important for explaining 
changes over time. Total weight consumption estimates assume equivalent potency of 
antimicrobials. In reality, potency varies between products, which makes weight 
estimates of questionable value for comparing use between countries or describing the 
selective pressure for resistance (24,31). For these reasons, a standard metric that 
accounts for potency is desirable. 
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Human pharmaceutical consumption is described by the internationally accepted 
system of defined daily doses (DDD). The DDD reflects the average maintenance dose 
per day in a human adult for the drugs major indication. Comparing DDDs provides a 
rough estimate of consumption: it is not exact because the DDD may differ from the 
prescribed daily dose (PDD) (24,31). A veterinary classification based on the DDD 
concept has been implemented in Denmark (31). Animal daily doses (ADD) have been 
established which are specific to age-class and species (31). To date, the ADD system has 
not gained widespread international acceptance because of concerns about differences in 
prescribed doses (as primary indications differ among regions) and the variable size of 
animals within production classes. Substantial differences between the ADD and PDD 
limits the validity of extrapolating data to consumption estimates (31).  
 
The ADD concept has been used in a peer-reviewed paper describing 
antimicrobial use in pigs. Timmerman et al. described group treatments in pigs in 
Belguim using ADDpigs that reflected drug use in Belgium. Despite using a national 
metric, substantial differences were identified between the used daily dose (UDD) and 
PDD (32). Such within country discrepancies between ADD, PDD and UDD could 
plausibly be magnified at the international level. This is one factor that has hindered 
development of ADDanimal definitions. A second concern with using PDD-type data to 
describe antimicrobial use is that assumptions are often necessary. Timmerman et al. used 
a growth table to make assumptions about pig body weight to estimate consumption. Data 
assumptions should be clearly stated: in this instance, differences in growth rates and feed 
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intakes between herds could not be accounted for. The potential effect of this variability 
on antimicrobial use estimates was not addressed.    
 
Antimicrobial use in North American pigs has been described through targeted 
on-farm studies (12,33-39). All studies stratified exposure by production phase and 
administration route, which makes them valuable in comparison to national weight 
consumption estimates. Although comparisons between studies are hindered by the 
variety of metrics used, each provided valuable insight into the reasons antimicrobials are 
used. Collectively, these studies provide insight into trends in the proportion of herds 
using drugs and commonly used products.  
 
North American pigs are managed in phases. The suckling phase extends from 
birth until weaning. Pigs are weaned at an average of 19.3 days (Standard deviation (S), 
0.2), although there is substantial variation among herds (40). Large herds tend to wean 
pigs earlier (average, 17.2 days) while small herds tend to delay weaning (average, 30.0 
days) (40). Weaning marks the beginning of the nursery phase. Piglets may be moved to 
a separate pen in the same room as sows but are more commonly moved to separate 
rooms or even sites. The nursery phase is associated with increased disease risk because 
pig stressors, including mixing and diet changes, occur concurrently with declining 
maternal immunity (41). Pigs generally remain in the nursery phase until they are 6 to 10 
weeks of age (average, 61.8 days; S, 0.6) (40). There is less variation between small and 
large herds in the timing for moving pigs to the grow-finish phase (40). The grow-finish 
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phase completes the production cycle. Pigs remain in this phase until marketed or 
selected for the breeding herd.  
 
North American swine producers use antimicrobials to treat disease, prevent 
disease, and improve feed efficiency and daily gain (13,42). Antimicrobials are 
predominantly administered by feed; more than 90% of producers use feed-grade 
antimicrobials. Feed-grade antimicrobial use is more common in younger pigs. As pigs 
age, fewer diets contain medication (33,35,37,38). Recent reports indicate that products 
containing combinations of tetracyclines, sulfonamides, and penicillin are commonly 
used in nursery pigs, while tylosin is the most commonly used drug in grow-finish pigs 
(33,38). In-feed medication use appears to be relatively static over time within herds. 
Rajić et al. reported that most producers used antimicrobials in diets more than 95% of 
the time in the previous 12 months (38). Furthermore, Dunlop et al. found few producers 
changed medication practices over 18 months (43). This suggests that producers use feed-
grade antimicrobials to manage disease risk rather than treat disease occurrences.  
 
Antimicrobial use in water is less common than in feed. In Alberta, 50% of study 
herds used water medications in nursery pigs, 21% in grower pigs and 18% in finisher 
pigs (38). Similarly, 25% of surveyed Ontario producers and 30% of United States 
producers used water medication in grow-finish pigs (33,37). In Alberta, penicillin was 
the most common water soluble antimicrobial used in all production phases. Other 
commonly used products in grow-finish pigs included chlortetracycline and 
sulfamethoxine in the United States and dimetridazole and tetracycline in Alberta 
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(33,38). Dimetridizole was banned from use in pigs in Canada in 2003 (44). Two studies 
have found large herds are more likely to administer antimicrobials through water than 
small herds (33,37). In Canada, 7% of herds produce half of the nation’s pigs (45). In 
western Canada, this trend is even more pronounced; 1% of herds produce half of 
Saskatchewan’s pigs (46). Hence, accurate estimates of antimicrobial exposure require 
data on the proportion of herds using water soluble antimicrobials stratified by herd size. 
Failing to account for herd size could substantially underestimate antimicrobial exposure.  
 
Parenteral antimicrobial use is more common in suckling piglets and sows than in 
nursery or grow-finish pigs (38,43). As pigs approach market, fewer herds use any 
injectable drugs and those continuing to use injectable antimicrobials report lower 
exposure rates (43). Pigs are exposed to substantially less antimicrobial (by volume) 
through injection than through feed or water because the duration of treatment is shorter 
and fewer animals are exposed. Despite this, it is important to describe injectable 
antimicrobial use because some antimicrobials are only available as injectable products.  
 
Fluoroquinolones and third generation cephalosporins are among the drugs 
considered critically important in human medicine, hence the use of these drugs in 
livestock is of particular interest (47,48). There are currently no fluoroquinolones 
licensed for use in pigs in Canada (49). Ceftiofur is the only third generation 
cephalosporin licensed for use in pigs and is available only as an injectable drug (49). An 
Alberta study found ceftiofur was used in 10% percent of herds which made it the fourth 
most common injectable product in nursery pigs and the fifth most common product in 
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grower and finisher pigs(38). A United States report indicated ceftiofur was the third 
most commonly used injectable antimicrobial on swine farms (33). Extended-spectrum 
cephalosporin resistant Salmonella are a public health problem, and human cases have 
been occasionally linked to livestock sources (50). Furthermore, Salmonella and E. coli 
from cattle, pigs, and people carry the extended-spectrum beta-lactamase gene CMY-2 on 
similar plasmids (6,51). These findings suggest that using third generation cephalosporins 
in food animals may influence human exposure to extended-spectrum cephalosporin 
resistant pathogens. Such links between human and veterinary medicine reinforce the 
importance of describing injectable antimicrobial use in livestock.  
 
The rate of antimicrobial exposure in North American pigs is essentially 
unknown. Rajić et al. categorized herds by the frequency of antimicrobial use in feed and 
water. Ninety percent of farrow-to-finish herds medicated nursery diets more than 95% of 
the time and 82% of herds medicated grower diets more than 95% of the time (38). 
However, this study did not report the duration of exposure. Pig-exposure incidence has 
only been reported for injectable drug use in Ontario herds. That study found highly 
variable exposure rates between phases and herds (43). Rate based data might enable 
estimation of antimicrobial consumption in Canadian pigs, potentially improving the 
precision of antimicrobial use risk factor analyses.  
 
In summary, most swine herds in North America use antimicrobials and many use 
them extensively (33,37,38). Three studies found almost all herds use feed-grade 
antimicrobials and one-third to one-half use water-soluble drugs (33,37,38). These 
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findings were consistent despite different locations, times and data collection methods. 
More information is needed describing the rate of antimicrobial use within herds. These 
data would allow authorities to estimate national antimicrobial consumption and 
minimize fallacies when investigating the association between antimicrobial use and 
resistance in pigs.  
 
2.4 Antimicrobial Resistance in Salmonella from pigs 
Salmonella is the second leading cause of foodborne disease in Canada, surpassed 
only by Campylobacter (52). Six thousand cases of human salmonellosis are reported 
annually and for each reported illness an estimated 13 to 37 cases remain unreported (53). 
In Canada, over one-third of human clinical isolates are resistant to at least one 
antimicrobial, and 11% are resistant to five or more (12). This is concerning because 
resistant Salmonella can cause even greater morbidity than their susceptible counterparts. 
Treatment failure, increased disease severity, and increased risk of infection in people 
taking antimicrobials for other reasons all contribute to an increased disease burden 
(1,54-56). Antimicrobial resistant Salmonella in livestock are a food safety concern 
because most resistant Salmonella are acquired, rather developing resistance in people 
post-infection (14,57,58). 
 
Although Canadian estimates are not available, 15% (95% Confidence interval 
(CI), 5 to 25%) of Salmonella cases in The Netherlands and 9% (95% CI, 8 to 10%) in 
Denmark have been attributed to pork consumption (59,60). In the United States, pork 
consumption is estimated to cause 99,430 cases (90% CI, 20,970 to 245,560) of 
salmonellosis annually (61). Globally, most human non-typhoid Salmonella infections 
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are S. Enteritidis (65%) followed by S. Typhimurium (17%) (62). In Canada, these 
serovars each account for approximately 20% of the reported human cases (52). S. 
Typhimurium (including variant Copenhagen) is also among the most common serovars 
reported in healthy pigs on-farm (39,63-67). The Canadian Integrated Program for 
Antimicrobial Resistance Surveillance (CIPARS) found that S. Typhimurium (including 
var. Copenhagen) accounted for 15% of isolates collected from healthy pigs at slaughter 
(12).  
 
Antimicrobial resistance in Salmonella spp. from sick pigs has been described 
(12,51,68). Clinical isolates had more resistance and a different serovar distribution than 
Salmonella from healthy pigs at slaughter (12,68). This increased resistance could be due 
to any, or all of the following: antimicrobial use in sick pigs, associations between 
resistance and serovar, or associations between resistance and virulence genes (64,69,70). 
Monitoring AMR in Salmonella from sick animals provides a sensitive warning for 
emerging resistance but does not reflect the consumer risk from pork. For this, 
Salmonella must be isolated from healthy animals that enter the food chain. Salmonella 
from retail meats more closely reflects the consumer risk from improperly prepared food, 
while isolates from pigs in abattoirs reflect the risk of carcass contamination. Salmonella 
from pigs on farms provide a baseline prevalence of resistance entering the food 
processing chain from live pigs (71). 
 
Resistance in Salmonella collected at slaughter can differ from isolates collected 
on-farm. Nollet et al. reported significantly less resistance in Salmonella spp. isolated 
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from the mesenteric lymph nodes, jejunum and colon than from fecal samples collected 
on-farm (72). Erdman et al. found additional serovars and resistance patterns at slaughter 
that had not been identified on-farm (73). Gebreyes et al. found the genetic fingerprints of 
S. Typhimurium (including var. Copenhagen) collected at slaughter were different from 
those on-farms, but identical to those collected from transport trucks. This indicates that 
pigs can be infected during transport, even when trailers are washed between loads (64). 
Infection during transport and lairage means antimicrobial use and farm management 
practices should be evaluated as risk factors for resistance in Salmonella collected on-
farm. Additionally, post-shipping infection means that abattoir-based and on-farm studies 
are complementary but not equivalent. Abattoir studies can sample pigs from many 
herds; samples can be collected proportional to regional or national production and better 
reflect the consumer risk from resistant bacteria. In contrast, on-farm studies can 
investigate risk factors for the development and persistence of resistance in pigs.  
 
In Canada, most Salmonella AMR data are from abattoirs or clinical isolates 
(12,68,70,74,75). On-farm data are available from healthy grow-finish pigs in Alberta 
and national monitoring has been initiated but results are not yet available (12,76). In the 
United States, data from targeted research projects and national monitoring are available 
(39,63-65,77). The proportion of isolates susceptible to all drugs on tested 
(pansusceptible) was higher in Alberta (53%) than in the United States (6%) when similar 
panels were used (39,76). Rajić et al. and CAHFSE also reported the same top three drug 
resistances but CAHFSE had markedly more resistance: tetracycline, 39 vs. 90%; 
streptomycin, 26 vs. 69% and sulfamethoxazole, 21 vs. 63% (39,76). Initially, it seems 
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plausible that Rajić et al.’s geographic limitation to Alberta could account for this 
difference. However, the Alberta data were similar to the rates of resistance reported by 
CIPARS in Salmonella from healthy pigs at slaughter; tetracycline 42%, streptomycin 
26% and sulfamethoxazole 28% (12). Therefore, other factors should be investigated to 
explain these substantial differences between Salmonella from Canadian and American 
swine farms. Such factors could include serovar differences, management practices, or 
antimicrobial exposures. 
 
Resistance to extended-spectrum cephalosporins and fluoroquinolones among 
Salmonella is particularly important because these antimicrobials are used to treat 
salmonellosis in people (48,57). To date, North American on-farm studies have not found 
Salmonella resistant to ciprofloxacin (39,63-65,76). Likewise, no resistance has been 
identified to ceftiofur or ceftriaxone in abattoir or on-farm studies in Canada (12,76). 
This is markedly different from United States farms where 21% of Salmonella were 
ceftiofur resistant (39).  
 
A recent investigation describing Salmonella AMR in three herds found 
significantly less resistance in sows than in production animals (72). Salmonella serovars 
can differ between production phases within herds (78). This, along with antimicrobial 
exposure and physiological differences, may explain why antimicrobial resistance differs 
between production phases (38,43). Currently, data describing AMR in Salmonella from 
pigs distant from market are scarce. These data might provide insight into how resistance 
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persists and spreads within herds, and identify phase specific risk factors. Defining risk 
factors for resistance is crucial for developing AMR intervention plans. 
 
Studies considering the effect of antimicrobial exposure on resistance in 
Salmonella have reached contradictory conclusions. Two studies found antimicrobial 
exposure in feed had no or minimal effect on resistance in experimentally induced S. 
Typhimurium (79,80). Resistance to 12 drugs did not differ between Salmonella from 
pigs exposed to 100 ppm of tylosin for 56 days (N = 10 pigs; n = 107 Salmonella) and 
Salmonella from pigs fed a non-medicated control ration (N = 10 pigs; n = 110 
Salmonella) (81). Similarly, no significant time-treatment-antibiotic interactions were 
found in a study comparing three antimicrobial exposures and a non-medicated control (n 
= 12 pigs per group) indicating resistance did not vary over time within treatments. In 
contrast, an observational study found Salmonella spp. from antibiotic free (ABF) herds 
were significantly more likely to be pansusceptible than isolates from conventional swine 
herds (82). The odds of resistance to every antimicrobial except tetracycline were higher 
in Salmonella from the conventional herds compared to ABF herds (82). The difference 
between these experimental and observational studies could be attributable to serovar 
because resistance is associated with serovar (64,70). The experiments only used S. 
Typhimurium while the observational study did not describe the serovars. The differences 
may also be due to the antimicrobial exposures tested; Salmonella resistance may develop 
differently with certain exposures (such as drug, dose, duration or frequency) and the 
experimental and on-farm exposures could have differed substantially. Conversely, the 
on-farm study was cross-sectional and cannot ascribe causality (83). Conventional and 
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ABF herds could have had Salmonella with different resistance patterns because of 
variables other than antimicrobial use. Management variables were not considered as 
independent risk factors or potential confounders (82).   
 
Antimicrobial resistant Salmonella are a food safety hazard given that resistant 
salmonellosis outbreaks have been traced to pork products (84,85). However, monitoring 
AMR in Salmonella is challenging because sub-clinically infected pigs shed 
intermittently, barns fluctuate between a Salmonella-positive and apparent-negative 
status, and isolation techniques can have poor sensitivity (67,86). Two studies recently 
illustrated the challenges of studying AMR in Salmonella. The first was a trial examining 
AMR in pigs with and without subtherapeutic chlortetracycline exposure in feed. 
Twenty-two barns with a history of Salmonella spp. contamination participated. Despite 
this, Salmonella spp. were isolated from only 15 of 2112 fecal samples (17). A second 
study compared AMR in Salmonella spp. from ABF and conventional swine herds. Four 
of the seven herds had no positive samples isolated. Additionally, the 143 isolates 
collected may have represented as few as 44 unique strains because multiple isolates 
were harvested from samples cultured with selective enrichment (87).  
 
In contrast to Salmonella, E. coli are highly prevalent and easily isolated. 
Salmonella and E. coli from pigs can share resistance genes in vitro and molecular 
evidence suggests transmission occurs in vivo (6,88). The resistance phenotypes for these 
bacteria ranked in a similar order in both the CIPARS and CAHFSE reports (12,39). To 
date, the feasibility of using E. coli as a herd level sentinel for AMR in Salmonella has 
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not been reported. As a sentinel species, E. coli would provide more cost effective 
monitoring of resistance and might improve the power of investigations for resistance 
risk factors.  
 
In summary, Salmonella in North American pigs carry a concerning level of 
resistance (12,39,76). The potential food-safety risk from resistance to quinolones and 
extended-spectrum cephalosporins should impel more on-farm studies (57). As the 
prevalence of resistance becomes better known, and associations with serovar become 
better described, risk factors for resistance can be investigated. Ultimately, the goal of on-
farm studies should be to identify interventions that control or reduce antimicrobial 
resistant Salmonella in pigs. Farm-level sentinel bacterial such as E. coli, have the 
potential to advance this objective and should be investigated.   
 
2.5 Antimicrobial Resistance in commensal Escherichia coli from pigs 
2.5.1 Phenotypic antimicrobial resistance 
Antimicrobial resistance in E. coli poses at least three health concerns for humans 
and animals. Two concerns are only relevant to pathogenic E. coli; resistant infections 
have an increased risk of treatment failure and are potentially more virulent than their 
susceptible counterparts (89-93). The third concern applies to both pathogenic and non-
pathogenic E. coli; antimicrobial resistant bacteria have a competitive advantage in 
people or animals taking antimicrobials as they are more likely to colonize and persist in 
the gut (56,93). Colonization with resistant commensal strains is a concern because E. 
coli can transmit resistance genes to other bacteria. Resistance gene exchange can occur 
between bacteria from diverse ecological niches, including from animals to humans (6-8). 
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Therefore, AMR in E. coli is a public health concern, although the magnitude of risk is 
undefined.   
 
Unless otherwise stated, this review describes commensal E. coli from healthy 
pigs. This is noteworthy because the rates of phenotypic resistance and the AMR genes 
differ between porcine pathogenic and commensal E. coli (90,92). Studying commensal 
E. coli is important because they reflect the reservoir of resistance genes available for 
dissemination to other bacteria, and indicate the selective pressure for resistance in the 
normal gut flora (9,71). Because E. coli are prevalent in healthy animals, they enable 
resistance to be compared between pigs in different locations and times, and between pigs 
and other species (9,94).  
  
Antimicrobial resistance in E. coli is studied on-farm because transportation, 
stress and lairage can alter the rates and patterns of resistance in pigs (95-98). In Canada, 
on-farm studies have been conducted in British Columbia and Ontario and national 
monitoring was initiated in 2006 (12,15,99). In the United States, the National 
Antimicrobial Resistance Monitoring System (NARMS) collected E. coli from swine 
farms in 2000 and CAHFSE collected repeated samples from 2003 to 2005 (39,77,100). 
Research projects have also described resistance in sows and younger pigs in Tennessee 
(101,102). With the exception of the national surveillance projects, study herds have been 
selected based on antimicrobial use.  
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Observed antimicrobial resistance rates, and the most common drug resistances, 
have been similar in Canada and the United States. In the United States, resistance was 
most common to tetracycline (86 and 92%), sulfamethoxazole (42 and 44%) and 
streptomycin (29 and 35%). A low rate of resistance to ceftiofur (1.5 and 3.2%) and no 
resistance to ceftriaxone or ciprofloxacin was reported (39,77). Dunlop et al. described 
resistance in E. coli from pigs in Ontario while Akwar described E. coli from pigs in both 
Ontario and British Columbia (15,99). These studies also found E. coli were most 
commonly resistant to tetracycline (71 and 81%) and sulfamethoxazole / sulfisoxazole 
(38 and 59%) (15,99). Akwar also found frequent resistance to streptomycin (32%), no 
resistance to ceftiofur or ciprofloxacin, and 0.3% resistance to ceftriaxone (99).  
 
The studies describing E. coli AMR on Ontario and British Columbia swine farms 
were cross-sectional (99,103). Both studies purposively selected herds by antimicrobial 
use and, therefore, extrapolating the reported resistance prevalences to other herds in 
these provinces may be inappropriate (99,103). Of these two studies, the external validity 
of the study by Dunlop et al. was better because the resistance prevalences were 
standardized to reflect Ontario hog farms. The author used a mail-based survey to 
describe the drug-use in Ontario herds. This knowledge of the sampling frame was used 
to weight the prevalence of resistance in each drug-use strata by the percentage of 
Ontario herds in each stratum (103). In contrast, Akwar’s findings could have 
underestimated the prevalence of resistance in Ontario and British Columbia. Farms 
using in-feed medication had significantly more resistance than farms without exposure 
and the proportion of study herds with no feed-grade drug use was higher than the source 
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population (37,99). However, it is also important to consider that Akwar’s findings may 
overestimate resistance in finishing pigs. Escherichia coli from weaned pigs had 
significantly more resistance than from finisher pigs, but resistance to individual drugs 
was pooled across production phases (99). This could be important if these data were 
compared to E. coli from close-to-market animals. Preliminary results describing on-farm 
E. coli AMR in Alberta have been published (104). Complete findings from Alberta, 
along with the findings of this thesis, may identify differences between herds in eastern 
and western Canada as well as changes over time within Alberta herds (104). 
 
On-farm studies have investigated the variation in resistance at different 
organizational levels (17,105,106). Focusing limited resources on the most variable levels 
improves the chance of finding risk factors for resistance (83). Three studies have 
provided information on how resistance clustered within pigs, pens and production 
companies (17,105,106). Brun et al. explored variation at two hierarchical levels; the 
variation in repeatedly sampling animals as they moved through a production phase, and 
the variation in isolates from an animal within a sampling (106). The variation in 
resistance between sampling times within a production phase was assessed by sampling 
sows three weeks post-farrowing, at weaning, and four weeks before the next farrowing. 
Offspring from these sows were sampled at three weeks of age, upon entry to the grower 
barn and pre-slaughter. The variation in resistance between E. coli within an animal at 
each sampling was explored by testing 10 isolates per sample. Isolates were tested for 
susceptibility to 11 antimicrobials. Every resistance outcome, except ampicillin in sows, 
had negligible variation within an animal relative to the variation within a production 
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phase. This suggests testing many isolates per animal is not valuable. It also indicates that 
resistance in a pig class (i.e. sows) cannot be described unless all points in the production 
cycle (i.e. breeding, gestation, farrowing) have been sampled. Again, isolates should 
represent as many animals as possible. Brun et al.’s study sampled only two farms. 
Although variation between herds could not be described, herd was a significant fixed 
effect for resistance to some drugs. This suggests that variation between herds might be 
important for describing resistance in a target population (106). 
 
A second study described the variation in resistance within a barn of finishing 
pigs (105). More than 80% of the variation was attributed to differences between pigs 
within pens, compared to pens within rooms, and rooms within the barn. Variation 
between isolates within an animal was not considered (105). Dunlop et al.’s findings 
suggest risk factor studies should target individual animals rather than pens or rooms. 
However, growing pigs are managed in groups. As it may not be feasible to implement 
pig-level interventions, it may be more valuable to describe resistance at the level of the 
grow-finish phase. Simulation modeling determined phase level resistance was optimally 
described by pooling feces from 20 animals and selecting five isolates per pooled sample. 
This sampling plan was used in the subsequent on-farm study. Substantial variation in 
resistance occurred between herds with different antimicrobial exposure histories (15). 
For each resistance, antimicrobial use risk factors were identified, while other herd level 
variables were not important confounders (16). This work suggests the production phase 
is a rewarding level to investigate AMR risk factors (15,16,105).  
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A third study compared AMR in E. coli from finisher pigs exposed to diets with, 
and without, subtherapeutic chlortetracycline (17). Three production companies each 
enrolled two to twelve finishing barns in the trial. Treatment allocation was at the 
finishing barn level. Variation was considered at the isolate, pig and production company 
level while variation between barns was not investigated. Consistent with previous 
reports, most variation occurred at the pig level, although more variation was found 
between isolates within a pig than reported by Brun et al. (105,106). Based on this, Funk 
et al. suggest risk factor studies should target more pigs per farm (production company), 
and more E. coli per pig, rather than more farms (17). This conclusion is appropriate for 
antimicrobial exposure trials; however, observational studies describing associations 
between herd- or phase-level antimicrobial exposure and resistance still require many 
herds because variable exposures are needed to test hypotheses.   
 
Together, these three studies provide guidelines for investigating AMR on swine 
farms. First, antimicrobial use is a risk factor for AMR in pigs (16,17). Therefore, herds 
purposively selected for antimicrobial use, although ideal for risk factor studies, may 
provide biased estimates of resistance in a population. Second, if findings are inferred to 
the entire herd, sampling should be stratified across production phases. The results 
obtained in one production phase are not inferable to another (106). Third, the optimal 
sampling plan differs with the study objective. Studies describing the prevalence of 
resistance in a region, or investigating phase level risk factors, should collect composite 
samples from many herds. Studies investigating pig- or pen- level risk factors should 
collect samples from as many individual animals as feasible with a limited number of 
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isolates per sample. However, it may not be rewarding to investigate pen-level risk 
factors because within pen variation is minimal. Pig-level risk factors are more likely to 
be identified but may not result in practical interventions (105).  
 
2.5.2 Genotypic antimicrobial resistance 
Each resistance phenotype can arise from the expression of numerous different 
resistance genes (90,107). Thus, AMR genes can identify differences masked by 
phenotypic AMR. Describing AMR genotypes also provides insight into how resistance 
is transmitted, how genes interact and the potential for co-selection (108).  
 
Genotypic AMR data are important for developing hypotheses on where 
resistance develops and how it spreads between animal and human populations. For 
example, sul3 has emerged in human and pig populations in Europe, Canada and the 
United States (90,109-113). This suggests resistance is transmitted between these species 
and countries, although it does not indicate the original source of this gene (108). 
Although molecular epidemiology is in its infancy, this is an indication of how links 
between AMR in food animals and people may be explained. 
  
Many genes encode for each resistance but a few genes often dominate in a 
bacterial population. For example, at least 36 genes encode for tetracycline resistance but 
three genes almost completely describe tetracycline resistance in E. coli from pigs: tetA, 
tetB and tetC (90,107,114-116). The relative distribution of these genes varies across 
swine populations (90,107,114-116). This variation could be due to temporal, 
antimicrobial exposure, or serovar differences. Maynard et al. noted temporal changes in 
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pathogenic E. coli collected over 23 years. From 1978 to 1994, few isolates carried tetA, 
and none carried tetC. In contrast, these genes each accounted for one-third of the 
tetracycline resistance from 1995 to 2000. Antimicrobial exposures or management 
systems may also select for different genes. Blake et al. found tetracycline resistant E. 
coli from extensively raised pigs did not carry tetB, while those from intensively raised 
pigs did not carry tetA (117).  
 
As with Salmonella, some E. coli strains appear to have a predilection for certain 
AMR genes. Continuing with tetracycline resistance as an example, Boerlin et al. found 
tetA predominated in Enterotoxigenic E. coli (ETEC) while tetB was more common in 
pathogenic non-ETEC and in commensal E. coli (90). The association between E. coli 
type and chloramphenicol resistance genes has been studied more thoroughly. 
Escherichia coli from piglets with diarrhea in Oklahoma almost exclusively carried cmlA 
as did non-ETEC from pigs with diarrhea in Ontario (92,109). In contrast, 
chloramphenicol resistant ETEC from pigs in Ontario predominantly carried catA1 and 
commensal E. coli carried floR (92). Examining associations between E. coli strains, 
virulence genes and AMR genes may clarify how AMR spreads and persists in pig 
populations. These associations should be accounted for when considering associations 
between risk factors such as antimicrobial use and AMR. 
 
Antimicrobial resistance can be acquired through genetic mutation or by obtaining 
resistance genes (118). Once acquired, resistance genes are passed to successive 
generations of bacteria during replication. Bacteria can acquire resistance genes 
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independent of replication by taking up naked DNA (known as transformation), through 
bacteriophages (known as transduction), or through horizontal transmission of genetically 
mobile elements including plasmids, transposons and integrons (118). Horizontal 
transmission is the principal route for AMR dissemination (118). Within gram-negative 
bacteria, transmission by genetically mobile elements predominates. These elements link 
unrelated resistance genes, transmit them as a unit, creating multiple drug resistant 
bacteria. Excellent reviews provide detailed explanations of resistance gene transmission 
(119-121). For the purposes of this review, it is important to understand that multiple 
drug resistant bacteria have a competitive advantage over susceptible bacteria in the 
presence of any antimicrobial in their resistance phenotype (5).  
 
Resistance genes are not linked arbitrarily. Certain genes have an affinity for each 
other; sul1 and aadA genes often occur together because sul1 is a component of type1 
integrons and aadA is a common gene cassette accumulated by integrons (119,122). 
Other genes, such as tetA and tetB, are carried on incompatible plasmids (90). Studies 
using molecular epidemiological techniques, such as conjugation, DNA sequencing and 
hybridization, have provided evidence of gene linkages and transfers (8,92,123). 
However, because of laboratory time and expense most studies examine only a few 
purposively selected isolates. Therefore, results rarely provide definitive information on 
how genes behave in a larger bacterial population. Statistical associations provide an 
alternative for investigating gene interactions. Associations describe the probability of 
identifying genes together (90,92,107). Statistically, investigators can consider many 
more isolates and genes than is feasible in molecular experiments. Identified associations 
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generate hypotheses about how genes are transmitted, which can be tested with more 
expensive laboratory techniques.  
 
Three Canadian studies have described the associations between AMR genes. One 
considered the association between AMR genes in E. coli O149:K91 obtained from pigs 
with diarrhea in Quebec between 1978 and 2000 (107). Two other studies considered the 
same set of E. coli from Ontario and are described together (90,92). Approximately half 
of these E. coli were from pigs with diarrhea while half were commensal E. coli from 
healthy finisher pigs. Nine genes were tested in both studies but only three corresponding 
associations were identified; aac(3)-IV / catI were positively associated while sul1 / sul2 
and tetA / tetB were negatively associated. Four associations were identified only in 
Quebec isolates and ten were found in only the Ontario isolates. One association was 
observed in both studies but in opposite directions. In Ontario, sul1 and tetB were 
negatively associated while in Quebec they were positively associated. Interestingly, sul1 
was positively associated with tetA in Ontario and in the Quebec isolates obtained from 
1990 to 2000. This association was negative in the full set of Quebec isolates (1978 to 
2000), which suggests associations between genes can change over time. In the Ontario 
isolates, the AMR genes were distributed differently between ETEC, non-ETEC 
pathogens and commensal E. coli (90,92). Certain virulence and resistance genes were 
also associated (90,92). Investigating only E. coli O149:K91 in Quebec, compared to 
diverse E. coli isolates in Ontario, could explain the different associations reported by 
these studies. However, temporal and geographic differences may also have been factors.  
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Through transformation, Travis et al. confirmed that many of the statistical 
associations were explained by plasmids carrying linked genes (92). Other associations 
occurred because clones, carrying multiple plasmids, had been tested. This emphasizes 
that statistical associations between genes only provide hypotheses about linkages, which 
require confirmation. It also illustrates the importance of selecting unrelated isolates 
because statistical associations assume independence (83). 
 
Molecular epidemiology is a rapidly expanding area. Understanding the 
epidemiology of AMR genes will undoubtedly improve our ability to track the 
dissemination of resistance within bacterial population and between animals and humans 
(108). Few studies have investigated associations between antimicrobial use and AMR 
genes (117). As new technologies, automation, and decreasing costs make genotyping 
more feasible, future studies may investigate risk factors for resistance genes rather than 
resistance phenotypes.  
 
2.5.3 Associations between antimicrobial use and resistance  
Laboratory experiments, on-farm trials and observational studies have explored 
the effect of antimicrobial exposure on resistance in E. coli from pigs. In contrast to 
Salmonella, antimicrobial use has been associated with increased resistance in both 
observational and experimental studies (16,87,99,124-128). Laboratory experiments have 
provided causal evidence that antimicrobial exposure can directly select for resistance. In 
one study, nursery pigs receiving therapeutic doses (15 mg/kg) of tetracycline in feed for 
seven days had more tetracycline resistant E. coli than those receiving a subtherapeutic 
dose (1.5 mg/kg). Both treatment groups had more resistance than untreated controls 
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(126). In another study, weaned pigs exposed to apramycin continuously for 14 days had 
more apramycin resistance than pigs fed diets pulsed with apramycin (sequentially in 
three days and out three days) (125). These studies showed the dose and frequency of 
exposure to antimicrobials can affect AMR in pigs.  
 
Co-selection occurs when antimicrobial exposure selects for unrelated drug 
resistances (5,129). Tetracycline exposure has selected for apramycin resistance 
experimentally. Young pigs, treated with apramycin, were exposed to different stresses 
including cold, crowding, and oxytetracycline. Pigs receiving oxytetracycline in feed at 
100 g/ton for 141 days had more apramycin resistant E. coli than pigs with no 
antimicrobial exposure, and more resistant E. coli than pigs receiving apramycin but not 
oxytetracycline (130). This difference was significant between the second and ninth week 
of the trial. In another experiment, sows were allocated diets with or without 
oxytetracycline (100 g/ton for 14 days pre-farrowing). Piglets nursing treated sows had 
more apramycin resistant E. coli than piglets from untreated sows (124). These 
experiments show that antimicrobial use causes resistance to unrelated drugs in E. coli 
from pigs. Despite this, the clinical importance of these trials is difficult to interpret 
because treated and control animals had similar rates of resistant E. coli at the end of both 
studies despite isolation between treatment groups.  
 
Experimental studies are the gold standard for determining causality (83). 
However, extrapolating conclusions from experimental studies to commercial swine 
operations may be invalid if environmental or animal factors differ substantially. To 
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address this weakness, other study methodologies have been used to investigate the 
association between antimicrobial use and resistance. 
 
Randomized controlled clinical trials (RCCT) provide insight into how 
antimicrobial exposure can affect AMR in pigs on-farm. Management practices, such as 
stocking densities, feeding regimes and animal mixing, are similar to commercial barns. 
This improves the external validity of findings (83). An on-farm trial compared AMR in 
E. coli from finisher pigs receiving oxytetracycline (50 g/ton) for the entire grow-finish 
period (14 weeks) to E. coli from pigs without treatment. Treatment was allocated by 
barn after stratification by production company. Resistance to four antimicrobials was 
investigated. The odds of resistance to any drug were eight times higher in treated pigs 
compared to controls, and the odds of resistance to tetracycline, ampicillin and ceftiofur 
were each significantly higher in exposed pigs. Gentamicin resistance did not differ 
significantly between groups. These findings suggests low-dose, continuous exposure to 
tetracycline directly selected for tetracycline resistance and co-selected for resistance to 
unrelated drugs. This study’s primary weakness was non-random treatment allocation. 
Randomization minimizes bias created by known and unknown risk factors so the extent 
to which this study’s results are biased is difficult to determine (83). Until these results 
are substantiated, the possibility of bias should be considered when inferring these 
findings to other herds.  
 
Of field epidemiological studies, RCCTs provide the strongest evidence for 
causation (83). However, they can only examine limited drugs, doses, and exposure 
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frequencies, all of which may affect resistance. Observational studies are ideal for 
investigating complex problems with many causes or hypotheses (83). To date, most on-
farm studies have been cross-sectional. These have described associations between 
antimicrobial exposure and resistance at the national, herd and production phase level 
(16,87,99,128).  
 
The Danish Program for Surveillance of Antimicrobial Resistance (DANMAP) 
collects E. coli from healthy animals at slaughter and sick animals (128). It also monitors 
national antimicrobial use in livestock. Monitoring programs can identify trends for 
retrospective investigation. The DANMAP program noted increased apramycin and 
gentamicin resistance following authorization of oral apramycin use in livestock. The 
odds of E. coli resistance to apramycin increased 1.9 times for every year following 
approval, and increased by 1.6 times with every 50U increase in apramycin consumption 
annually (128). The association between apramycin use and resistance in swine herds was 
investigated to avoid potential fallacies from inferring national-level associations to 
farms. No herds used apramycin in finisher pigs, but herds with apramycin and 
gentamicin resistant E. coli were significantly more likely to have used apramycin in 
nursery pigs. By considering associations between antimicrobial use and resistance at the 
farm and national level, this study identified risk factors for resistance and gave 
perspective to the public health risk from resistance in food animals.    
 
Cross-sectional studies have compared AMR in E. coli from herds with different 
antimicrobial exposures. Mathew et al. compared the resistance in three herds with no 
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antimicrobial use to four herds using antimicrobials (87). Antimicrobial use was 
described in each phase but was only considered as the dichotomous variable ‘no use’ 
versus ‘any use’ in the analysis. State was the only herd descriptor. Dunlop et al. 
described associations between antimicrobial use and resistance in Ontario swine farms 
(16,103). Hog farms in Ontario were stratified by size and a subset of producers was 
surveyed about antimicrobial use. Respondents that met the inclusion criteria were 
eligible to participate. Thirty-four herds, selected for antimicrobial use practices, were 
enrolled. Antimicrobial use data were collected for two months, described by phase and 
product, and considered as risk factors for numerous resistances in E. coli from finisher 
pigs. Analyses adjusted for clustering within herds and considered numerous herd 
characteristics as potential confounders. Akwar expanded on this study by including more 
herds in Ontario, herds in British Columbia, and E. coli from weaned pigs (99). All three 
studies found that antimicrobial use was associated with increased resistance (16,87,99).  
 
Of these studies, Mathew et al.’s provided the weakest evidence linking 
antimicrobial use to resistance (87). Based on a tendency for lower MICs in E. coli from 
herds without antimicrobial use the authors concluded, “excluding antibiotics from swine 
herds reduced the number of resistant bacteria…”. This conclusion is flawed because 
cross sectional studies cannot ascribe causality (83,87). Simultaneous data collection on 
exposures and outcomes precludes stating which came first. This can create the problem 
of reverse causality. For example, a herd could have high levels of AMR, leading to 
increased disease, causing increased antimicrobial use. This study’s second weakness was 
its failure to consider different antimicrobial exposures as risk factors, and herd variables 
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as confounders. This omission was likely because the only seven herds participated in the 
project. However, it resulted in the authors attributing the entire difference between herds 
to the antimicrobial exposure. Finally, this study provided no insight into high risk 
antimicrobial use practices.  
 
In contrast, Dunlop et al. and Akwar both considered drug specific antimicrobial 
exposures in each production phase and considered management variables as potential 
confounders. Their findings corroborate other results from on-farm and laboratory 
experiments (16,99). Antimicrobial exposure in suckling piglets, nursery pigs and sows 
were each associated with at least one resistance outcome in E. coli from finisher pigs 
(16,99). This corresponds with experimental evidence that piglets from sows exposed to 
oxytetracycline in gestation diets had increased resistance (124). It also complements 
Jensen et al.’s observation that apramycin use in nursery pigs was associated with 
resistant E. coli in market age pigs in Denmark (128). Both Akwar and Dunlop et al. 
identified associations between antimicrobial use and resistance to unrelated drugs 
(16,99). Some associations have since been identified by others. For example, Dunlop et 
al. found the odds of ampicillin resistance were two times higher in herds using 
tetracyclines in grow-finish diets than those with no exposure (16). This is similar to 
Funk et al.’s observation that the odds of ampicillin resistance were 1.4 times higher in 
the herds allocated tetracycline exposure in finishing diets (17). Dunlop et al. also found 
tetracycline use in grow-finish diets was a risk factor for sulfisoxazole resistance (16). A 
corresponding association was subsequently identified between tetA and sul1 in porcine 
E. coli from Ontario (90). These findings demonstrate the utility of cross sectional 
39 
studies; statistical associations can provide hypotheses for experiments and stimulate 
investigations into the physical linkage of resistance genes.  
 
In conclusion, E. coli from pigs on farms in North American are commonly 
resistant to many different drugs (39,77,99). Antimicrobial use is a primary cause of this 
resistance (16,17,124). Further research is needed to identify what antimicrobial 
exposures pose the greatest risk for creating resistance to drugs important for human 
therapy (47,48,131). Molecular epidemiology will help on-farm studies identify 
interventions by distinguishing between apparently equivalent resistances and accounting 
for co-selection. In the meantime, producers and veterinarians should feel compelled to 
use antimicrobials as sparingly as possible.  
 
2.6 Antimicrobial Resistance in Campylobacter from pigs 
Campylobacter is the leading reported cause of bacterial foodborne enteric 
infections in many developed nations (132). In Canada, approximately 12,000 cases are 
reported annually with an estimated 23 to 29 unreported illnesses for every reported case 
(52,53). Campylobacter infections do not generally require antimicrobial therapy. 
However, macrolides may be prescribed for severe cases or immuno-compromised 
patients. Campylobacter infections are also treated with fluoroquinolones because 
ciprofloxacin is a front-line drug for undifferentiated gastroenteritis. However, resistance 
to fluoroquinolones is increasing, as are concerns about treatment failure (133-135). 
Similar to the situation with Salmonella, resistant Campylobacter infections may have 
increased virulence. People with ciprofloxacin resistant Campylobacter suffer from 
diarrhea longer than those with susceptible infections (3,4,136). Resistant Campylobacter 
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are generally acquired rather than selected for by antimicrobial use during therapy 
(4,135). This raises concerns about AMR in Campylobacter from food animals as most 
cases of Campylobacter are foodborne (134,137).  
 
Eighty to ninety percent of campylobacteriosis cases are caused by 
Campylobacter jejuni while Campylobacter coli accounts for 5 to 10% (52,138). 
Although less significant than C. jejuni, C. coli can rank among the top four causes of 
enteric infection in people (139). Campylobacter infections in people are generally 
sporadic. This, along with the ubiquity of Campylobacter in many food animals, and the 
lack of an effective typing system, has hindered understanding the risk factors for 
infection (140).  
 
Poultry are the primary reservoir of C. jejuni while pigs are a reservoir for C. coli 
(133,141,142). Almost all swine herds are Campylobacter positive and most pigs carry 
Campylobacter at slaughter (70 to 100%) (39,142,143). The importance of pigs and pork 
as a source of human campylobacteriosis is unclear (144-146). Many risk factor studies 
aggregate C. jejuni and C. coli cases (144). Because C. coli accounts for a small 
proportion of cases, risk factors unique to C. coli are likely to be missed (147). This may 
explain the discrepant findings of pork as a risk factor for C. coli infection (144-146).  
 
 A Canadian study investigated the relationship between Campylobacter from 
healthy pigs and ill people (148). Geographically and temporally related isolates had low 
relatedness. However, the clinical relevance of this null finding was difficult to interpret 
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because all species of Campylobacter were included (148). A case-case study conducted 
in England and Wales compared C. jejuni (controls) to C. coli (cases). A significant risk 
factor for C. coli infection was eating paté, which is commonly made with pork liver 
(147). This suggests that pork may play a role in C. coli infections in people. In contrast, 
a recent molecular epidemiological investigation found C. coli from ill people were 
closely related to isolates from poultry, including turkeys and ducks, but not to isolates 
from pigs (140). While risk factors for C. coli infection require more investigation, AMR 
in Campylobacter from pigs warrants investigation because macrolide resistance is highly 
prevalent and quinolone resistance is regularly observed (149-151).  
 
No published studies have described AMR in Campylobacter from pigs on 
Canadian farms. A few have been conduced in the United States (100,152,153). The 
annual reports released by CAHFSE in 2003 – 2004 and 2004 – 2005 described 
Campylobacter AMR in nationally representative herds (39,100). In 2004 – 2005, broth 
microdilution susceptibility testing was used rather than the Etest®. Results were 
markedly different between years thus both reports are discussed. Knowledge of 
Campylobacter AMR in Canadian pigs is limited to abattoir based studies from Ontario 
and Quebec (149,151).  
 
Although not every drug was tested in every study, Campylobacter spp. were 
most commonly resistant to tetracycline (range, 35 to 83%), erythromycin (28 to 77%), 
azithromycin (28 to 67%) and clindamycin (0 to 59%) (39,100,149,151-153). For these 
antimicrobials, the lowest resistance was reported by CAHFSE in 2004 – 2005. The 
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opposite situation occurred with chloramphenicol resistance; all studies reported 3% or 
less resistance except CAHFSE (2004 – 2005) which reported 24%. Of the above studies, 
CAHFSE (2004 – 2005) was the only study using broth microdilution for susceptibility 
testing. It was also the only report that did not provide the breakpoints used (39). These 
factors could account for the difference from other reports and the previous CAHFSE 
report (100,149,151-153). In all reports, resistance to nalidixic acid ranged from three to 
eleven percent. Ciprofloxacin resistance was minimal (<3%) with the exception of C. coli 
from Quebec pigs (11% resistance) (39,100,149,151-153).  
 
In the United States, AMR in Campylobacter spp. from pigs raised in 
conventional and ABF herds has been described (153). Less than 10% of the isolates 
were resistant to chloramphenicol, ciprofloxacin, gentamicin and nalidixic acid, and 
resistance was not significantly different between herd types. In contrast, over half of the 
isolates were resistant to tetracycline and erythromycin and these resistances were more 
common in conventional herds. Conventionally raised pigs received oxytetracycline and 
tylosin in nursery and finisher feed, which suggests antimicrobial exposure increases 
certain Campylobacter resistances (153). Environmental factors also appear important in 
Campylobacter resistance. In ABF herds, tetracycline and erythromycin resistance was 
significantly higher in pigs raised indoors compared to outdoors. As in the previous 
study, chloramphenicol, ciprofloxacin, gentamicin and nalidixic acid resistance was less 
common and not associated with herd type (152). Management factors, including housing 
and feeding practices, appear important in the epidemiology of Campylobacter AMR 
(151-154).  
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 There is a temporal correlation at the ecological level between the approval of 
fluoroquinolones for use in livestock and emergence of resistant Campylobacter in 
animals and people (133,134). Biologically it is plausible that fluoroquinolone use 
contributed to resistance in porcine Campylobacter. This is supported by experimental 
evidence; pigs exposed to enrofloxacin for five days had more resistant C. coli than 
controls and resistance persisted for 35 days post-exposure (155). However, risk factors 
other than fluoroquinolone use also appear to exist. Ciprofloxacin resistant 
Campylobacter have been found in Canadian pigs and on ABF farms in the United States 
(49,149,151-153). The ABF farms reported no fluoroquinolone exposure. No 
fluoroquinolones are licensed for use in Canada for pigs. It is possible that pigs in Canada 
could be exposed to fluoroquinolones if enrofloxacin (Baytril 100®), which is licensed for 
therapeutic use against respiratory disease in beef cattle, were used off-label or if 
fluoroquinolones were imported and used as active pharmaceutical ingredients (49). An 
on-farm study in Switzerland considered herd health variables as risk factors for AMR in 
Campylobacter from finisher pigs (154). Data quality prevented considering 
antimicrobial exposure, so herd health variables acted as a proxy. Every outcome 
(resistance to ciprofloxacin, erythromycin, streptomycin, tetracycline, and resistance to 
three or more drugs) was associated with health problems such as lameness, coughing 
and tail chews. The odds of ciprofloxacin resistance were three times higher in herds with 
tail-biting, even though fluoroquinolones are not a recommended treatment for this 
problem. However, the odds of ciprofloxacin resistance decreased with lameness in 100-
kg pigs (Odds Ratio (OR) = 0.3) and coronary band lesions in 30-kg pigs (OR = 0.3). 
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Ciprofloxacin resistance was the only outcome that occurred less frequently in herds with 
health problems. These counter-intuitive risk factors may be the result of type I error; 
however, it is concerning that no biologically plausible risk factors were identified. These 
findings, along with ciprofloxacin resistant Campylobacter in fluoroquinolone naïve pigs 
in North America, raise questions about the source of fluoroquinolone resistance 
(148,149,152-154). Considering the public health importance of fluoroquinolone resistant 
Campylobacter, identifying risk factors for this resistance should be a priority for on-
farm AMR studies.  
 
Pork is a potential source of C. coli as the majority of healthy market-ready hogs 
are carriers (142,143). Although the role of pork in human infection is unknown, frequent 
resistance to macrolides and observed resistance to ciprofloxacin is extremely concerning 
(39,149,151). More on-farm studies are needed to identify risk factors for antimicrobial 
resistance in this potentially zoonotic pathogen. 
 
2.7 Conclusions and Rationale for this Study 
This review described the public health significance of antimicrobial resistant 
Salmonella, E. coli and Campylobacter in pigs, depicted the current situation on swine 
farms in North America, and discussed known risk factors for resistance. Developing on-
farm control strategies for AMR requires more knowledge of how resistance varies 
regionally within Canada and between swine farms within a region. These findings, along 
with continued evaluation of on-farm risk factors, may identify production practices that 
either create unacceptable risks or could be changed easily and economically.   
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Together, Alberta and Saskatchewan produce more than 20% of Canada’s market 
hogs (45). Despite this, the data describing AMR in western Canadian pigs are scarce. 
Only Salmonella from grow-finish pigs in Alberta, and E. coli from 10 swine herds in 
British Columbia, have been described. Antimicrobial resistance in Campylobacter has 
not been investigated on-farm anywhere in Canada. Finally, there is a lack of semi-
quantitative antimicrobial exposure data in Canada. These data are needed to improve 
risk factor analyses describing antimicrobial use and resistance thus furthering 
understanding of the selective pressures created by antimicrobials for resistance.  
 
Based on these knowledge gaps, this thesis was designed to address these research 
objectives: 
• To describe the incidence of antimicrobial exposure of pigs on farms in 
Alberta and Saskatchewan.  
• To describe the prevalence of phenotypic antimicrobial resistance in 
Salmonella, E. coli and Campylobacter from healthy pigs on farms in 
Alberta and Saskatchewan.  
• To describe the association between antimicrobial use and phenotypic 
antimicrobial resistance in E. coli from healthy grow-finish pigs. 
• To describe the genetic basis of antimicrobial resistance in E. coli from 
healthy grow-finish pigs. 
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CHAPTER 3 
ANTIMICROBIAL USE THROUGH FEED, WATER AND INJECTION IN PIGS ON-
FARMS IN ALBERTA AND SASKATCHEWAN, CANADA 
3.1 Introduction 
Antimicrobial resistance is an animal welfare and public health problem; resistant 
bacterial infections are associated with greater morbidity, mortality and expense than 
their susceptible counterparts (1-4). Agricultural antimicrobial use (AMU) provides many 
benefits to livestock and producers including disease treatment, prevention and growth 
promotion (5). However, it also increases the prevalence of resistant bacteria, some of 
which are zoonotic (6-9). Despite this, descriptions of the quantities and reasons for 
antimicrobial use in Canadian livestock are scarce. This knowledge gap impedes our 
understanding of the link between antimicrobial use and antimicrobial resistance in food 
animals.  
 
Antimicrobial use in North American pigs has been investigated through targeted 
research projects in Ontario and Alberta and national surveys in the United States (10-
15). This project used on-farm records to describe the antimicrobial exposure incidence 
through feed, water and injection of suckling, nursery, grow-finish pigs and sows over 12 
months.  
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3.2 Materials and Methods 
3.2.1 Herd selection and data collection 
Twenty farms were enrolled in the study by eight swine veterinarians in 
Saskatchewan (thirteen farms) and Alberta (seven farms). Each veterinarian enrolled two 
to four farms that met the study inclusion criteria of a minimum of 100 sows and 
enrollment in the Canadian Quality Assurance® (CQA®) Program (16). Each herd was 
visited once between May and September of 2004. A study veterinarian collected data 
from the herd owner or manager on antimicrobial use in the previous 12 months. Data 
were obtained from CQA® forms and by the completion of supplemental questionnaires 
that further described the antimicrobial use, herd inventory and animal flow through 
production (Appendix A). The data were organized using a relational database (Microsoft 
Access, Microsoft Corporation, Redmond, WA, USA) and descriptive statistics were 
calculated with Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA).  
 
3.2.2 Feed and water (group) exposure 
The following data were collected on antimicrobial exposures through feed or 
water in the previous 12 months: the production phase exposed, antimicrobial used, 
number of pigs exposed, duration of exposure, concentration of drug administered and 
reason for drug use. The group antimicrobial exposure incidence (AEIG) per 1000 pig-
days was determined for each use (Equation 1). Each day antimicrobials were offered 
was an exposure event. Every herd had open populations with animals entering and 
leaving the herd during previous 12 months. The pigs-at-risk was the average number of 
pigs moved into and out of each phase over this time. This assumed mortality and culls 
occurred, on average, halfway through each phase. The time-at-risk was the average 
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number of days spent in each phase. Time-weighted averages accounted for groups of 
pigs within a phase with different durations at risk. This occurred in herds where animals 
were sold as breeding stock or where batches of nursery pigs were sold at a younger age 
than the typical transfer age to grow-finish. Combination drug products were considered 
a single exposure regardless of the number of antimicrobials they contained with one 
exception. These exposures were stratified into the constituent drugs when describing 
exposure to individual antimicrobials. 
 
Equation 1. Formula for Group Antimicrobial Exposure Incidence (AEIG) 
AEIG = [(Pigs E* Days E) / (Pigs R * Days R)] * 1000 
E = exposed 
R = at risk 
 
3.2.3 Parenteral (individual) exposure  
Data on parenteral antimicrobial use in the previous 12 months were obtained 
through one of two methods. When existing records were unvavailable, a survey was 
administered by the study veterinarian (A.6). This survey collected data on the typical 
frequency of antimicrobial exposures, the most commonly used antimicrobials, typical 
dose, duration and reason for use. In herds with parenteral exposure records, data were 
entered into the database at the level of detail maintained in each herd. These data sources 
were used with herd inventory to calculate the parenteral antimicrobial exposure 
incidence (AEIP) (Equation 2). All pig exposures to a drug within five days were 
considered a single exposure because the existing records in many herds only indicated if 
a pig had been exposed, not the number of times. This is was the only difference between 
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individual and group antimicrobial exposure incidences. In some herds, data were 
missing due to records having been lost or not maintained for portions of the previous 
twelve months. In these cases, the parenteral antimicrobial exposure incidence (AEIP) 
was adjusted by multiplying the denominator by the percent of records available. Data 
were assumed to be missing at random.  
 
Equation 2. Formula for Parenteral Antimicrobial Exposure Incidence (AEIP) 
AEIP = Pigs E / [Pigs R * Days R * percent records available] 
 
3.2.4 Exposure by all routes 
Total antimicrobial exposure for each phase, of each herd, was the sum of the 
feed, water and parenteral exposure incidences. On any day, a pig could be exposed by 
every route resulting in a maximum of three exposures per pig-day. Antimicrobial 
exposure by any route reflected the exposure by feed, water or injection and was the sum 
of these incidences constrained to a maximum of one. 
 
3.2.5 Statistical analysis and data comparisons 
Statistical models were adjusted for clustering in herds through generalized 
estimating equations (PROC GENMOD, SAS version 9.1 SAS Institute Inc., Cary, North 
Carolina). All models had a logit-link function, binomial distribution, exchangeable 
correlation structure, and were adjusted for the production phase exposed. Associations 
were reported as statistically significant if P < 0.05. The association between each 
outcome and variable of interest was reported as an odds ratio (OR = expβ) with 95% CI 
(17). 
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 Binomial response models estimated the probability of exposure to an 
antimicrobial by any route, by feed, by water, or by injection for pigs in each production 
phase. The outcome was the number of exposure events in the numerator and the pig-
days-at-risk in the denominator. Model convergence was a problem when estimating 
exposure by water. Therefore, this model was restricted to exposures of nursery pigs, 
grow-finish pigs and sows because no water exposure occurred in suckling piglets. The 
probability of exposure was estimated by the effect estimate (β) and 95% confidence 
intervals in the formula 1/[1 + exp(-β)] (17). Significant pair-wise comparisons between 
phases, within routes, were noted.  
 
The difference between the two methods used to collect parenteral AMU data was 
investigated by considering the data source, ‘survey’ versus ‘existing records’, as a 
predictor of AEIP. Similarly, the possibility that the study inclusion criteria were 
associated with antimicrobial exposure was investigated. Two separate analyses 
examined the association of exposure by any route and with herd size and veterinary 
practitioner.  
 
3.3 Results 
Antimicrobial exposure was most frequent in nursery pigs. Exposure of grow-
finish and suckling pigs was less than half that of nursery pigs. Antimicrobial exposure in 
sows was comparatively low (Table 3.1). Feed was the predominant route of 
administration for all production phases with 88% of the exposure incidence through 
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feed, 9% through water and 3% through injection. Grow-finish pigs in two herds were not 
exposed to any antimicrobials. In every other herd, pigs in all production phases had 
some antimicrobial exposure. 
 
In every phase, the probability of exposure through feed was almost identical to 
exposure by all routes (Table 3.1). The probability of exposures by feed, and by all 
routes, was significantly different between every production phase except suckling 
piglets and grow-finish pigs. The probability of exposure through water was negligible 
for all phases except nursery pigs. This was reflected by a significantly higher probability 
of exposure in nursery pigs compared to the other production phases. Finally, the 
probability of parenteral antimicrobial exposure was significantly higher in suckling 
piglets than in other production phases.  
 
3.3.1 Group exposure  
Existing records were available in every herd describing the herd inventory and 
animal movement through each production phase. Additionally, in every herd CQA® 
records were available describing in-feed antimicrobial use. The herd representative was 
able to provide supplemental data beyond these records describing the administration of 
antimicrobials through feed and water. One herd representative reported no antimicrobial 
use through feed in any production phase. Of the other nineteen, all added antimicrobials 
to nursery diets, fifteen to grow-finish diets, ten to suckling piglet diets (commonly 
referred to as creep diets) and eight to sow diets (Table 3.1). Reflecting the pattern seen 
with exposure by all routes, the median exposure of nursery pigs was twice any other 
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production phase. Chlortetracycline, lincomycin, tiamulin and tylosin were the 
predominant drugs administered through feed (Table 3.2).   
 
Producers reported more than 90% of the antimicrobials added to sow diets were 
to treat disease compared to less than 20% in the other pig phases (Table 3.3). The 
opposite occurred with AMU for disease prevention. Producers reported that roughly 
80% of creep and nursery diet exposure was to prevent disease compared to less than 
10% of the incidence in sows. The only production phase with substantial growth 
promotion AMU reported was grow-finish (Table 3.3).  
 
Antimicrobials were administered by water in ten herds; six producers reported 
use in nursery pigs only, two in nursery and grow-finish pigs, one in grow-finish pigs 
only and one in sows. In herds with water antimicrobial use, the median nursery 
incidence was many times higher in than the other phases (Table 3.1). In nursery pigs, the 
predominant reason for water exposure was to prevent disease. The reported reason for 
all use in grow-finish pigs and sows was to treat disease (Table 3.3). In nursery and grow-
finish pigs, the most commonly used antimicrobial was penicillin G (Table 3.4). 
 
3.3.2 Parenteral exposure  
The availability of parenteral exposure records differed markedly between herds. 
One herd had no existing records and one provided records for all production phases. 
Overall, on-farm records were supplied for parenteral exposure of suckling pigs in 1 herd, 
nursery pigs in 4 herds, grow-finish pigs in 19 herds, and sows in 12 herds. For all 
production phases, 12 months of data were collected from most herds. The minimum 
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collected was eight months. The data maintained differed between herds; all recorded the 
antimicrobial used, production phase exposed, and number of pigs exposed, while the 
dose and duration of exposure was variable. With one exception, producers unable to 
supply parenteral exposure records completed a survey describing their AMU. Data from 
one herd were insufficient to calculate the AEIP in the nursery. 
 
Every producer administered parenteral antimicrobials to suckling piglets and 
sows, one reported no use in nursery pigs, and five reported no use in grow-finish pigs. 
Suckling piglets were routinely injected in nine herds; all piglets were injected once in six 
herds, and twice in three herds. All sows were routinely injected with an antimicrobial 
after farrowing in one herd. For all phases, the parenteral exposure incidence was very 
low relative to exposure by feed or water (Table 3.1).  
 
Although suckling piglets received the most parenteral antimicrobials, records 
were least available for this phase. Therefore, the most common products used in 
suckling piglets were described from survey data. Fourteen producers listed penicillin G 
as one of the two most common drugs used in their suckling piglets, nine listed 
trimethoprim-sulfadoxine and six listed ceftiofur. Other antimicrobials mentioned less 
frequently were oxytetracycline, spectinomycin and gentamicin. In the other phases, the 
description of parenteral products used was based on existing records becauset this 
allowed comparison based on the exposure incidence rather than the relative ranking by 
producers. Penicillin G was used in every herd and trimethoprim-sulfadoxine was used in 
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most (Table 3.5). Some antimicrobials were used in only a few herds, but were used 
extensively in those herds.  
 
Study herds had a median of 456 sow (Inter-quartile range, 274 to 1042). 
Exposure by any route was not associated with the herd size (P = 0.3) or the veterinary 
practitioner (P = 0.1). The AEIP was higher in herds providing data by survey compared 
to existing records (OR, 2.9; 95% CI, 1.5 to 5.6; P = 0.002).  
 
3.4 Discussion 
This study used on-farm records to describe the antimicrobial use in 20 swine 
herds in western Canada. Pigs received antimicrobials primarily by feed and secondarily 
by water. As data describing feed and water exposures were consistently available on 
every study farm, we determined that existing farm records are a feasible way to describe 
group medication rates. A previous study described injectable exposure rates from 
purposively collected data (12). Demonstrating that sufficient on-farm data were 
available to calculate a rate-based description of AMU for group exposures is an 
important advancement for describing antimicrobial use in Canadian pigs.  
  
Antimicrobial use differed significantly between the production phases. 
Biological differences likely account for the high parenteral exposure of suckling piglets 
compared to older animals. Feed and water dosage regimens are inappropriate for treating 
disease in suckling piglets because consumption is low and variable (18). Both biological 
and production differences could explain the higher exposures in nursery and grow-finish 
pigs compared to breeding stock. Growing animals are more susceptible to many 
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respiratory and gastrointestinal infections due to waning maternal immunity, mixing and 
other stressors. Additionally, growing animals may be exposed to antimicrobials to 
improve growth (18,19). To address these differences, AMU guidelines must be 
production phase specific. When evaluating the effect of guidelines on AMU, data should 
be stratified by phase because herd-level estimates could mask substantial phase-level 
changes.  
 
The high probability of nursery pig exposure raises two food safety concerns. 
First, pigs marketed substantially below the typical live-weight of 110 kg (commonly 
known as barbeque hogs) exceed maximum drug residue limits more often than market 
age animals or sows (20). Second, antimicrobial exposure in nursery pigs is associated 
with increased antimicrobial resistance in market age animals (8,21-23). Producer 
education on responsible drug use appears to have decreased residue violations (20). This 
suggests education has the potential to change AMU practices associated with 
antimicrobial resistance.  
 
Not only did AMU vary between production phases, it also varied substantially 
between herds, within phases. Most notably, the grow-finish feed AEI ranged from 0 to 
1000 exposures per 1000 pig-days. This is partially explained by growth-promotional 
use, which could be a target for judicious use campaigns since benefits decrease as pigs 
age (19). Variation between herds could also be due to different disease pressures, facility 
designs and production practices. Investigating if these factors are associated with AMU 
might identify practical interventions to decrease pig exposures.  
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 Tylosin use in feed was notable considering macrolides are classified as being of 
‘high’ or ‘critical’ importance to human health (24-26). Given the variable exposures 
between herds, targeted judicious-use campaigns might alter the use of this drug. 
However, before efforts to change drug use practices are undertaken, veterinarians, 
producers and policy-makers need to know if effective alternatives are available. This 
ensures the continued health and welfare of the livestock that may be affected by a drug 
ban or changes in label use.  
 
The AEIG illustrated the relatively minor contribution of water antimicrobials to 
mass medication exposure; a fact that was not elucidated by previous qualitative 
descriptions (13,14). This project did not investigate the appropriateness of antimicrobial 
use. However, using penicillin G in water warrants comment because it is largely 
degraded in gastric acid and poorly absorbed with oral administration (27,28). Swine 
veterinarians have traditionally recommended penicillin G because alternative beta-
lactam formulations, such as penicillin V, are not registered for use in food animals in 
Canada, and amoxicillin has just recently been registered for swine in Canada (29). This 
suggests that limited treatment choices can result in inappropriate AMU.  
 
The AEIG had two limitations. First, it was a semi-quantitative measure of AMR 
as it did not reflect the amount of antimicrobials consumed. Study farms provided data on 
the duration of antimicrobial exposures but not the pig weights or feed / water 
consumption estimates. This precluded calculating the amount of antimicrobials 
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consumed in study herds. Others have applied standard animal weights and feed budgets 
to similar data to approximate consumption (30). In contrast, AMU was presented as an 
incidence for two reason: to demonstrated the available on-farm data and to avoid 
imprecise exposure estimates. The precision of the exposure estimates was important 
because the antimicrobial exposure data were used in risk factor analyses that assume no 
error in the predictor variables (Chapter 7 and 8) (17). The second limitation of the AEIG 
was it described the intention to expose pigs to antimicrobials and assumed every animal 
consumed the offered feed or water. This means creep feed estimates overstated exposure 
because consumption in suckling piglets is low and variable, and feed wastage is not 
accounted for (18). Future studies should consider validating exposure data collected 
from existing records by comparing reported values to feed tags, invoices or 
disappearance. This study was unable to validate drug-use estimates as the data were 
collected retrospectively. 
 
Describing parenteral exposure was more challenging than feed or water 
exposure. Parenteral AMU records for nursery and suckling piglets were not available in 
most herds because, at the time of data collection, the CQA® program required producers 
to maintain records only for animals over 22 kg (16). Sow exposure data were not 
available in some herds because records were maintained on sow cards that traveled with 
the sow and were often not retained between parities. In addition to a lack of records, two 
concerns arose with estimating AEIP from existing records. First, the records supplied by 
most herds only indicated that pigs were exposed, not the number of exposures in the 
treatment regimen. This made it impossible to describe multiple exposures to a product 
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within five days. Secondly, AEIP was significantly different depending on the data 
source: the odds of exposure were three times higher for pigs in herds reporting AEIP by 
survey than by existing records. Although the surveys could have overestimated use, 
others have found treatment records underestimated injectable use by 35% compared to 
inventory disappearance (12). It is plausible that the existing records underestimated the 
AEIP because these were often kept in the rooms with the pigs and would be subject to 
loss and damage. Additionally, in times of staff shortages or disease outbreaks it is 
plausible that treatments may not be recorded.  
 
 The herd representatives that complete parenteral antimicrobial use surveys 
described the typical exposure rates, reasons for antimicrobial use and doses. However, 
antimicrobial use may be inconsistent across seasons or groups of pigs. The producer’s 
estimate of drug use could be biased by the current rate of use in the barn: resulting in an 
over or under estimation of the true exposure incidence. As the study was retrospective, 
we were unable to assess the extent of this potential bias. The second limitation of the 
parenteral exposure survey was the failure to describe the proportion of treatment 
incidence attributable to different antimicrobials. Producers listed the two most 
commonly used antimicrobials in the production phase as well as the first and second 
choice treatments for common disease problems. However, data were insufficient to 
estimate the exposure incidence by antimicrobial. This was a serious limitation: it limited 
the number of herds in the description of AEIP by product and precluded considering 
AEIP in risk factor analyses for AMR (Chapter 7 and 8).  
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Considering the small contribution of parenteral exposure to total use, it is 
unlikely that bias from existing records substantially affected total exposure estimates. 
However, in light of the problems identified with collecting parenteral exposure data, 
future studies should attempt to validate existing records or seek alternative methods for 
estimating parenteral antimicrobial exposure.  
 
The exposure incidence to antimicrobials that were used in both parenteral and 
oral forms was dominated by the feed and water exposure; parenteral exposure could be 
considered negligible relative to oral exposure. However, quantifying the exposure to 
drugs used only as parenteral products, such as ceftiofur and trimethoprim-sulfadoxine, 
was valuable. The World Health Organization (WHO) considers third generation 
cephalosporins critically important for human health, thus researchers may be interested 
in evaluating the associations between ceftiofur use and AMR (25). The relatively low 
rates of exposure, and number of herds with no use, indicate case-control studies would 
be a feasible way to investigate such associations (17).  
 
The herd selection, and the study inclusion criteria, could have affected AMU 
estimates. However, given that the associations between antimicrobial exposure and 
veterinarian and herd size were not significant, it is unlikely that the inclusion criteria 
substantially biased AMU estimates. This study was limited to herds with more than 100 
sows to better represent market hog production in western Canada. Although 70% of 
Saskatchewan pig farms marketed less than 1000 pigs in 2004 (which roughly 
corresponds to herds of 50 sows or less) these farms marketed less than 3% of 
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Saskatchewan’s pigs (31). The herds enrolled in this study were a convenience sample 
based on the presence of a veterinary – client – patient (VCP) relationship. This could be 
important considering, in the United States, producers with a VCP relationship were more 
likely to use feed grade antimicrobials than those without (32). All study herds were 
enrolled in the CQA® program (16). While this may have affected AMU, the herds were 
reflective of western Canada at the time of the study: 98% of market hogs produced in 
Alberta and 99.8% in Saskatchewan came from herds enrolled in the CQA® program 
(Personal communication: Harvey Wagner, Sask Pork; Sarah Turner, Alberta Pork).  
 
The semi-quantitative description of AMU made it difficult to compare these data 
to previous reports. However, the proportion of herds with antimicrobials administered 
by each route, and the most commonly used products, were similar to an Alberta based 
survey of 90 swine herds conducted in 2000 (14). Combining the detailed, semi-
quantitative data from this study with the robust, but qualitative, data from the previous 
larger study provides a detailed account of antimicrobial use in this important swine-
producing region of Canada (14). Future research should investigate if descriptions of 
exposure incidence, common dosage regimens, and feed budgets can be applied to 
qualitative data to estimate the volume of antimicrobials used in Canadian pigs. If 
validated, authorities could efficiently respond to international recommendations that 
countries monitor and report antimicrobial use in livestock (33,34). 
 
This description of feed and water antimicrobial exposure incidence is unique in 
Canadian pigs. This project illustrated the variability in AMU between phases and herds. 
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Identifying the reasons for these variations might focus future interventions to decrease 
AMU. Most importantly, this study demonstrated that on-farm records were sufficient to 
describe pig antimicrobial exposure through feed and water.  
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Table 3.1 Probability and 95% confidence intervals of antimicrobial exposure by a given 
route per pig-day (all, n = 80 (20 herds with four production phases per herd); feed, n = 
80; injection, n = 79; water, n = 60 (20 herds with three production phases per herd)) and 
distribution of the antimicrobial exposure incidences per 1,000 pig-days of each 
production phase in herds with an incidence greater than zero (N = 20 herds). 
 
AEI in herds reporting use 
Phase 
Administration 
Route* 
Probability 
of 
exposure 
95% 
confidence 
interval Herds Median IQR** 
Suckling All routes b,d 0.21 0.08 - 0.46 20 95 34 - 403 
 Feed b,d 0.17 0.05 - 0.44 10 333 276 - 492 
 Water - - 0 - - 
 Parenteral b,c,d 0.04 0.02 - 0.07 20 29 11 - 57 
        
Nursery All routes a,c,d 0.79 0.56 - 0.92 20 677 327 - 1019 
 Feed a,c,d 0.78 0.55 - 0.92 19 667 394 - 1000 
 Water c,d 0.06 0.02 - 0.19 8 200 125 - 514 
 Parenteral a 0.001 .0004 - .002 18 1 0 - 1 
       
Grow- All routes b,d 0.31 0.16 - 0.51 18 455 108 - 927 
finish Feed b,d 0.31 0.16 - 0.51 15 714 160 - 977 
 Water b 0 0 - 0.001 3 5 3 - 8 
 Parenteral a,d 0.0003 .0001 - .0009 15 0 0 - 0 
       
Sow All routes a,b,c 0.03 0.01 - 0.09 20 1 0 - 21 
 Feed a,b,c 0.03 0.01 - 0.09 8 49 15 - 197 
 Water b 0 0 - 0.004 1 7 - 
  Parenteral a,c 0.001 .0004 - 0.002 20 1 0 - 1 
* All routes: the probability describes exposure by any route (maximum probability of 
one) while median and IQR describes the total antimicrobial exposure (maximum of three 
per pig-day)  
** IQR: Inter-quartile Range 
a: different from suckling piglets (P < .05) 
b: different from nursery pigs (P < .05) 
c: different from grow-finish pigs (P < .05) 
d: different from sows (P < .05) 
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Table 3.2 Antimicrobial exposure incidence per 1,000 pig days through feed, by product, 
in herds with an exposure incidence greater than zero (N = 20). 
 
    Feed antimicrobial exposure incidence 
Phase Antimicrobial Herds Median IQR 
Suckling Chlortetracycline 5 333 232 - 455 
 Tiamulin 4 184 29 - 465 
 Lincomycin 3 700 333 - 778 
 Spectinomycin 3 700 333 - 778 
 Penicillin G 3 286 190 - 333 
 Sulfonamides* 3 286 190 - 333 
 Tylosin 1 286 - 
      
Nursery Chlortetracycline 13 226 198 - 614 
 Lincomycin 10 433 248 - 826 
 Tiamulin 9 264 190 - 475 
 Spectinomycin 6 319 137 - 525 
 Tylosin 5 316 257 - 750 
 Penicillin G 4 175 126 - 221 
 Sulfonamides* 4 175 126 - 221 
 Tilmicosin 1 200 - 
 Oxytetracycline 1 173 - 
 Neomycin 1 173 - 
      
Grow- Tylosin 11 500 111 - 953 
finish Lincomycin 5 697 217 - 1000 
 Chlortetracycline 1 720 - 
 Tilmicosin 1 52 - 
 Penicillin G 1 24 - 
 Sulfonamides* 1 24 - 
     
Sow Oxytetracycline 3 37 16 - 233 
 Chlortetracycline 2 99 - 
 Lincomycin 2 18 - 
 Tylosin 1 300 - 
 Penicillin G 1 64  
* the specific sulfonamide used was not available in all herds 
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 Table 3.3 Percent of group antimicrobial exposure incidence (AEIG) according to 
producer-declared reason for antimicrobial use. 
 
  Percent group antimicrobial exposure incidence 
Route Phase 
Disease 
Treatment 
Disease 
Prevention 
Growth  
Promotion 
Feed Suckling 18.5 81.5 0.0 
 Nursery 12.9 79.9 7.2 
 Grow-finish 10.8 47.1 42.1 
 Sow 93.0 7.0 0.0 
     
Water Nursery 13.6 86.4 - 
 Grow-finish 100.0 0.0 - 
 Sow 100.0 0.0 - 
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Table 3.4 Antimicrobial exposure incidence per 1,000 pig-days through water, by 
product, in herds with a treatment incidence greater than zero (N = 20). 
 
    
Water antimicrobial exposure 
incidence 
Phase Antimicrobial Herds Median 1QR 
Nursery Penicillin G 4 252 194 - 823 
 Neomycin 3 71 12 - 600 
 Sulfonamide* 2 108 - 
 Tetracycline  1 600 - 
 Amoxicillin 1 194 - 
     
Grow-finish Penicillin G 2 6 - 
 Tetracycline  1 5 - 
     
Sow Tetracycline  1 7 - 
* the sulfonamide derivative was not available in all herds 
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Table 3.5 Parenteral antimicrobial exposure incidence per 1,000 pig days, by product, in 
herds with an exposure incidence greater than zero and providing data by existing records 
(Nursery N = 4, Grow-finish N = 19, Sow N = 12). 
 
  Parenteral antimicrobial exposure incidence 
Phase Antimicrobial Herds Median IQR 
Nursery Penicillin G a  4 0.14 0.02 - 0.56 
 Trimethoprim-sulfadoxine 4 0.04 0.01 - 0.45 
 Oxytetracycline 4 0.04 0.01 - 0.18 
 Ceftiofur 2 0.16 - 
 Lincomycin 2 0.04 - 
      
Grow-finish Penicillin G 14 0.08 0.01 - 0.41 
 Trimethoprim-sulfadoxine 8 0.03 0.01 - 0.18 
 Ceftiofur 7 0.01 0.002 - 0.03 
 Oxytetracycline 5 0.05 0.00 - 0.10 
 Lincomycin 4 0.14 0.01 - 0.45 
 Tylosin 3 0.001 0.000 - 0.004 
 Tiamulin 1 0.22 - 
 Ampicillin 1 0.1 - 
      
Sow Penicillin G 12 0.16 0.06 - 0.46 
 Trimethoprim-sulfadoxine 9 0.11 0.02 - 0.23 
 Oxytetracycline 8 0.2 0.01 - 0.61 
 Tylosin 4 0.05 0.01 - 0.11 
 Ceftiofur 3 0.004 0.002 - 0.01 
 Lincomycin 2 0.23 0.01 - 0.45 
 Ampicillin 1 0.03 - 
a: procaine and benzathine penicillin G use could not be distinguished 
 
 
CHAPTER 4 
ANTIMICROBIAL RESISTANCE OF FECAL SALMONELLA SPP. ISOLATED FROM ALL 
PHASES OF PIG PRODUCTION IN 20 HERDS IN ALBERTA AND SASKATCHEWAN, 
CANADA 
4.1 Introduction 
Salmonella spp. are second only to Campylobacter spp. as the leading cause of foodborne 
disease in Canada. Approximately 6,000 to 9,000 cases of human salmonellosis are reported 
annually, and for each reported illness 13 to 37 cases remain unreported (1-3). Antimicrobial 
resistant Salmonella can cause even greater morbidity than their susceptible counterparts due to 
treatment failure, increased infection severity, and increased rates of disease in people taking 
antimicrobials for other reasons (4-7). Although pork is not a major cause of salmonellosis in 
North America, it has been responsible for disease outbreaks of multiresistant Salmonella in 
humans elsewhere (8-10).  
 
Most Salmonella infections are acquired from contaminated food. Therefore, studying 
antimicrobial resistance (AMR) in live, close-to-market pigs indirectly estimates the potential for 
carcass contamination at slaughter and the risk to consumers from resistant organisms in pork 
(11,12). In Canada, Salmonella AMR data are available from pigs at slaughter (13-17). However, 
these data may differ from those acquired on-farm because AMR patterns and serovars can 
change after transport and lairage (18). Extending AMR investigations to other pig categories, 
such as sows and nursery pigs, might improve our understanding of the occurrence and spread of 
AMR within pig production systems. This could lead to identifying control measures. Currently, 
on-farm Salmonella AMR data from healthy pigs in Canada are limited to a longitudinal study of 
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finishing pigs from Alberta (19). The main goal of this study was to investigate and describe the 
AMR profiles of Salmonella isolates from apparently healthy nursery pigs, grow-finish pigs and 
sows in 20 herds in Alberta and Saskatchewan, Canada.  
 
4.2 Materials and methods 
4.2.1 Herd and sample selection 
A convenience sample of 20 farms was allocated to eight swine veterinarians in 
Saskatchewan (13 farms) and Alberta (7 farms). Farms were selected by veterinarians based on a 
minimum size of 100 sows and enrollment with the Canadian Quality Assurance® Program (20). 
The number of farms per veterinarian ranged from two to four. Half of the veterinarians were 
asked to identify the presumed Salmonella status of the herds. Ten herds were enrolled with 
knowledge of the presumed Salmonella status; seven Salmonella-positive and three Salmonella-
negative (based on clinical disease or test results in the previous 12 months) were selected to 
address the needs of a separate research project. The principle investigator and laboratory 
personnel were blind to the presumed herd status. The remaining 10 herds, with an unknown 
Salmonella status, were selected from as many veterinarians as possible in order to minimize 
clustering by geography and management practices.  
 
Each herd was visited once between May and September 2004. Fresh fecal samples were 
collected from pens, which were selected using a random numbers table. Pooled pen samples 
(PPS) consisted of freshly voided feces from five pigs for a pooled sample weight of 
approximately 75 g. In the 10 herds of unknown Salmonella status, 25 PPS were collected from 
grow-finish pigs. In the 10 presumed-known Salmonella status herds, samples were collected 
from each phase of pig production: 20 PPS from sows, 30 PPS from nursery pigs, and 30 PPS 
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from grow-finish pigs. Sow samples were collected from both the farrowing and gestation stages. 
Although each pooled sample contained feces from five sows, animals were often housed in 
individual crates. In addition, 30 individual-animal samples were collected from grow-finish pigs 
and 10 from sows (Figure 4.1). The intensive sampling strategy was implemented on presumed 
known-Salmonella status farms because investigating differences in AMR between production 
phases was a secondary objective to the primary study objective of describing Salmonella AMR 
on swine farms in Alberta and Saskatchewan.  
 
4.2.2 Laboratory methods 
Salmonella isolation. All samples were shipped on ice to one of three laboratories within 
24 h of collection. Samples from ten herds were cultured for Salmonella by Agri-Food 
Laboratories Branch (AFLB), Food Safety Division of Alberta Agriculture, Food and Rural 
Development, Edmonton, AB; samples from four herds by Prairie Diagnostic Services (PDS), 
University of Saskatchewan, Saskatoon, SK; and samples from six herds by Laboratory Services 
Division, University of Guelph, Guelph, ON.  
 
AFLB Food Safety Division of Alberta Agriculture – Edmonton, AB  
Salmonella Typhimurium ATCC 14028 was used as the quality control organism. Unless 
otherwise specified, the incubation temperature was 35° C. A 10 g fecal aliquot per sample was 
pre-enriched in 90 ml of Buffered Peptone Water (BPW) for 20 to 24 h. From the BPW, 0.1 ml 
was transferred into 10 ml Rappaport Vassiliadis (RV) enrichment broth and incubated at 42° C 
for 24 h. Concurrently, 1.0 ml was transferred into 10 ml of Tetrathionate (TT) enrichment broth 
containing 0.2 ml of iodine solution and incubated for 24 h. Aliquots from the RV and TT broths 
(0.15 ml each) were pooled and screened by real-time polymerase chain reaction (RT-PCR) for 
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the presence of Salmonella (21). Following incubation, 10 μl of RV broth and 10 µl of TT broth 
were transferred to Xylose-Lysine-Tergitol 4 Agar (XLT4) and Rambach Agar (RAM) plates 
and incubated for 24 to 48 h. The TT broth (0.1 ml) was transferred to three sites on Modified 
Semi-Solid Rappaport Vassiliadis (MSRV) (Difco) media and incubated at 42° C for up to 72 h. 
Each MSRV plate with a halo was subcultured onto XLT4 and RAM plates. Samples testing 
positive by RT-PCR, but culture negative, were tested with ImmunoMagnetic Separation (IMS) 
technology (DynabeadsTM anti-Salmonella, Dynal® Biotech, ASA, Oslo, Norway). Beads were 
enriched in TT broth and processed as described above. In general, one suspect Salmonella 
colony per sample was selected for further characterization unless morphologically different 
colonies were identified, in which case both were harvested. Isolates were initially screened with 
triple sugar iron agar (TSI), lysine iron agar (LIA), urea agar slants and purity checked using 
one-quarter MacConkey agar and blood agar plates respectively. Isolates were further screened 
with Salmonella Poly 0/01 agglutination (Denka Seiken Co. Ltd. Japan) and atypical colonies 
were tested with Vitek GNI or API-20E (bioMérieux Canada, Inc.). Presumptive Salmonella 
isolates were frozen at -70° C in defibrinated sheep’s blood and sent to the Office International 
des Épizooties (OIÉ) Reference Laboratory for Salmonellosis, Guelph, ON for confirmation by 
serotyping.  
 
Prairie Diagnostic Services – University of Saskatchewan – Saskatoon, SK 
The protocol developed by AFLB was utilized by PDS with minor modifications; RT-
PCR and IMS were not used. Screening differed in that suspect colonies were incubated for 2 to 
4 h in trypticase soy (TS) broth and subsequently tested with a citrate slant rather than LIA. 
Isolates were sent in TS broth to the Saskatchewan Health Provincial Laboratory for serotyping.  
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 Laboratory Services Division – University of Guelph – Guelph, ON 
Health Canada’s standard Salmonella isolation protocol was used with the IMS 
technology (DynabeadsTM anti-Salmonella, Dynal® Biotech, ASA, Oslo, Norway) (22). Suspect 
colonies were tested with TSI, LIA and urea slants to confirm Salmonella status, frozen at -80° C 
in glycerol, and sent to the OIÉ Reference Laboratory for Salmonellosis, Guelph, ON for 
serotyping.  
 
Serotyping and phagetyping 
Office International des Épizooties (OIÉ) Reference Laboratory for Salmonellosis, 
Guelph, ON 
The O antigens of the Salmonella isolates were determined by slide agglutination (23). 
The H antigens were identified using a microtechnique that employs microtitre plates (24). The 
antigenic formulae of Le Minor and Popoff were used to name the serovars (25). The standard 
phagetyping technique described by Anderson and Williams was followed (26). The phagetyping 
scheme and phages for Salmonella Typhimurium, developed by Callow, and further extended by 
Anderson, and Anderson and colleagues, were obtained from the International Centre for Enteric 
Phage Typing (ICEPT), Central Public Health Laboratory, Colindale, United Kingdom via the 
National Microbiology Laboratory (NML), Public Health Agency of Canada, Winnipeg, 
Manitoba (27-30). The Salmonella Heidelburg phagetyping scheme and phages were supplied by 
the NML (31). Isolates that reacted with the phages but did not conform to any recognized phage 
type were considered atypical. Strains that did not react with any of the typing phages were 
considered untypable.  
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 Saskatchewan Health Provincial Laboratory – Regina, SK 
The O antigens of the Salmonella isolates were determined by slide agglutination and the 
H antigens were identified by a broth culture method (32). The antigenic formulae of Le Minor 
and Popoff were used to name the serovars (25). Samples identified as S. Typhimurium 
(including var. Copenhagen), S. Heidelberg or S. Enteriditis were sent to the OIÉ Reference 
Laboratory for Salmonellosis, Guelph, ON for phagetyping as described above.  
 
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was conducted 
by AFLB and PDS using a broth microdilution technique following Clinical and Laboratory 
Standards Institute (CLSI) guidelines (33,34). National Antimicrobial Resistance Monitoring 
System (NARMS) minimum inhibitory concentration (MIC) susceptibility panels CMV7CNCD 
(SensititreTM, TREK Diagnostic Systems, Westlake, Ohio), were used to test isolates for 
susceptibility to 16 antimicrobials across a standard range of dilutions (Figure 4.2). Each isolate 
was grown up on a non-selective media. A 0.5 McFarland standard was made in 5 ml of 
demineralized water, of which 10 µl was transferred into 11 ml of cation-adjusted Mueller-
Hinton broth with TES buffer. A 50 µl aliquot was inoculated into each of the 96 wells on the 
panel. Inoculated plates were incubated and read by the Sensititre ARIS® (Automated Reading 
and Incubation System) (TREK Diagnostic Systems, Inc., Westlake, Ohio). Readings were 
transferred to Sensititre® Automated Microbiology Systems (SAMS) (TREK Diagnostic 
Systems, Inc.) computer software and interpreted according to CLSI breakpoints for animals or 
humans (33,34) (Figure 4.2). The MIC breakpoints for streptomycin, which does not have CLSI 
guidelines, were taken from the National Antimicrobial Resistance Monitoring System 
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(NARMS) 2003 Salmonella report (15). Quality control organisms used were Escherichia coli 
ATCC 25922, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and 
Pseudomonas aeroginosa ATCC 27853.  
 
4.2.3 Data comparisons and statistical analysis 
Culture, serovar and MIC data were maintained in a relational database (Microsoft 
Access, Microsoft Corporation, Redmond, Washington, USA). Intermediate MIC values were 
categorized as susceptible for all analyses (33,34). Isolates susceptible to all drugs in the panel 
were designated ‘pansusceptible’. This definition does not imply isolates are susceptible to drugs 
not on the panel. Isolates resistant to two or more drugs were designated ‘multiresistant’ 
(14,19,35).  
 
Descriptive analyses were conducted using commercially available software (Microsoft 
Excel, Microsoft Corporation, Redmond, Washington, USA). Statistical analyses were 
performed with generalized estimating equations (GEE) to account for clustering of resistance 
within herds (PROC GENMOD, SAS for Windows version 9.1, SAS Institute Inc., Cary, North 
Carolina). All models had a binary outcome, logit-link function, and an exchangeable correlation 
structure.  
 
Null binomial response models estimated the prevalence of pansusceptibility, 
multiresistance and resistance to each drug. From each model the intercept (β0) and 95% 
confidence intervals (CI) were used to calculate population-average prevalence estimates using 
the formula [1 + exp(-β0)]-1 (36). Univariate logistic regression examined the source of isolates 
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(production phase) as a predictor for the following outcomes: resistance to each drug, 
pansusceptibility and multiresistance.  
 
Four additional sets of univariate analyses explored potential biases introduced by study 
design. The factors known prior to susceptibility testing, presumed known versus unknown herd 
Salmonella status, herd size, individual sample versus PPS, and laboratory performing isolation 
were each considered as predictors for drug resistances observed in more than 5% of the isolates. 
Associations between variables of interest and outcomes were reported as an odds ratio (OR = 
expβ) with 95% CI. All associations with P < 0.05 were reported as significant (36).   
 
4.3 Results 
Salmonella was identified in 14 herds with a range of 2 to 95 positive samples per herd. 
Overall, 32% of the samples were positive for Salmonella and 16 samples had two distinct 
isolates harvested, resulting in 468 isolates for susceptibility testing. Thirty serovars were 
identified with nine accounting for 89% of the isolates (Table 4.1). These nine serovars were 
each identified in at least two herds and all except serovar Banana were found in every 
production phase (Table 4.2).  
 
Most of the Salmonella tested (293) were pansusceptible. Fifty-one isolates were resistant 
to one drug on the test panel, 27 were resistant to two, 24 were resistant to three, 61 were 
resistant to four, 10 were resistant to five, and two isolates were resistant to six of the sixteen 
drugs on the test panel. The highest prevalence of resistance was to tetracycline. Every tested 
isolate was susceptible to five of the drugs on the panel (Figure 4.2). All isolates also appeared 
susceptible to amikacin but the status of one isolate was indeterminable because the dilution 
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range did not cross the breakpoint and the MIC was greater than the dilution range. More than 
85% of the isolates from six of the nine most common serovars were pansusceptible (Table 4.1). 
In contrast, only 8% of S. Mbandaka, 20% of S. Typhimurium var. Copenhagen, and 55% of S. 
Derby were pansusceptible (Table 4.1).  
 
Salmonella was isolated from 32% of the nursery samples, 28% of the grow-finish 
samples and 47% of the samples from sows (Table 4.3). A higher percent of nursery, compared 
to grow-finish or sow, isolates demonstrated resistance. This pattern was evident across all drugs 
except trimethoprim-sulfamethoxazole, cefoxitin, and gentamicin (Table 4.4). The probability of 
observing resistance to four of the drugs was significantly higher in isolates obtained from 
nursery pigs than from grow-finish pigs. Likewise, the probability of an isolate demonstrating 
resistance to two of the drugs was higher if obtained from nursery pigs than from sows (Table 
4.4).  
 
Overall, 59% (95% CI, 42 to 75) of the Salmonella were pansusceptible. The majority of 
isolates from sows (74%; 95% CI, 53 to 88) were pansusceptible, as were approximately half of 
the isolates from grow-finish (56%; 95% CI, 36 to 73) and nursery pigs (48%; 95% CI, 26 to 71). 
The odds of an isolate being pansusceptible were significantly higher in sows compared to the 
other production phases (Table 4.4). Multiresistance was observed in 29% (95% CI, 16 to 48) of 
the isolates. The prevalence of multiresistance was higher in isolates from nursery pigs (48%; 
95% CI, 26 to 71) than from grow-finish pigs (26%; 95% CI, 13 to 46) or sows (22%; 95% CI, 
10 to 42). The difference between Salmonella from nursery pigs and sows was statistically 
significant (Table 4.5).  
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 Twenty-nine resistance patterns were identified and nine occurred in more than five 
isolates (Table 4.6). Eight of these nine were found in more than one phase in a herd. Despite 
this, isolates with the same pattern, from the same phase, and same herd, were not always the 
same serovars. Unobserved resistance patterns were also notable; resistance to ampicillin, 
chloramphenicol, streptomycin, sulfamethoxazole and tetracycline (ACSSuT), suggestive of a 
chromosomally located gene cluster (37), was not identified in any isolate. Also noteworthy, the 
13 S. Typhimurium var. Copenhagen phage type 104 isolates were all pansusceptible.  
 
Herd size was associated with resistance to streptomycin; the odds of resistance increased 
1.02 times (95% CI, 1.01 to 1.03; P = 0.003) for every 1000 pigs marketed annually. No other 
resistance outcome was significantly associated with herd size (P > 0.05). Sample type was a 
significant predictor of two resistance outcomes. The odds of resistance to kanamycin were 1.2 
times higher (95% CI, 1.1 to 1.3; P < 0.0001) in isolates from individual animals compared to 
PPS. In contrast, the odds of streptomycin resistance were decreased 0.47 times (95% CI, 0.26 to 
0.86; P = 0.02) in samples collected from individual animals. Resistance to ampicillin, 
chloramphenicol, sulfamethoxazole and tetracycline were not significantly associated with 
sample type (P > 0.1). Finally, knowledge of the presumed herd Salmonella status and laboratory 
performing isolation were not significantly associated with resistance to streptomycin, 
sulfamethoxazole or tetracycline (P > 0.2). For resistance to ampicillin, chloramphenicol, and 
kanamycin, the significance of these variables as predictors of resistance could not be determined 
because all isolates from unknown-status herds were susceptible.  
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4.4 Discussion 
Describing AMR in Salmonella from live pigs reflects the food safety risk for 
contaminated pork while providing insight into the epidemiology of resistance on-farms. 
Different rates of resistance in each production phase shows Salmonella from each pig-class may 
pose unique food safety risks and suggests that resistance is dynamic within barns. Hence, future 
on-farm studies should investigate risk factors for resistance in each production phase. 
Identifying variables associated with changes in resistance between phases might lead to 
interventions to mitigate AMR in Salmonella. 
 
The prevalence of pansusceptible isolates was consistent with previous reports from 
Canada (40 to 53%), and higher than observed in the United States (6%) (13,16,19,38). 
Resistance to both tetracycline and sulfamethoxazole was also similar to previous Canadian 
studies (tetracycline, 38 to 49%; sulfamethoxazole, 21 to 36%) (13,14,16,19). These Canadian 
data contrast with numerous United States studies, which have found more than 80% of 
Salmonella were resistant to tetracycline (17,35,38). Such differences could be partially 
attributable to serovar; in 2004 CAHFSE described 59% of the tested Salmonella as S.  Derby or 
S. Typhimurium (including Copenhagen) while the top two serovars identified by CIPARS 
(Derby and London) accounted for only 31% of the Salmonella isolates. Annual reports for both 
programs noted that AMR patterns were related to serovar. However, other factors in addition to 
serovar must be considered as the two most common serovars in this study matched those 
described by CAHFSE. 
 
Antimicrobials included on the susceptibility test panels were selected based on their 
importance in human, rather than swine, medicine. Hence, resistance to numerous drugs were 
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examined which are not used in Canadian pigs including amikacin, cefoxitin, ceftriaxone, 
cephalothin, chloramphenicol, ciprofloxacin, kanamycin and nalidixic acid (39). Despite the lack 
of pig exposures to these drugs, there was notable resistance to kanamycin and chloramphenicol. 
This study was not designed to explain the source of these resistances; co-selection, cross-
resistance, and clonal resistance are all possible explanations. However, these findings 
emphasize the complexity of antimicrobial resistance in livestock. Finding resistance to drugs 
not used in pigs illustrates that the risk factors for resistance can be complex and multifactorial.  
 
Fluoroquinolones are used to treat invasive salmonellosis in humans, while third-
generation cephalosporins are indicated for Salmonella infections in children. There are few 
therapeutic alternatives to these antimicrobial classes (12,40). Because humans generally acquire 
resistant Salmonella, rather than the resistance developing during treatment, resistance to these 
drugs in isolates from food animals is of utmost importance (12). Like other North American 
reports, no resistance was noted to ceftriaxone, ciprofloxacin or nalidixic acid (15,16,19,38). 
Likewise, no resistance was found to ceftiofur, which contrasts with a report of frequent 
resistance on United States farms (21%) (38). Over 75% of the ceftiofur resistant Salmonella 
described by CAHFSE were serovar Derby (38). Thus, as Canadian swine abattoir surveillance 
has noted changing serovar distributions over time, this report of ceftiofur resistance in the 
United States suggests Canadian authorities and the swine industry should be vigilant for 
emerging third-generation cephalosporin resistance in Salmonella from pigs (38,41).  
 
Antimicrobial resistance studies typically focus on close-to-market pigs to reflect 
consumer-risk from contaminated pork (17,19). However, people can also be exposed to resistant 
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bacteria from pigs through direct contact or contaminated environments (42,43). Additionally, 
resistant bacteria in other pig classes are also a potential food safety hazard. Young animals are 
slaughtered in provincially regulated abattoirs for local consumption (44). Culled breeding stock 
from Canada are predominantly slaughtered in the United States, where this class accounts for 
approximately five percent of slaughtered pigs (45,46). In addition to providing a food safety 
perspective, information on resistance within pig categories provides insight into AMR within 
farms. Nollet et al. also observed less resistance in Salmonella from sows compared to growing 
pigs, but did not corroborate our observation of increased resistance in nursery pigs (47). Others 
have reported relatively more resistance in coliforms from young pigs (48,49). These reports 
speculate that young animals carry more resistant organisms due to increased antimicrobial 
exposure and physiological differences (48,49). Identifying risk factors for resistance in nursery 
pigs is crucial; weaned pigs commonly receive antimicrobials, and in some instances are 
continuously exposed to drugs, which raises concerns about selection for resistance (50,51) 
(Chapter 3). Determining if antimicrobial use in nursery pigs is a risk factor for AMR in 
Salmonella should be a research priority: low-risk drug use practices could be incorporated into 
judicious use guidelines. 
 
Elevated rates of AMR in nursery pigs may also be important in the spread of resistance 
between and within herds. Pigs are often mixed at transition to the grow-finish stage, either with 
other pens or with pigs from other farms. This creates an opportunity for Salmonella, and AMR 
genes, to spread to new animals. Despite this, there was a lower rate of resistance in Salmonella 
from grow-finish pigs. This suggests that resistant Salmonella populations may be unstable 
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within barns. Therefore, there are great potential benefits if studies can explain why Salmonella 
resistance declines as pigs progress to market. 
 
Describing how resistance in Salmonella related to herd and phase was complicated by 
the relationship with serovar. The most common resistance pattern in this study (ampicillin-
kanamycin-sulfamethoxazole-tetracycline) occurred only in S. Typhimurium var. Copenhagen, 
and only in two herds, although S. Typhimurium var. Copenhagen occurred in four other herds 
without this pattern. Describing the relatedness of these isolates might clarify if this resistance 
was due to common selective pressures or the spread of a resistant clone. Such information could 
prove important, as the control efforts to prevent the development of resistance could differ from 
those aimed to suppress a dominant clone. In numerous situations, Salmonella with the same 
resistance pattern and serovar were found in different production phases of the same herd. Thus, 
also describing the relatedness of isolates from different production phases could improve our 
understanding of how resistance spreads and persists within farms. Regardless of how these 
isolates were related, the apparent clustering of serovars and resistance patterns within herds 
helped to put the food safety risk from these Salmonella in perspective. For example, although S. 
Typhimurium var. Copenhagen with resistance to ampicillin, kanamycin, sulfamethoxazole, and 
tetracycline was a common finding in this study, the two herds with these bacteria produced less 
than 2% of the pigs marketed by study herds. This demonstrates why abattoir based monitoring, 
which can sample farms proportionate to the pork supply, can better estimate the food-safety risk 
from resistant Salmonella. 
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The primary weakness of this study was the small number of purposively selected herds. 
Selecting half of the herds with knowledge of the presumed Salmonella status did not appear to 
introduce a systematic bias, as the odds of resistance in these herds were not significantly 
different between herds of known- versus unknown- Salmonella-status. The other herd factor 
known at selection, herd size, was a significant predictor of resistance to streptomycin. By 
excluding herds with less than 100 sows, resistance to streptomycin might have been slightly 
overestimated. However, as most pigs in Saskatchewan and Alberta are raised on large farms, 
restricting this study to herds with more than 100 sows more realistically reflected the source of 
market pigs from these provinces (52). Additionally, this difference is clinically insignificant in 
comparison to the confidence estimates around the streptomycin resistance estimate.  
 
Collecting both pooled and individual samples allowed us to address other research 
hypotheses. Identifying decreased odds of streptomycin resistance and increased odds of 
kanamycin resistance in Salmonella from individual-pig fecal samples compared to pooled pen 
samples is difficult to explain. An investigation of AMR in E. coli from cattle identified a non-
significant trend towards less resistance in pooled, compared to individual, samples (53). Further 
investigation of this issue is needed because recently initiated Canadian and United States on-
farm surveillance programs describe AMR from pooled fecal samples (16,38). Understanding the 
impact of sample type on resistance may influence the interpretation of these reports. 
 
Using three isolation methodologies may have affected Salmonella recovery. However, 
the methods employed by two labs were very similar and this methodology was used on 89% of 
the samples. Culture methods can affect the serovars isolated, which could have introduced bias 
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into the data (35,54). Although this potential bias will continue to hinder efforts to compare 
AMR between labs until Salmonella isolation protocols are standardized, laboratory (and thus 
isolation procedure) was not a significant predictor of resistance to streptomycin, 
sulfamethoxazole or tetracycline. Although MIC testing occurred in two labs, 90% of the isolates 
were tested in one lab and the same MIC panels, methodology and quality control organisms 
were used by both labs to ensure comparability.  
 
In summary, we described the resistance of Salmonella isolates from swine farms in 
Alberta and Saskatchewan. A high frequency of pansusceptibility, no resistance to six of the 
sixteen antimicrobials including ceftiofur and ciprofloxacin, and no resistance in the Salmonella 
Typhimurium DT 104 isolates are all encouraging findings. Even so, the extent of 
multiresistance in these isolates was concerning. Few on-farm studies have described AMR in 
Salmonella from all age categories of pigs (35,47). This project identified many future research 
needs. Age-specific risk factor studies are needed to investigate reasons for differences in 
resistance between production phases. Likewise, further description of the associations between 
resistance and serovar, and how resistance spreads within herds, are needed before effective 
intervention strategies can be designed to control AMR in Salmonella from pigs.  
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Table 4.1 Frequency of the nine most common Salmonella serovars, the number of isolates per 
serovar with any resistance and number of isolates resistant to each antimicrobial (n = 468). 
 
Salmonella Serovar Number of isolates from each serovar resistant to each antimicrobial 
(any resistance /  
all isolates) AMP CEP CHL COT FOX GEN KAN  STR SMX TET
Derby (56/124) - 4 22 12 3 - - 17 24 31 
Typhimurium var. 
Copenhagen (65/81) 58 2 2 - - - 54 9 58 61 
Putten (2/49) - - 1 1 - - - 1 2 2 
Infantis (0/37) - - - - - - - - - - 
I:ROUGH-O:d:l,w (3/34) - - - 2 - - - 1 3 2 
Banana (0/27) - - - - - - - - - - 
Mbandaka (24/26) 1 - - - - - - 19 12 24 
Anatum (1/20) - - - - - - - 1 1 1 
Give (3/19) - - 1 - - - - - 3 - 
All others (21/51) 3 - 5 3 - 1 1 7 11 17 
a: AMP = ampicillin, CEP = cephalothin, CHL = chloramphenicol, COT = trimethoprim-
sulfamethoxazole, FOX = cefoxitin, GEN = gentamicin, KAN = kanamycin, STR = 
streptomycin, SMX = sulfamethoxazole, TET = tetracycline 
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Table 4.2 Distribution of production phases from which nine most common serovars were 
isolated (n = 468). 
 
 
Serovar Total Nursery Grow-finish Sow 
Derby 124 6 83 35 
Typhimurium var. 
Copenhagen 81 24 28 29 
Putten 49 7 25 17 
Infamtis 37 4 22 11 
I:Rough-O:d:l,w 34 15 11 8 
Banana 27 0 27 0 
Mbandaka 26 14 12  
Anatum 20 3 9 8 
Give 19 1 3 15 
All Others 51 9 21 21 
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Table 4.3 Distribution of production phases from which 1394 samples were collected, 452 
Salmonella positive samples were identified and 468 Salmonella isolates were harvested.  
 
Production Sample Samples Salmonella Isolates 
Phase Type Collected (%) Positive (%) Harvested (%) 
Nursery PPS a 255 (18) 81 (18) 83 (18) 
Grow-finish Individual 295 (21) 73 (16) 80 (17) 
 PPS 545 (39) 158 (35) 161 (34) 
Sow Individual 100 (7) 38 (38) 38 (8) 
  PPS 199 (14) 102 (23) 106 (23) 
 Total   1394  452  468  
a: PPS: pooled pen sample 
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Table 4.4 Percent of Salmonella isolates from nursery pigs (n = 83), grow-finish pigs (n = 241) 
and sows (n = 144) resistant to each drug. 
 
Percent resistant 
Antimicrobial Nursery Grow-finish Sow 
Tetracycline b 47.0  27.4  22.9 
Sulfamethoxazole  41.0  16.6 27.8 
Streptomycin a,b 22.9 8.7 10.4 
Ampicillin a 19.3 9.1 16.7 
Kanamycin a 16.9 7.9 15.3 
Chloramphenicol 7.2 7.1 5.6 
Trimethoprim-
Sulfamethoxazole  2.4 3.7 4.9 
Cephalothin a 2.4 0.8 1.4 
Cefoxitin* 0.0 0.4 1.4 
Gentamicin* 0.0 0.4 0.0 
a: significant difference between isolates from nursery and grow-finish pigs (P < 0.05) 
b: significant difference between isolates from nursery pigs and sows (P < 0.05) 
c: significant difference between isolates from grow-finish pigs and sows (P < 0.05) 
* models did not converge because frequency of resistance was too low 
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Table 4.5 Unconditional odds ratios for Salmonella pansusceptibility and multiresistance 
between isolates from each production phase (n = 468). 
 
Outcome 
Risk Factor 
Source of Salmonella 
Odds 
ratio 
95% confidence 
interval P 
Pansusceptible a Sow compared with nursery 3.0 1.2 - 7.8 0.02 
 Sow compared with grow-finish 2.3 1.1 - 4.6 0.02 
 Grow-finish compared with nursery 1.3 0.7 - 2.5 0.37 
      
Multiresistant b Nursery compared with sow 3.2 1.1 - 9.1 0.03 
 Nursery compared with grow-finish 2.6 1.0 - 7.0 0.05 
  Grow-finish compared with sow 1.2 0.8 - 1.9 0.36 
a: pansusceptible defined as susceptible to all sixteen drugs considered 
b: multiresistant defined as resistant to two or more of the sixteen drugs considered 
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Table 4.6 Salmonella spp. resistance patterns observed in more than five isolates; number of 
isolates identified in each production phase, number of herds pattern was identified in, and 
number of serovars with pattern identified. 
 
 Number of isolates Number Number 
Resistance pattern Nursery Grow-finish Sow of Herds of Serovars 
AMP-KAN-SMX-TET 11 15 19 2 1 
TET 1 31 4 4 6 
SMX-STR-TET 5 4 5 4 3 
STR-TET 6 8 0 2 3 
CHL 0 6 1 3 2 
CHL-SMX-STR-TET 5 2 0 1 5 
AMP-KAN-SMX-STR-TET 2 1 3 1 1 
SMX-TET 5 0 1 3 3 
CHL-SMX-STR-COT 0 3 3 1 1 
a: AMP = ampicillin, CHL = chloramphenicol, COT = trimethoprim-sulfamethoxazole, KAN = 
kanamycin, SMX = sulfamethoxazole, STR = streptomycin, TET = tetracycline 
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Figure 4.1 Schematic of herd and sample selection strategy.  
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PPS: pooled pen sample 
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Figure 4.2 Minimum inhibitory concentration distributions, population average prevalence estimates, and 95% confidence intervals for 
resistance to each drug in Salmonella isolates (n = 468). 
   Distribution of Isolates (Count) Across Dilution Ranges 
Antimicrobial Prevalence  95% CI ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512 
Tetracycline 34.5 19.4 - 53.6         329 1     138     
Sulfamethoxazole 26.7 13.3 - 46.3           36 80 193 45   1 113 
Streptomycin 13.6 7.5 - 23.3              413 27 28    
Ampicillin 12.6 3.4 - 36.7       263 60 72 5 6 1 61     
Kanamycin 10.2 2.6 - 33.0          413       55    
Chloramphenicol 5.0 1.6 - 14.3        1 60 265 111 11 20     
Trimethoprim-
Sulfamethoxazole 2.7 0.6 - 11.2    363 83 1   3 2 16        
Cephalothin 1.2 0.5 - 3.4        134 208 83 37 6      
Cefoxitin 0.6 0.2 - 2.2       2 137 207 45 74 3      
Gentamicin 0.2 0.0 - 1.7     382 48 37       1       
Amikacin 0 0.0 - 0.6       73 316 73 5 1         
Amoxicillin-
Clavulanic Acid 0 0.0 - 0.6       315 90 2 54 7        
Ceftiofur 0 0.0 - 0.6      1 191 200 76            
Ceftriaxone 0 0.0 - 0.6     467     1               
Ciprofloxacin 0 0.0 - 0.6 379 50 38 1                   
Nalidixic Acid 0 0.0 - 0.6              41 343 81 3             
Shaded fields indicate the range tested for each antimicrobial. Counts outside of shaded cells indicate isolates with growth in all wells 
within the tested range. For these isolates the actual MIC is greater than that range of dilutions. Vertical double bars mark the 
breakpoint between sensitive and resistant. Bold font indicates the median MIC.  
 
 
 
 
CHAPTER 5 
ANTIMICROBIAL RESISTANCE OF FECAL ESCHERICHIA COLI ISOLATED 
FROM GROW-FINISH PIGS IN 20 HERDS IN ALBERTA AND SASKATCHEWAN, 
CANADA  
5.1 Introduction 
Antimicrobial resistance (AMR) in bacteria from food animals is a worldwide 
public health issue. Zoonotic infections and the transmission of resistance genes to 
commensal and pathogenic bacteria of humans are frequently cited concerns (1-3). The 
frequency of AMR in commensal organisms reflects the selective pressure exerted on 
bacteria to develop resistance and the potential reservoir of resistance genes available for 
dissemination to pathogens (2,4). For these reasons, the World Health Organization 
(WHO) and World Organization for Animal Health (OIÉ) recommend monitoring AMR 
in commensal organisms including E. coli (5,6). Escherichia coli are highly prevalent in 
healthy animals, facilitating comparisons of AMR within and between species (2,7,8).  
 
Pork is among the three most commonly consumed animal proteins in Canada and 
is the most common worldwide (9,10). The frequency of resistance in E. coli from pigs 
sampled at Canadian abattoirs, and pork sampled at retail, has been intermediate between 
chicken and beef (7). This resistance, combined with the extensive use of antimicrobials 
in pork production, (11-13), has created interest in antimicrobial resistant bacteria in pigs.  
 
Previous Canadian studies have considered E. coli from swine farms in Ontario 
and British Columbia, and on-farm surveillance has been initiated (7,14,15). This study 
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investigated AMR in E. coli from apparently healthy grow-finish pigs on farms in Alberta 
and Saskatchewan, Canada. Three analyses described the resistance in these isolates. 
First, unconditional associations between resistance phenotypes described the potential 
for co-selection in these isolates. Second, E. coli was evaluated as a farm-level sentinel 
for AMR in Salmonella. Finally, others have observed that resistance clusters within pigs, 
pens and herds (16-19); this project quantified the variation in resistance between 
isolates, within herds, to determine the value of investigating farm-level risk factors for 
AMR.  
 
5.2 Materials and Methods 
5.2.1 Herd and sample selection 
A convenience sample of 20 farms was allocated to eight swine veterinarians in 
Saskatchewan (13 farms) and Alberta (7 farms). Farms were selected by veterinarians 
based on a minimum herd size of 100 sows and enrollment with the Canadian Quality 
Assurance® (CQA) Program (20). The number of farms per veterinarian ranged from two 
to four. Half of the veterinarians were asked to identify the presumed Salmonella status of 
the herds and 10 herds were enrolled with knowledge of the presumed Salmonella status 
(see accompanying Salmonella paper). Each herd was sampled once between May and 
September of 2004. Fecal samples were collected from 20 randomly selected pens per 
herd. Samples were pooled at the pen level and each consisted of feces from five grow-
finish pigs.  
 
115 
5.2.2 Laboratory methods 
Samples were manually mixed, shipped on ice to a commercial veterinary 
laboratory (Prairie Diagnostic Services (PDS), University of Saskatchewan, Saskatoon, 
SK) and cultured for E. coli within 24 h of collection. Each sample was streaked onto a 
whole Blood Agar and MacConkey plate with a heavily coated cotton swab and 
incubated at 37° C for 18 h. Three lactose-positive colonies were selected from each 
MacConkey plate unless distinct colonies, such as hemolytic and non-hemolytic or 
mucoid and dry were identified; up to six were harvested from those samples. Selected 
colonies were incubated in trypticase soy (TS) broth for 3 to 4 h at 37° C. Each TS broth 
was inoculated onto urea and citrate slants with a 1 µl loop, and a blood agar plate was 
concurrently inoculated to ensure sample purity. These were incubated at 37° C for 18 h. 
Samples requiring further confirmation were tested with Triple Sugar Iron / Indole. Pure, 
confirmed E. coli cultures were frozen in 25% glycerol at -80° C until tested for 
antimicrobial susceptibility.  
 
Antimicrobial susceptibility testing was conducted by the Agri-Food Laboratories 
Branch (AFLB), Food Safety Division of Alberta Agriculture, Food and Rural 
Development, Edmonton, AB and PDS, Saskatoon, SK. Isolates were tested using a broth 
microdilution technique following Clinical and Laboratory Standards Institute (CLSI) 
guidelines (21,22). National Antimicrobial Resistance Monitoring System (NARMS) 
minimum inhibitory concentration (MIC) CMV7CNCD susceptibility panels 
(SensititreTM, TREK Diagnostic Systems, Westlake, Ohio) were used to test isolates for 
susceptibility to 16 antimicrobials across a standard range of dilutions (Figure 5.1). Each 
isolate was grown up on a non-selective media. A 0.5 McFarland standard was made in 5 
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ml of demineralized water of which 10 µl was transferred into 11 ml of cation-adjusted 
Mueller-Hinton broth with TES buffer. A 50 µl aliquot was inoculated into each of the 96 
wells on the panel. Inoculated plates were incubated and read by the Sensititre ARIS® 
(Automated Reading and Incubation System) (TREK Diagnostic Systems, Inc., Westlake, 
OH). Readings were transferred to Sensititre Automated Microbiology Systems (SAMS) 
computer software (TREK Diagnostic Systems) and interpreted according to CLSI 
breakpoints for animals or humans (21,22) (Figure 5.1). The MIC breakpoint for 
streptomycin, which does not have a CLSI guideline, was taken from the National 
Antimicrobial Resistance Monitoring System (NARMS) 2000 E. coli report (23). Quality 
control organisms used were Escherichia coli ATCC 25922, Staphylococcus aureus 
ATCC 29213, Enterococcus faecalis ATCC 29212 and Pseudomonas aeroginosa ATCC 
27853.  
 
5.2.3 Data comparisons and statistical analysis 
Intermediate MIC values were categorized as susceptible (21,22). Descriptive 
analyses were calculated with commercially available software (Microsoft Excel, 
Microsoft Corporation, Redmond, Washington, USA) and statistical analyses were 
performed using generalized estimating equations (GEE) (PROC GENMOD, SAS 
version 9.1, SAS Institute Inc., Cary, North Carolina) to adjust for clustering of resistance 
within herds. All models had a logit-link function, binomial distribution and 
exchangeable correlation structure. Unless stated otherwise, the outcome variable was 
‘any resistance’ to a given drug versus ‘no resistance’ (dichotomous) at the isolate level. 
The association between each variable of interest and outcome was reported as an odds 
ratio (OR = expβ) with 95% confidence intervals (CI) (24). 
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 The population average prevalence for resistance to each antimicrobial was 
calculated using the intercept (β0) and 95% CI from a null binomial response model in [1 
+ exp(-β0)]-1(24). Beyond these prevalence estimates, analyses were restricted to drugs 
with more than five percent prevalence of resistance to minimize problems with power, 
model stability and convergence.  
 
In the first set of analyses, the associations between different resistance 
phenotypes were considered. As there were seven drugs with more than five percent 
prevalence of resistance, each outcome was unconditionally considered against six other 
drug-resistances. Based on this, the cut off for statistical significance was adjusted with a 
Bonferroni correction and reported significant if P < 0.007 (0.05/7) (24).  
 
The second set of analyses explored potential biases introduced by study design. 
The unconditional associations between E. coli resistance phenotypes and two herd 
characteristics known at selection, herd size and knowledge of the presumed-herd-
Salmonella status, were evaluated. These associations were reported significant if P < 
0.05.  
 
The associations between resistances observed in Salmonella spp. and E. coli 
were measured to assess the potential for herd-level E. coli AMR data to predict 
resistance in Salmonella. Susceptibility data were generated concurrently in these herds 
(Chapter 4). The outcome variables represented Salmonella resistance to each drug, and 
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were modeled as the number of resistant isolates in the herd as the numerator and the 
number of isolates tested in each herd as the denominator. The predictor variable was the 
proportion of E. coli in the herd that were resistant to the same drug. These associations 
were reported significant if P < 0.05.  
 
A different approach to modeling AMR estimated the extent that resistance 
clustered within herds, and within the veterinarians servicing the herds. The variance at 
each level was determined using restricted maximum likelihood estimation. The 
resistance phenotype outcome was modeled as the proportion of resistant isolates in the 
herd as the numerator and the number of isolates tested in each herd as the denominator. 
The restricted generalized iterative least-squares (RIGLS) algorithm in MLwiN (MLwiN 
version 2.0r, Centre for Multilevel Modelling, Institute of Education, University of 
London, London, England) was used and second-order penalized quasi-likelihood (PQL-
2) estimates were reported. Under-dispersion was accounted from by allowing random 
variation at the lowest level (25). Non-significant hierarchical levels, based on the liberal 
criteria of the standard error being larger than the variance estimate, were excluded from 
further consideration. The intra-class correlation (ICC) between isolates within herds was 
approximated by the latent variable approach (24,25). Specifically, the herd variance was 
divided by the total variance after fixing the error variance at π2/3. 
 
5.3 Results 
Four hundred and five fecal samples were cultured and 1439 E. coli harvested for 
an average of 63 isolates per herd (range, 60 to 88). The prevalence of resistance was 
highest to tetracycline, sulfamethoxazole and streptomycin, while no resistance was 
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observed to ceftriaxone or ciprofloxacin (Figure 5.1). For amikacin, six isolates had an 
MIC greater than the dilution range tested. Because the breakpoint was also above the 
highest dilution, the status of these isolates was indeterminable.  
 
Twenty-one percent of the E. coli were susceptible to all drugs on the test panel 
while 57.0% (95% CI, 47.2 to 66.2) were resistant to two or more (Table 5.1). Two 
isolates were resistant to nine antimicrobials. Ninety-two unique resistance patterns were 
identified. Combinations of resistance to tetracycline, sulfamethoxazole and streptomycin 
accounted for the four most common patterns, and these antimicrobials were involved in 
all of the ten most common resistance patterns (Table 5.2).  
 
In these E. coli, resistance to each drug was significantly associated with 
resistance to at least two other drugs. The odds of an isolate being resistant to 
sulfamethoxazole increased significantly if it was resistant to any other drug considered 
(Table 5.3). Because only one isolate was both resistant to trimethoprim-
sulfamethoxazole and susceptible to sulfamethoxazole, the associations between these 
resistances were very strong. The next strongest associations were between resistance to 
sulfamethoxazole and chloramphenicol.  
 
The odds of an isolate being resistant to streptomycin, sulfamethoxazole and 
tetracycline each decreased by 0.99 times for every 1000 pigs finished annually (P = < 
0.0001, 0.007 and 0.049 respectively). E. coli resistance to ampicillin, chloramphenicol, 
kanamycin and trimethoprim-sulfamethoxazole were not significantly associated with 
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herd size (P > 0.23). No resistance was significantly associated with knowledge of the 
presumed Salmonella status (P > 0.09).  
 
The frequency of E. coli resistance in the herd was a significant predictor of 
Salmonella resistance to two drugs. For each one percent increase in E. coli resistance to 
kanamycin the odds of Salmonella resistance to kanamycin increased 1.24 times (95% 
CI, 1.15 to 1.34; P = 0.001). Similarly, for trimethoprim-sulfamethoxazole, a one percent 
increase in E. coli resistance increased the odds of Salmonella resistance by 1.32 times 
(95% CI, 1.10 to 1.58, P = 0.003). The associations for the remaining five drugs were not 
significant (P > 0.19). 
 
For all resistance phenotypes, the variance at the veterinary practitioner level was 
not significant (P > 0.31) while the variance at the herd level was highly significant (P = 
0.003 to 0.017). Hence, variance at the veterinary practitioner level was not considered 
when calculating the ICCs. The ICC between isolates within herds was smallest for 
streptomycin and largest for kanamycin (Table 5.4).  
 
5.4 Discussion 
Antimicrobial resistance in E. coli from pigs has been well described in North 
America. Nationally representative, abattoir-based monitoring in Canada and the United 
States is ongoing, an on-farm monitoring program completed its pilot phase in the United 
States, and a similar Canadian program is beginning its second year (7,23,26). Targeted 
cross-sectional studies in Ontario and British Columbia have described E. coli AMR on 
Canadian swine farms (14,15). This study differed from these previous reports by 
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describing E. coli from swine farms in Alberta and Saskatchewan, Canada. Identifying 
substantial regional-level variation in AMR could prompt investigation into differences in 
management or antimicrobial use between provinces. This study also considered the 
ability of E. coli to predict Salmonella AMR within herds and the extent resistance 
clustered within herds.  
  
The frequency of resistance to at least one drug, and to each individual drug, was 
comparable to other North American reports (7,14,23,26). Therefore, despite describing 
resistance in a small number of herds, our findings appear relevant to other regions in 
North America. Slight differences between these findings and previous reports were a 
lower prevalence of resistance to ampicillin (19 versus 22 to 35%) and a higher 
prevalence to chloramphenicol (17 versus 8 to 13%) (7,14,26).  
 
Resistance to chloramphenicol was particularly interesting because this drug was 
banned for use in Canadian food animals in 1985 (27). Florfenicol was not used in study 
herds in the 12 months prior to sample collection (Chapter 3). Therefore, direct selection 
for the floR gene, which confers resistance to both florfenicol and chloramphenicol, is 
unlikely (28). Rather, chloramphenicol resistance likely persisted due to co-selection. Co-
selection occurs with transmission of linked AMR genes on plasmids, transposons, and 
integrons. Bacteria resistant to multiple drugs have a competitive advantage in a wider 
range of environments (4,29,30). The strong associations between chloramphenicol and 
sulfamethoxazole resistance suggests co-selection may be occurring between resistance 
genes encoding for these drugs. This hypothesis is supported by reports of co-
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transmission of chloramphenicol and sulfonamide genes on transmissible plasmids, and 
significant odds ratios between genes encoding for resistance to these drugs (28,31). 
However, further molecular study of these isolates is required to confirm this hypothesis.  
 
In addition to being associated with chloramphenicol, sulfamethoxazole resistance 
was associated with every other drug resistance. The sul1 gene, which encodes for 
sulfamethoxazole resistance, is a component of class I integrons, genetic elements that 
acquire and link resistance gene cassettes (29). Thus, integrons carrying resistance genes 
could explain the associations between sulfamethoxazole and other drug resistances. 
Sulfonamide use has been associated with sulfamethoxazole resistance (14). By 
extension, our findings suggest it could be influencing resistance to many other 
antimicrobials. This is important considering sulfonamides are commonly administered to 
Canadian pigs (12,13). Overall, identifying numerous associations between resistances 
means co-selection between unrelated antimicrobials must be considered when making 
drug use decisions.  
 
Antimicrobial resistant Salmonella are a more obvious food safety hazard than E. 
coli, given that outbreaks of resistant salmonellosis in human have been linked to 
consuming contaminated pork (32,33). However, monitoring Salmonella AMR is 
challenging because sub-clinically infected pigs shed intermittently, barns fluctuate 
between a Salmonella-positive and apparent-negative status, and isolation techniques can 
have poor sensitivity (34,35). In contrast, E. coli, another member of the 
Enterobacteriaceae family, is highly prevalent and easily isolated. Salmonella and E. coli 
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from pigs can share resistance genes in vitro and molecular evidence suggests 
transmission occurs in vivo (36,37). Despite this, herd-level resistance in E. coli was not 
a predictor of resistance in Salmonella for five of seven phenotypes. Although this 
appears inconsistent with using E. coli as indicator bacteria, the lack of associations may 
be due to study design. There was a relatively low number of Salmonella isolates in some 
herds, which precluded considering serovar as a confounding variable. Additionally, the 
relationship was described at the herd, rather than pen, level. Our findings could be also 
due to describing resistance by phenotype rather than genotype or clonal resistance in 
Salmonella within herds. These factors could easily overshadow any shared resistance 
genes between E. coli and Salmonella within herds.   
 
Swine barns have a hierarchical structure; pigs are grouped in pens, pens in 
rooms, rooms in barns, and barns in production companies. The variation in resistance 
between each of these levels, as well as between pigs at different time points, has been 
estimated (15-17,38). Variation between herds (operated by different people or 
production companies) has been described (15,18,19). Describing the extent that 
resistance varies within herds is valuable because many management decisions, including 
antimicrobial use, are made at this level. Identifying substantial variation suggests these 
practices may influence resistance (24). The intra-class correlations between isolates 
within farms, which were similar to those reported by Dunlop et al., demonstrated that 
on-farm risk factor studies for resistances should be undertaken, and statistical analyses 
should account for the lack of independence in AMR data (15,24). In contrast, the lack of 
variation between veterinary practitioners indicated that interventions targeted at 
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veterinary practitioners would likely have a negligible impact on resistance compared to 
those targeted at farms.  
 
Comparisons with other AMR data should be made cautiously because selection 
criteria, sampling strategy and laboratory methods may influence results. Antimicrobial 
susceptibility testing methods were chosen to allow direct comparison with existing 
national surveillance data from Canada and the United States (7,23,26). Antimicrobial 
resistance in E. coli could vary with geographical, temporal or management factors: 
Despite this our findings were similar to AMR data from other North American farms 
and Canadian abattoirs  (7,14,15,23,26). This suggests data from regional studies is useful 
for understanding AMR in E. coli from healthy pigs in North America.  
 
Exploring herd characteristics influenced by the selection strategy found no 
significant associations between any resistance and knowledge of the herd Salmonella-
status. This indicates that participation bias, due to the more intensive sampling in 
known-Salmonella-status herds, was unlikely. In contrast, herd size was significantly 
associated with three resistance outcomes. For these drug-resistances, limiting our study 
to herds with more than 100 sows may have resulted in slightly less observed resistance 
than if all herds had been eligible. However, although 70% of Saskatchewan pig farms 
market less than 1000 pigs annually (which roughly corresponds to herds of 50 sows or 
less) they produce less than 3% of Saskatchewan’s pigs (39). Therefore, restricting the 
study to larger herds improved study representation of market hog production in western 
Canada. Although this study utilized a convenience sample of herds, the investigators had 
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no knowledge at selection of the antimicrobial use patterns in the herds. This was 
presumed to be the primary influence on resistance. Participation in this study was 
restricted to herds enrolled in the CQA® program to ensure adequate antimicrobial use 
records for other aspects of the study (20). Although participation in the CQA® program 
may influence antimicrobial use practices, it is unlikely to have biased results as more 
than 98% of production units in Alberta and Saskatchewan participate in this program 
(personal communication Sarah Turner, Alberta Pork and Harvey Wagner, Sask Pork).  
 
The findings of this study reflect the on-farm selection pressure for AMR and the 
potential food-safety risk from near-market animals. Describing E. coli AMR in Alberta 
and Saskatchewan herds provides baseline information for monitoring on-farm AMR in 
E. coli. With further study on swine farms, there is potential to identify risk-factors for 
antimicrobial resistance. 
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Table 5.1 Frequency, prevalence and 95% confidence intervals of number of 
antimicrobials in E. coli antimicrobial resistance pattern (n = 1439). 
 
Drugs in 
resistance pattern Frequency Prevalence 
95% Confidence 
Interval 
None 298 20.9 15.0 - 28.3 
One 320 22.2 18.3 - 26.7 
Two 269 18.6 15.7 - 21.8 
Three 263 18.3 14.5 - 22.7 
Four 186 12.8 9.4 - 17.3 
Five 75 5.4 3.4 - 8.4 
Six 23 1.6 0.9 - 2.7 
Seven 3 0.2 0.1 - 0.8 
Eight 0 0.0 0.0 - 0.2 
Nine 2 0.1 0.0 - 0.5 
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Table 5.2 Ten most common antimicrobial resistance patterns observed in E. coli (n = 
1439). 
 
AMR Pattern a Frequency  Percent  
TET 235 16.3 
SMX-TET 98 6.8 
STR-SMX-TET 97 6.7 
STR-TET 94 6.5 
CHL-STR-SMX-TET 56 3.9 
CHL-SMX-TET 45 3.1 
STR 36 2.5 
SMX 35 2.4 
AMP-STR-TET 34 2.4 
AMP-TET 31 2.2 
a: AMP: ampicillin; CHL: chloramphenicol; SMX: sulfamethoxazole; STR: streptomycin; 
TET: tetracycline 
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Table 5.3 Significant univariate associations between antimicrobial resistances (P < 
0.007), (n = 1439). 
 
  Variable  Odds 95% Confidence  
Outcome Predictor Ratio Interval P 
Ampicillin Kanamycin 3.1 1.6 - 6.0 0.001 
 Streptomycin 2.0 1.2 - 3.1 0.004 
 Tetracycline 2.5 1.8 - 3.5 ≤0.001 
 Sulfamethoxazole 2.3 1.4 - 3.7 ≤0.001 
 Trimethoprim-sulfamethoxazole 5.7 2.6 - 12.6 ≤0.001 
     
Chloramphenicol Sulfamethoxazole 34.6 12.6 - 95 ≤0.001 
 Trimethoprim-sulfamethoxazole 3.3 1.7 - 6.4 ≤0.001 
     
Kanamycin Ampicillin 2.8 1.5 - 5.2 0.001 
 Streptomycin 4.2 1.9 - 8.9 ≤0.001 
 Sulfamethoxazole 5.9 3.2 - 10.9 ≤0.001 
 Trimethoprim-sulfamethoxazole 1.4 1.1 - 1.7 0.005 
     
Streptomycin Ampicillin 2.1 1.3 - 3.4 0.002 
 Kanamycin 5.2 2.1 - 12.5 ≤0.001 
 Tetracycline 5.6 3.9 - 7.9 ≤0.001 
  Sulfamethoxazole 2.7 1.9 - 3.8 ≤0.001 
     
Sulfamethoxazole Ampicillin 2.2 1.4 - 3.5 0.001 
 Kanamycin 5.6 2.7 - 11.5 ≤0.001 
 Streptomycin 2.4 1.8 - 3.2 ≤0.001 
 Tetracycline 2.9 1.9 - 4.5 ≤0.001 
 Trimethoprim-sulfamethoxazole 118 14 - 968 ≤0.001 
 Chloramphenicol 31 13 - 73 ≤0.001 
     
Tetracycline Ampicillin 2.3 1.7 - 3.2 ≤0.001 
 Streptomycin 4.6 3.3 - 6.5 ≤0.001 
 Sulfamethoxazole 3.1 2.1 - 4.7 ≤0.001 
     
Trimethoprim-  Ampicillin 6.5 3.0 - 14.2 ≤0.001 
sulfamethoxazole Sulfamethoxazole 215 9.0 - 5170 ≤0.001 
  Chloramphenicol 3.6 1.8 - 7.2 ≤0.001 
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Table 5.4 Distribution of within herd prevalence of resistance, variance attributed to 
clustering within herds and intra-class correlation between isolates within herds (N = 20 
herds; n = 1439 E. coli). 
 
 Within Herd prevalence Herd Variance  
Antimicrobial Median IQR (standard error) ICCa 
Ampicillin 14.2 11.1 - 27.6 1.0 (0.35) 0.23 
Chloramphenicol 10.5 4.2 - 20.9 2.0 (0.71) 0.37 
Kanamycin 4.6 0.9 - 11.2 2.8 (1.1) 0.46 
Streptomycin 34.0 22.5 - 43.2 0.4 (0.14) 0.10 
Sulfamethoxazole 42.3 28.6 - 64.7 1.2 (0.39) 0.26 
Tetracycline 62.1 49.9 - 82.0 1.4 (0.48) 0.30 
Trimethoprim- 
Sulfamethoxazole 
8.1 1.4 - 11.3 1.1 (0.04) 0.24 
a: ICC = Intra-class correlation coefficient between isolates within herd 
 Figure 5.1 Minimum inhibitory concentration distributions, population average prevalence estimates, and 95% confidence intervals for 
resistance to each drug in E. coli isolates (n = 1439). 
Prevalence  Distribution of Isolates (Count) Across Dilution Range 
Antimicrobial 
of 
resistance 95% CI ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512 
Tetracycline 66.8 57.9 - 74.7                 452 21 23 98 845         
Sulfamethoxazole 46.0 36.4 - 56.0                     721 42 11 4   4 657 
Streptomycin 33.4 27.8 - 39.5                       961 256 222       
Ampicillin 18.6 17.9 - 19.2             138 615 381 33 6 2 264         
Chloramphenicol 17.3 10.7 - 26.7               76 601 453 60 117 132         
Kanamycin 9.3 4.6 - 18.0                   1299 7 2 3 128      
Trimethoprim-
Sulfamethoxazole 7.4 5.1 - 10.5       890 333 78 21 11 1 105               
Cephalothin 3.8 2.2 - 6.6               55 382 665 282 42 13         
Gentamicin 0.8 0.4 - 1.8         315 621 476 8 1 6 6 6           
Cefoxitin 0.6 0.2 - 1.6           2 24 406 767 223 8 9           
Amoxicillin-
Clavulanic Acid 0.4 0.1 - 1.3             88 508 609 206 22 4 2         
Ceftiofur 0.1 0.0 - 0.5       175 1002 249 6 3 3 1               
Nalidixic Acid 0.1 0.0 - 0.5           10 135 1037 246 10     1         
Amikacin 0 0.0 - 0.2           68 594 664 107 6               
Ceftriaxone 0 0.0 - 0.2         1427 4 6 2                   
Ciprofloxacin 0 0.0 - 0.2 1426 10 1 1  1                     
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Shaded fields indicate the range tested for each antimicrobial. Counts outside of shaded cells indicate isolates with growth in all wells 
within the tested range. For these isolates, the actual MIC is greater than that range of dilutions. Vertical double bars mark the 
breakpoint between sensitive and resistant. Bond font indicates the median. 
 
CHAPTER 6 
ANTIMICROBIAL RESISTANCE AND VIRULENCE GENES OF COMMENSAL 
ESCHERICHIA COLI FROM GROW-FINISH PIGS 
6.1 Introduction 
Antimicrobial resistance (AMR) in Escherichia coli is a serious concern in human 
and veterinary medicine. Resistant infections are associated with increased morbidity, 
mortality and treatment expense compared to their susceptible counterparts (1-4). 
Resistant commensal E. coli, while not causing direct disease, are a reservoir of 
antimicrobial resistance genes. These genes can be transferred to zoonotic pathogens, 
such as Salmonella, or to other gram-negative bacteria in the gut (5,6). Pathogenic and 
commensal strains of E. coli have different rates of resistance and carry different genes 
(7,8). Therefore, describing the antimicrobial resistance genes in commensal E. coli 
documents the diversity of genes available for dissemination to other bacteria. 
 
In a previous paper, we described the frequency and patterns of phenotypic AMR 
in E. coli from healthy grow-finish pigs in western Canada. Of 1439 isolates, 21% were 
susceptible to all of the sixteen drugs considered while 57% were resistant to two or more 
antimicrobials (Chapter 5). This paper describes the presence of resistance and virulence 
genes in a subset of those isolates. The data were described through three sets of analyses. 
First, unconditional associations between resistance genes were assessed; these 
associations generate hypotheses about the physical relationships between genes that 
dictate co-selection. Secondly, associations among resistance phenotypes were analyzed 
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and compared to the associations among resistance genes. Identifying similar 
relationships in these analyses would suggest that phenotypic resistance data could also 
generate hypotheses about co-selection. Finally, associations between resistance and 
virulence genes were investigated. Others have reported more frequent resistance, and 
numerous associations between resistance and virulence genes, in pathogenic E. coli 
(7,8). This has created concerns that antimicrobial exposure contributes to the persistence 
and spread of virulence in E. coli (4,9,10). Describing similar associations in commensal 
E. coli would indicate a potential for antimicrobial use to increase virulence in E. coli 
carried by healthy pigs. 
 
6.2 Materials and Methods 
6.2.1 Herd and sample selection 
Twenty herds were enrolled in the study by eight swine veterinarians in 
Saskatchewan (thirteen herds) and Alberta (seven herds). Herds were selected by each 
veterinarian to match the study inclusion criteria of a minimum of 100 sows and 
enrollment in the Canadian Quality Assurance® Program (11). The number of herds per 
veterinarian ranged from two to four. Each herd was visited once between May and 
September of 2004. Twenty pens of apparently healthy, grow-finish pigs were randomly 
identified in each herd. Freshly voided fecal samples were collected from five pigs in 
each of these pens, and then pooled to create a pen-level sample.  
 
6.2.2 Culture and antimicrobial susceptibility testing 
Samples were manually mixed, shipped on ice to a commercial veterinary 
laboratory (Prairie Diagnostic Services (PDS), University of Saskatchewan, Saskatoon, 
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SK) and cultured for E. coli within 24 h of collection. Each sample was streaked onto 
whole Blood Agar and MacConkey plates then incubated at 37° C for 18 h. Three 
lactose-positive colonies were selected from each MacConkey plate unless distinct 
colonies, such as hemolytic and non-hemolytic or mucoid and dry were identified; up to 
six were harvested from those samples. Pure, confirmed E. coli cultures were stored in 
25% glycerol at -80° C for susceptibility testing.  
 
Antimicrobial susceptibility testing was conducted by the Agri-Food Laboratories 
Branch, Food Safety Division of Alberta Agriculture, Food and Rural Development, 
Edmonton, AB and PDS, Saskatoon, SK. Isolates were tested for antimicrobial 
susceptibility using a broth micro-dilution technique following Clinical and Laboratory 
Standards Institute (CLSI) guidelines. National Antimicrobial Resistance Monitoring 
System (NARMS) minimum inhibitory concentration (MIC) CMV7CNCD susceptibility 
panels (SensititreTM, TREK Diagnostic Systems, Westlake, Ohio) were used to test 
isolates for susceptibility to 16 antimicrobials across a standard range of dilutions 
(12,13). Each isolate was grown up on a non-selective media. A 0.5 McFarland standard 
was made in 5 ml of demineralized water, of which 10 µl was transferred into 11 ml of 
cation-adjusted Mueller-Hinton broth with TES buffer. A 50 µl aliquot was inoculated 
into each of the 96 wells on the panel. Inoculated plates were incubated and read by the 
Sensititre ARIS® (Automated Reading and Incubation System) (TREK Diagnostic 
Systems, Inc., Westlake, OH). Readings were transferred to Sensititre Automated 
Microbiology Systems (SAMS) computer software (TREK Diagnostic Systems) and 
interpreted according to CLSI breakpoints for animals or humans (12,13). Streptomycin 
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does not have a CLSI MIC breakpoint, therefore this breakpoint was taken from the 
National Antimicrobial Resistance Monitoring System (NARMS) 2000 E. coli report 
(14). Quality control organisms used were Escherichia coli ATCC 25922, 
Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and 
Pseudomonas aeroginosa ATCC 27853.  
 
6.2.3 Isolate selection 
One hundred and fifty-one E. coli were selected from the 1439 available isolates. 
Isolate selection was purposive to ensure a minimum of 15 isolates were resistant to each 
of the following antimicrobials: ampicillin, chloramphenicol, kanamycin, streptomycin, 
sulfamethoxazole, tetracycline and trimethoprim-sulfamethoxazole. More than 5% of the 
1439 available E. coli were resistant to these antimicrobials (Chapter 3). Only these seven 
resistance phenotypes and genes encoding for resistance to these seven drugs were 
considered in this study. Clustering was minimized by selecting a maximum of one 
isolate per pen while maintaining the original herd distribution.  
 
6.2.4 Antimicrobial resistance gene detection 
AMR gene testing was performed by the Département de Pathologie et 
Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-
Hyacinthe, Québec. The 28 strains used as positive controls and templates for DNA 
amplification were obtained from different laboratories (Table 6.1) (2,15). These strains 
were maintained as frozen stocks at -80° C in tryptic soy broth medium containing 10% 
glycerol (vol/vol). They were propagated on Luria-Bertani broth or agar containing one of 
the following antimicrobial agents at the appropriate concentrations: ampicillin (50 
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µg/ml), gentamicin (30 µg/ml), kanamycin (50 µg/ml), tetracycline (10 µg/ml), 
chloramphenicol (10 µg/ml), trimethoprim (10 µg/ml), and sulfamethazine (200 µg/ml).  
 
The primers for cmlA, strA, strB and sul3 had been previously described and 
validated (7,8). Resistance gene primers were designed by using the software program 
Prime (Genetics Computer Group, Madison, Wis.). Oligonucleotide primers were 
synthesized with a DNA synthesizer (BioCorp Inc., Montreal, Quebec, Canada). The PCR 
primers, their amplified product sizes and the references for the corresponding strains 
used as amplification templates have been described by Maynard et al. (Table 6.1) (2,15). 
 
Template DNA was prepared from bacterial cultures by the boiling method of 
Daigle et al. (16). Amplifications were performed with 5 µl of supernatant from bacterial 
preparations that had been boiled for 10 m (16). The PCR mixture (total volume, 50 µl) 
included 29.6 µl of H2O, 5.0 µl of 10x PCR buffer (Amersham Pharmacia Biotech Inc., 
Piscataway, N.J.), 2 µM each of the four deoxynucleoside triphosphates, 1 U of Taq DNA 
polymerase (Amersham Pharmacia Biotech Inc.), 25 pmol of each primer and 5 µL of 
template. DNA amplification was carried out in a GeneAmp PCR system 9700 (Perkin-
Elmer, Foster City, Calif.) by using the following conditions: 5 m at 94° C, followed by 
30 cycles of 94° C for 30 s, 50° C for 30 s, and 72° C for 1.5 m. A 3 µl aliquot of the 
PCR product was verified for size and purity by gel electrophoresis (1.2% [wt/vol] 
agarose in 1x TAE [Tris-acetate-EDTA] buffer). The amplicons were labeled with [ -32P] 
dCTP by using a DNA labeling beads kit (Amersham Pharmacia Biotech Inc.). Colony 
hybridizations were performed as described previously (17).  
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6.2.5 Virulence gene detection 
Virulence gene testing was conducted by PDS, Saskatoon, SK. Each strain was 
grown up on blood agar plates and two to four E. coli colonies were randomly selected 
and mixed in 400 µl of D-Solution (4 M GuSCN, 25mM Na citrate at Ph 8.0, 0.5% 
sarcosyl, 0.1 M βME (700 µl in 100 ml)) (Sigma, Oakville, ON). To each tube, 100µl of 
TE-saturated phenol (Sigma) and 100 µl of chloroform (Sigma) were added and the tube 
was mixed. The DNA was lysed by incubation at -20° C for 10 m and then centrifuged 
for 5 m at 4° C and 15,000 g and the aqueous layer removed. The process of washing, 
mixing and centrifuging were repeated at least once, or until the interface was clear. Five 
hundred microlitres of 95% salted ethanol (VWR, Luterworth, Leicestershire, England) 
was added, inverted to mix, and incubated for 1 to 12 h at -20° C. The tube was then 
centrifuged for 15 m at 4 ° C at 15,000 g and the ethanol decanted off. The DNA pellet 
was dried for 5 to 10 m at 30 to 35 ° C and dissolved in 80 to 100 µl of sterile water.  
 
Oligonucleotide primers were used for the detection of virulence associated genes 
(Table 6.2). Bacterial DNA amplification was performed in 30 µl of sterile, ultra-pure 
water, 5 µl 10x PCR buffer, 4 µl (25 mM/µl) MgCl2, 0.5 µl dNTPs (25 mM/µl), 0.5 µl 
Taq polymerase (5 U/µl) and four primers (2 µl per primer, 20 pmol/µl) (Fermentas, 
Burlington, ON). Two microlitres of DNA were dispensed into each tube, centrifuged for 
30 s and then immediately placed into the preheated cycler. The cycler denatured the 
DNA for 2 m at 94° C then amplified it by 35 cycles of the following: denaturing for 30 s 
at 94° C, annealing of primers for 30 s at 60° C and extension for 30 s at 72° C. Final 
extension occurred for 10 m at 72° C and the reaction was concluded at 10° C. The PCR 
amplicons were visualized following electrophoresis on 1.25% agarose gel and staining 
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with ethidium bromide. Amplicons were compared to a sterile negative control and a 
positive reference strain (Table 6.2). Results were recorded with an Alpha Imager 
documentation camera (Fisher Scientific, Ottawa, Ontario).  
 
6.2.6 Statistical analyses 
Minimum inhibitory concentration, AMR gene, and virulence factor data were 
maintained in a relational database (Microsoft Access, Microsoft Corporation, Redmond, 
Washington, USA). For the purpose of this analysis, isolates with intermediate MICs 
were considered susceptible. Descriptive and non-parametric statistics were performed 
with commercially available software (SPSS version 14.0 for Windows, Chicago, IL, 
USA) while tests of association were conducted using generalized estimating equations 
(GEE) (PROC GENMOD, SAS version 9.1 for Windows; SAS Institute, Cary, North 
Carolina, USA). Model outcomes were at the isolate level and adjusted for clustering of 
resistance within herds.  
 
The association between the number of drugs in each isolate’s resistance 
phenotype (outcome) and number of resistance genes detected (predictor) was 
investigated using a Poisson distribution, a log link function, and an exchangeable 
correlation structure. Associations were considered statistically significant if P < 0.05 and 
were reported as a risk ratio (RR = expβ) with 95% confidence intervals (CI). 
 
Resistance to each drug was described in two ways: i) an isolate had a resistant 
phenotype if the MIC was greater than the breakpoint; and ii) an isolate had a resistant 
genotype if it carried a gene encoding for resistance to that drug. The agreement between 
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these descriptions was evaluated using the Kappa statistic (κ) and unconditional 
associations (odds ratios (OR)) (18). Each resistance phenotype was evaluated to 
determine whether it was associated with a summary description of the resistance genes 
(any resistance genes for that drug; yes or no) and then whether it was associated with 
each individual resistance gene for that drug.  
 
Three additional sets of analyses were conducted. The first set evaluated the 
unconditional associations between individual antimicrobial resistance genes. The second 
set described the unconditional associations between the various resistance phenotypes. 
The final set of analyses described the unconditional association between each 
antimicrobial resistance gene and the presence of each virulence factor. All models had a 
logit-link function, binomial distribution, and exchangeable correlation structure. The 
association between each variable of interest and outcome was considered significant if P 
< 0.05 and was reported as an odds ratio (OR = expβ) with 95% CI (18). Genes observed 
in less than 2% of the isolates were not considered in any analyses to avoid problems 
with model power, stability and convergence. Associations of interest with a zero in the 
contingency table were noted, and evaluated for significance with a two-sided Fisher’s 
Exact Test (significant if P < 0.05). 
 
6.3 Results 
Most isolates examined in this study were resistant to at least three of the seven 
drugs and carried at least three antimicrobial resistance genes (Table 6.3). Only 11% of 
the isolates were susceptible to all drugs and 9% had no resistance genes. The number of 
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AMR genes detected in an isolate was a significant predictor of the number of drugs in its 
resistance phenotype (RR; 1.19, 95% CI; 1.15 to 1.24, P = 0.0001).  
 
In this sample, the most common resistance genes identified were tetA and tetB. 
The second most common resistance genes were for streptomycin; all isolates with strA 
also carried strB, and vice versa. Therefore, all analyses considered these genes as one 
unit, the strA–strB gene pair. Five resistance genes were detected in less than 2% of the 
isolates (Table 6.4) while 11 were not identified in any of the E. coli: blaSHV, aac(3’)-IIa, 
ant(2”)-1a, catI, floR, cmlA, dhfr1b, dhfrV, dhfrVII, dhfrIX and dhfrXII.  
 
On average, 7.6 isolates were tested from each herd (range, 4 to 10). For the three 
drugs to which phenotypic resistance was most common, more than one type of 
resistance gene was identified in most herds. All three tetracycline efflux genes were 
detected in two herds, two were identified in sixteen herds and only one was noted in two 
herds. All three dihydropteroate synthetase (sul) genes were detected in five herds, two in 
ten herds and one in four herds. One herd had no sul genes detected despite having four 
sulfamethoxazole resistant isolates. One herd had three streptomycin resistance 
determinants, twelve herds had two, and seven herds had one.  
 
The agreement between resistance, as described by phenotype and genotype, 
ranged from a kappa of 0.85 for ampicillin to 0.33 for sulfamethoxazole. No outcome had 
perfect agreement because every antimicrobial-outcome had some isolates with a 
resistant phenotype but no genetic explanation (Table 6.4). This was most pronounced for 
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chloramphenicol resistance; no isolates carried any of the three chloramphenicol 
resistance genes examined. The reverse situation also occurred. Twelve different 
resistance genes were identified in at least one susceptible isolate. Despite these 
inconsistencies, each set of resistance genes was a significant predictor of its resistance 
phenotype, except for resistance to chloramphenicol. When each gene was considered 
individually, only sul3 was not a significant predictor of its own phenotypic resistance.  
 
Three genes, aph(3’)-1a, dhfrXIII and sul3, were not associated with any other 
resistance gene. In contrast, sul1 was associated with five other genes. Three associations 
showed an increased probability of detecting sul1 in the presence of another gene, while 
two suggested a decreased probability (Table 6.5). The strongest association identified 
was between aadA1 and sul1.  
 
Phenotypic resistance to each drug was associated with phenotypic resistance to at 
least one other drug, and every identified association was positive (showed an increased 
probability of observing the outcome resistance in the presence of the predictor 
resistance) (Table 6.6). The odds ratios could not be estimated for five pairs because no 
isolates demonstrated one of the combinations of resistance and susceptibility (i.e. 0-0, 0-
1, 1-0, or 1-1). However, these resistance combinations were all highly significant on 
non-parametric analysis (Fisher’s Exact; P <0.0001). Importantly, with the exception of 
the association between tetA and dhfrI, every significant association between AMR genes 
(Table 6.5) matched a significant association between the phenotypes encoding for those 
genes (Table 6.6). 
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 One virulence factor, LT (encoded by elt), was not identified and another, VTI 
(stx1), occurred in one isolate. The remaining factors were identified more frequently; 
intimin (eae), 17 isolates; F18 (fed1), 17; STb (estB), 23; AIDA (aida-1), 49; STa (estA), 
52; and VT2 (stx2 or stx2e), 58. Thirty-two percent of the E. coli isolates did not have 
any virulence factors identified, while almost half carried two or more (Table 6.1).  
 
The number of antimicrobial resistance genes identified in an isolate was not 
associated with the number of virulence genes detected (P = 0.97), nor was there an 
association between the presence of any resistance gene and any virulence gene (P = 
0.92). Three unconditional associations were identified between the presence of a specific 
antimicrobial resistance gene and a virulence factor. The odds of identifying STb were 
4.7 times higher (95% CI; 1.1 to 21, P = 0.04) in isolates with dhfrXIII. The odds of 
identifying VT2 were 5.2 times higher (95% CI; 1.7 to 16, P = 0.004) in isolates with 
dhfrI. The odds of identifying AIDA were decreased 0.5 times (95% CI; 0.2 to 0.9, P = 
0.03) in isolates with tetB.  
 
6.4 Discussion 
This study described the distribution of resistance and virulence genes in E. coli 
from healthy pigs in Alberta and Saskatchewan swine herds. It also described the 
associations between resistance genes, between resistance phenotypes and between 
resistance and virulence genes. The frequency of genes and phenotypes in these isolates 
do not represent the prevalence of these characteristics in the study herds, or other herds 
in western Canada, because isolate selection was not random. Therefore, prevalence data 
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should not be extrapolated beyond this study. Despite this limitation, comparing the 
genes found in these isolates to other North American reports is worthwhile because, to 
the author’s knowledge, other descriptions of AMR genes in E. coli from healthy pigs in 
western Canada are not available 
 
Tetracycline was the most common phenotypic resistance. Although at least 36 
genes encode for tetracycline resistance, two efflux genes explained more than 90% of 
the resistance in these isolates (19). This was similar to other reports of commensal and 
pathogenic E. coli from pigs (2,8,20,21). The next most commonly identified genes 
encoded for streptomycin resistance. In contrast to an Ontario study where E. coli from 
healthy pigs carried aadA genes almost twice as frequently as strA - strB, these isolates 
more commonly carried strA – strB (8). This finding could reflect regional differences 
but could also be an artifact of isolate selection. Resistant isolates (MIC ≥ 64) were more 
likely to be selected. These isolates would be more likely to carry strA - strB because they 
encode for high level resistance (MIC ≥ 64) than the adenylating genes (aadA) which 
encode for MICs < 64 (8,22). The sul3 gene was first described in 2003 in Switzerland 
(23). It has since been reported in E. coli from pigs in Ontario, Oklahoma and numerous 
European countries (1,8,24-26). The sul3 gene appears to be widespread in western 
Canada as it was the most common sulfonamide resistance gene in this study and was 
identified in two-thirds of study herds. Finally, resistance to ampicillin was well 
described by blaTEM which was similar to a description of E. coli O149:K91 from sick 
pigs in Quebec (2).  
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In contrast to the above resistance types, which were well described by the genes 
examined, resistance to kanamycin, trimethoprim-sulfamethoxazole and chloramphenicol 
were poorly explained. Only 59% of the kanamycin and 42% of the trimethoprim-
sulfamethoxazole resistant E. coli carried a putative resistance gene. Future studies may 
need to consider more of the known DHFR and kanamycin resistance genes (27,28). 
Even more notable was the failure to identify any chloramphenicol resistance genes. 
Although many different chloramphenicol resistance genes have been described, three 
have been reported in E. coli from North America pigs (1,7,29). Resistant E. coli from 
healthy pigs in Ontario and sick pigs in the United States predominately carried cmlA, 
while catI and floR occurred less frequently (1,7). Considering that chloramphenicol has 
been banned in Canadian livestock since 1985, resistance has presumably been 
maintained through co-selection of chloramphenicol genes with other resistance and 
virulence genes (7,30,31). Future research should investigate what chloramphenicol 
resistance genes are prevalent in western Canada. Identifying sul3 in various populations 
gave insight into how resistance can spread (1,8,23-26). Similarly, describing differences 
in the chloramphenicol resistance genes between pig populations might provide insight 
into barriers for the spread or persistence of resistance genes.  
 
Two methods described antimicrobial resistance: measurement of MIC and 
assessment of resistance genes. These tests had fair (κ 0.2 to 0.4) to almost perfect (κ > 
0.8) agreement (18). Yet no resistance-outcome was in complete agreement. Phenotypic-
resistant isolates with no AMR genes were identified, as were phenotypic-susceptible 
isolates carrying resistance genes. The apparent contradiction of susceptible isolates 
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carrying resistance genes has two possible explanations. First, there is a biological 
explanation. Resistance genes may be unexpressed if they are distant from or associated 
with a weak promoter in an integron. Similarly, free gene cassettes (not incorporated into 
an integron) are silent because the integron’s promoter is required for expression (32,33). 
Both of these situations could create a susceptible isolate with resistance genes. Low MIC 
test sensitivity provides an alternative explanation. Isolates could be falsely categorized 
as susceptible if the MIC breakpoint is higher than the resistance imparted by the gene. 
Such a situation is well known with aadA genes and streptomycin resistance (8,22).  
 
We previously described the clustering of phenotypic resistance within these 
herds. Based on those findings, we suggested investigating herd-level risk factors for 
resistance could be rewarding (Chapter 5). Finding that most herds had more than one 
type of resistance gene for tetracycline, sulfamethoxazole and streptomycin prompts us to 
modify that conclusion. Ideally, on-farm studies should explore risk factors for resistance 
genes rather than phenotypes. Resistance genes encoding for the same drug have different 
associations with other resistance genes, and so a given antimicrobial exposure would 
affect these genes differently. For example, the odds of phenotypic trimethoprim-
sulfamethoxazole resistance were 4.6 times higher in E. coli from herds with sulfonamide 
use in nursery pigs (Chapter 7). Considering that dhfrI was associated more strongly with 
sul1 than sul2, and dhfrXIII was not associated with sul1 or sul2, sulfonamide exposure 
might select for certain DHFRs but not others. Exploring the relationship between 
antimicrobial exposure and AMR genes may even explain some of the negative 
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associations between antimicrobial use and phenotypic antimicrobial resistance found in 
this thesis and other studies (34) (Chapter Seven). 
 
Positive statistical associations between resistance genes may reflect gene 
linkages, and thus co-transmission via plasmids, transposons or integrons, while negative 
odds ratios might indicate gene incompatibilities (7,8,35). For example, the strong 
association between aadA-1 and sul1 might be explained by the presence of aadA in gene 
cassettes and sul1 in type I integrons, which collect gene cassettes. Plasmid 
incompatibilities have been proposed as an explanation for negative associations between 
tetA and tetB (8). In general, our findings concurred with previous reports (8,25). As in E. 
coli from pigs in Ontario, two sets of resistance genes were observed (8). One set 
included tetA, aadA-1, and sul1 while the other included tetB, blaTEM, strA - strB and 
sul2. Boerlin et al. did not consider trimethoprim or beta-lactam resistance genes. 
However, in E. coli from various types of meat in Norway, a positive association was 
noted between sul1 and dhfrI (25). To our knowledge, the association between tetB and 
blaTEM has not been previously reported. Future studies should investigate this gene pair 
association. Both extended-spectrum beta-lactams and tetracyclines are used in pigs 
(Chapter 3). If exposure to one drug class increases resistance to the other, barns that use 
either class, or that cycle between them, could be selecting for resistance to both.  
 
Interestingly, our findings were distinctly different from the associations 
described in E. coli in from sick pigs in Quebec. For example, the association between 
sul1 and tetA was negative in Quebec but positive in this, and other, studies (2,8,25). 
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Different E. coli types (i.e. ETEC, pathogenic but non-ETEC and commensal) carry 
different AMR genes (7,8). So, it is plausible that the contradictions between this study 
and Maynard et al.’s study are because confounding by strain was not accounted for (2).  
 
Multiple drug resistances are generally described as phenotype patterns rather 
than pair-wise associations between drug-resistances (36,37). While patterns depict the 
relationships between many drugs, they are difficult to compare between populations. 
The observed associations between resistance phenotypes were expected because many 
had been previously reported and all had had been identified in the full E. coli collection 
from which these isolates were sourced (38). However, not all associations from the full 
set were significant here, reflecting the relatively low power in this subset analysis.  
 
Our most intriguing finding was that almost every associated pair of resistance 
genes matched an association between their purported phenotypes. The only exception 
was the association between tetA and dhfrI, which lacked a corresponding association 
between tetracycline and trimethoprim-sulfamethoxazole resistance. This suggests 
associations between resistance phenotypes might predict co-selection. Although this 
hypothesis requires validation, if proven it would advance our knowledge of co-selection 
dynamics and provide a cost-effective way to evaluate existing data. Thus, future 
research should investigate the similarity of gene and phenotype associations in other 
populations and datasets. Such research would have practical application if it allowed 
antimicrobial prescribers to consider the effects of specific drug use on other resistance to 
other drugs. 
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 Similar to antimicrobial resistance genes, E. coli virulence-factor genes are often 
located on plasmids or transposons (7,8). If resistance and virulence genes were linked, 
any competitive advantage of virulent isolates could explain AMR gene persistence in the 
absence of antimicrobial selective pressure, and the higher AMR observed in clinical 
isolates compared to those from healthy animals. Similarly, antimicrobial use could co-
select for virulent isolates. In this study, only three virulence and resistance genes were 
associated and one of those was a negative association. Escherichia coli can carry linked 
resistance and virulence genes (7,8); a hybridization study confirmed some of the 
numerous statistical associations described between these types of genes (7). However, in 
those studies, virulence genes predominantly occurred in ETEC but confounding by the 
three E. coli types (ETEC, pathogenic but non ETEC and commensal) was not described 
(7,8). Hence, our findings could differ from the two previous Ontario reports because of a 
connection between AMR genes and pathotype. This is plausible considering the E. coli 
virulence genes were associated with specific serotypes, serotypes with pathotypes, and 
the AMR genes differed between the three E. coli types considered (7,8). So although 
AMU could affect virulence in pathogens, showing that antimicrobial resistance genes 
and virulence genes are rarely associated in E. coli from healthy animals suggests on-
farm AMU is not selecting for increased virulence factors in the commensal E. coli 
population.  
  
This study considered the seven resistance phenotypes observed in more than 5% 
of the E. coli from the full dataset. Selection ensured these resistance phenotypes 
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occurred in more than 10% of these isolates. This restriction minimized problems with 
statistical power. Due to practical constraints, only some of the resistance genes known 
for each antimicrobial were considered. Future investigations in this region should 
consider additional genes for chloramphenicol, trimethoprim and kanamycin resistance as 
these were poorly explained.  
 
In reality, AMR genes do not interact as isolated pairs but as an interconnected 
system. While we do not have sufficient data to present these relationships as a causal 
pathway or multivariate models, associations between resistance genes and phenotypes 
appear to provide insight into co-selection. If validated, this simple statistical approach 
may identify unforeseen repercussions from antimicrobial use. This is an important 
finding, as it would allow policymakers and antimicrobial users to consider co-selection 
in antimicrobial use decisions.  
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Table 6.1 Antimicrobial resistance gene primers, amplicon size and source for 28 genes investigated. 
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Antimicrobial family Genetic marker PCR primer sequence (5' → 3') 
Amplicon 
size (bp) 
GenBank 
accession no. Source of DNA 
Beta-lactams blaTEM - F GAGTATTCAACATTTTCGT 857 AF309824 R. C. Levesque 
  blaTEM - R ACCAATGCTTAATCAGTGA      
  blaSHV - F TCGCCTGTGTATTATCTCCC 768 AF148850 R. C. Levesque 
  blaSHV -R CGCAGATAAATCACCACAATG      
Aminoglycosides ant(2")-Ia (aadB)a - F TCCAGAACCTTGACCGAAC 198 AJ238349 Pasteur Institute 
  ant(2")-Ia (aadB)a - R GCAAGACCTCAACCTTTTCC      
  aac(3)-IIa (aacC2) - F CGGAAGGCAATAACGGAG 591 X75562 R. C. Levesque 
  aac(3)-IIa (aacC2) - R TCGAACAGGTAGCACTGAG      
  aac(3)-IV - F GTGTGCTGCTGGTCCACAGC 705 J05162 R. C. Levesque 
  aac(3)-IV - R AGTTGACCCAGGGCTGTCGC      
  aph(3')-Ia (aphA1) - F ATGGGCTCGCGATAATGTC 701 X92506 A. Huletsky 
  aph(3')-Ia (aphA1) - R CTCACCGAGGCAGTTCCAT      
  aph(3')-IIa (aphA2) - F GAACAAGATGGATTGCACGC 700 X04555 R. C. Levesque 
  aph(3')-IIa (aphA2) - R GCTCTTCAGCAATATCACGG      
Tetracycline tet(A) -F GTGAAACCCAACATACCCC 740 X54723 D. Sandvang 
  tet(A) - R GAAGGCAAGCAGGATGTAG      
  tet(B) - F CCTTATCATGCCAGTCTTGC 627 X01385 J. Harel 
  tet(B) - R ACTGCCGTTTTTTCGCC      
  tetC - F ACTTGGAGCCACTATCGAC 600 M18329 J. Harel 
  tetC - R CTACAATCCATGCCAACCC      
Phenicols catI - F AGTTGCTCAATGTACCTATAACC 680 V00618 J. Harel 
  catI - R TTGTAATTCATTAAGCATTCTGCC      
 
      
Antimicrobial family Genetic marker PCR primer sequence (5' → 3') 
Amplicon 
size (bp) 
GenBank 
accession no. Source of DNA 
 Phenicols floR - F CGCCGTCATTCCTCACCTTC 888 X00006 J. Harel 
  floR - R GATCACGGGCCACGCTGTGTC      
  cmlA - F TTGCAACAGTACGTGACAT 293 AB212941.1 P. Boerlin 
  cmlA - R ACACAACGTGTACAACCAG      
Trimethoprim dhfrI - F AAGAATGGAGTTATCGGGAATG 774 J01830 J. Harel 
  dhfrI - R GGGTAAAAACTGGCCTAAAATTG      
  dhfrV - F CTGCAAAAGCGAAAAACGG 881 J01749 J. Harel 
  dhfrV - R AGCAATAGTTAATGTTTGAGCTAAAG      
  dhfrVII - F GGTAATGGCCCTGATATCCC 827 X65876 S. B. Levy 
  dhfrVII - R TGTAGATTTGACCGCCACC      
  dhfrIX - F TCTAAACATGATTGTCGCTGTC 853 L06940 M. C. Roberts 
  dhfrIX - R TTGTTTTCAGTAATGGTCGGG      
  dhfrXIII - F CAGGTGAGCAGAAGATTTTT 823 AF070999 M. C. Roberts 
  dhfrXIII - R CCTCAAAGGTTTGATGTACC      
Sulfonamides sul1 - F TTCGGCATTCTGAATCTCAC 547 M62822 J. Harel 
  sul1 - R ATGATCTAACCCTCGGTCTC      
  sul2 - F CGGCATCGTCAACATAACC 543 X53796 Pasteur Institute 
  sul2 - R GTGTGCGGATGAAGTCAG      
  sul3 - F GAGCAAGATTTTTGGAATCG 880 AY494779.1 P. Boerlin 
  sul3 - R CATCTGCAGCTAACCTAGGGCTTTGGA      
Streptomycin strA - F CCTGGTGATAACGGCAATTC 546 EF090911.1 P. Boerlin 
  strA - R CCAATCGCAGATAGAAGGC      
 strB – F ATCGTCAAGGGATTGAAACC 509 EF090911.1 P. Boerlin 
  strB - R GGATCGTAGAACATATTGGC       
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Table 6.2 Gene primer sequence, amplicon size and source for eight virulence factors tested in E. 
coli. 
 
Primer 
name Primer sequence (5’→3’) 
Length 
(base 
pairs) 
E. coli positive 
control Reference 
eae-F atc ttc tgc gta ctg cgt tca 790 STJ348 Beudry 
eae-R cat tat gga acg gca gag gt O157:H7   
stA-F tcc cct ctt tta gtc agt caa ctg 171 P97-2554B So, Nglekea 
stA-R gca cag gca gga tta caa caa agt O149:K91   
stB-F gca ata agg ttg agg tga t 377 P97-2554B Lortie 
stB-R gcc tgc agt gag aaa tgg ac O149:K91   
VT1-F tta gac ttc tcg act gca aag 530 STJ348 Woodward 
VT1-R tgt tgt acg aaa tcc cct ctg O157:H7   
VT2-F cta tat ctg cgc cgg gtc tg 327 STJ348 Woodward 
VT2-R aga cga aga tgg tca aaa cg O157:H7   
fedA1-F gtg aaa aga cta gtg ttt att tc 510 P88-1199 Imberechts 
fedA1-R ctt gta agt aac cgc gta agc O139:K82   
Aida1-F aca gta tca tat gga gcc a 585 2787 Benz, Ngeleka 
Aida1-R tgt gcg cca gaa cta tta 2787   
LT-F tta cgg cgt tac tat cct ctc ta 275 P97-2554B Furrer 
LT-R ggt ctc ggt cag ata tgt gat tc O149:K91   
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Table 6.3 Number of drug resistances, antimicrobial resistance genes and virulence genes in 
commensal E. coli (n = 151). 
 
Number of isolates Number of drug-
resistances or 
genes  
Drug 
phenotypes 
Resistance 
genes 
Virulence 
genes 
Zero 16 13 49 
One 3 24 28 
Two 24 29 45 
Three 37 17 22 
Four 35 34 3 
Five 25 21 2 
Six 11 10 1 
Seven 0 1 1 
Eight 0 2 0 
 
Table 6.4 Resistant E. coli (P+) with no resistance gene (G-), and susceptible isolates (P-) with resistance genes (G+); associations 
between drug-phenotypes and resistance genes and phenotype:genotype inter-test agreement (n=151). 
 
Antimicrobial NP Genes NG P+ / G- P- / G+ 
Odds 
ratio 
95% confidence 
interval P Kappa 
Ampicillin 69 any 60 10 1 534 54 - 5280 <0.0001 0.85 
    blaTEM 60  1 534 54 - 5280 <0.0001  
              
Chloramphenicol 48 any 0 48 0      
             
Kanamycin 34 any 21 14 1 55 16 – 182 <0.0001 0.67 
   aph(3’)-1a 16  0 32 9.4 - 108 <0.0001  
   aph(3’)-IIa 3  0    -  
   aac(3)-IV 2  1    -  
             
Streptomycin 82 any 79 20 17 10 5.3 - 20 <0.0001 0.51 
   aadA1 35  10 2.5 1.2 - 5.3 0.01  
   aadA6 1  0    -  
   strA - strB 51  7 11 5.3 - 22 <0.0001  
             
Sulfamethoxazole 111 any 69 42 8 3.3 2.6 - 16 <0.0001 0.33 
   sul1 22  1 9.7 1.2 - 78 0.03  
   sul2 27  1 13 1.2 - 142 0.03  
   sul3 40  6 2.7 0.9 - 8.0 0.06  
          
Tetracycline 125 any 124 5 4 95 29 - 312 <0.0001 0.77 
   tetA 52  3 3.5 1.2 - 10 0.03  
   tetB 81  1 17 4.6 - 61 <0.0001  
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Antimicrobial N Genes N P+ / G- P- / G+ 
Odds 
ratio 
95% confidence 
interval P Kappa 
Tetracycline  tetC 2  1 0.4 0.1 - 3.4 -  
             
Trimethoprim-
sulfamethoxazole 
24 any 14 14 4 23 4.6 - 116 <0.0001 0.46 
   dhfrI 7  3 8.3 1.6 - 44 0.01  
   dhfrXIII 6  1 35 2.0 - 619 0.01  
   dhfrXV 1  0    -  
NP: Number of E. coli expressing phenotypic resistance to antimicrobial 
NG: Number of E. coli carrying resistance gene 
P+ / G-: Number of phenotypically resistant E. coli with no resistance gene for that drug identified 
P- / G+: Number of phenotypically susceptible E. coli with a resistance gene for that drug identified  
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Table 6.5 Significant odds ratios between E. coli resistance genes and 95% confidence intervals. 
 
Outcome Predictor 
Odds 
Ratio 
95% confidence 
interval P 
blaTEM strA - strB 2.4 1.0 - 5.4 0.04 
  tetB 2.9 1.4 - 5.8 0.003 
        
aadA1 sulI 70.4 12.0 - 412.0 0.0001 
  tetA 7.8 2.7 - 23.0 0.0002 
        
strA - strB blaTEM 2.4 1.0 - 5.5 0.04 
  sul1 0.2 0.1 - 0.7 0.01 
  sul2 6.8 2.9 - 16.3 0.0001 
  tetA 0.3 0.2 - 0.7 0.003 
  tetB 4.3 1.9 - 9.8 0.0004 
        
sul1 aadA1 76.8 14.7 - 402.2 0.0001 
  strA - strB 0.2 0.0 - 0.6 0.005 
  tetA 9.0 3.2 - 25.2 0.0001 
  tetB 0.4 0.2 - 0.9 0.04 
  dhfrI 8.4 1.6 - 43.6 0.01 
        
sul2 strA - strB 8.5 3.4 - 21.7 0.0001 
        
tetA aadA1 8.1 2.7 - 24.4 0.0002 
  strA - strB 0.3 0.1 - 0.6 0.001 
  sul1 8.6 3.0 - 24.1 0.0001 
  tetB 0.1 0.0 - 0.1 0.0001 
  dhfrI 4.7 1.2 - 18.0 0.02 
        
tetB blaTEM 2.9 1.5 - 5.8 0.002 
  strA - strB 4.3 1.9 - 9.8 0.0005 
  tetA 0.1 0.1 - 0.2 0.0001 
        
dhfrI sul1 9.4 1.8 - 48.0 0.007 
  sul2 4.5 1.4 - 14.1 0.01 
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Table 6.6 Significant odds ratios between E. coli drug-resistance phenotypes and 95% 
confidence intervals. 
 
Outcome Predictor 
Odds 
Ratio 
95% confidence 
interval P 
Ampicillin Streptomycin 2.8 1.6 - 4.7 0.0002 
  Tetracycline 11.0 3.4 - 35.3 0.0001 
  
Trimethoprim-
Sulfamethoxazole 3.5 1.1 - 10.4 0.03 
        
Kanamycin Streptomycin 2.6 1.3 - 5.0 0.01 
        
Streptomycin Ampicillin 3.2 1.8 - 5.8 0.0001 
  Kanamycin 3.0 1.1 - 8.4 0.04 
  Tetracycline **   <.0001 
  Sulfamethoxazole 2.0 1.2 - 3.4 0.01 
        
Tetracycline Ampicillin 16.6 3.9 - 70.7 0.0001 
  Streptomycin **   <.0001 
 Sulfamethoxazole 7.8 3.9 - 15.7 0.0001 
        
Sulfamethoxazole Streptomycin 1.9 1.1 - 3.3 0.02 
  Tetracycline 8.4 4.3 - 16.4 0.0001 
  
Trimethoprim-
Sulfamethoxazole **   <.0001 
  Chloramphenicol **   <.0001 
        
Trimethoprim-
Sulfamethoxazole Ampicillin 3.5 1.2 - 10.1 0.02 
  Sulfamethoxazole **   <.0001 
        
Chloramphenicol Sulfamethoxazole **   <.0001 
 
CHAPTER 7 
ASSOCIATIONS BETWEEN FEED AND WATER ANTIMICROBIAL USE IN FARROW-
TO-FINISH SWINE HERDS AND ANTIMICROBIAL RESISTANCE OF FECAL 
ESCHERICHIA COLI FROM GROW-FINISH PIGS 
7.1 Introduction 
Swine veterinarians and producers use antimicrobials to treat and prevent bacterial 
infections, improving pig health and welfare. Antimicrobials are also used as feed additives to 
increase daily gain and improve feed efficiency (1-3). Although antimicrobials are indispensable 
tools for managing bacterial disease, their use also contributes to acquired antimicrobial 
resistance (AMR) in commensal and pathogenic bacteria (1,4-10).  
 
Resistant bacteria can survive and propagate in the presence of an antimicrobial. Some 
bacteria are intrinsically resistant, while others develop resistance through chromosomal 
mutations or acquiring resistance genes (5,11). Horizontal transmission of resistance genes 
occurs through plasmids, transposons, and integrons. These elements can carry multiple 
resistance genes and transmit them as a unit (5,12-14). Therefore, bacteria with acquired AMR 
are frequently resistant to unrelated drugs.  
 
Resistant zoonotic pathogens, such as Salmonella spp., pose a direct risk to consumers 
eating contaminated pork (15,16). Resistant pathogens have an higher infection rate, limited 
treatment options and increased virulence (4,17,18). Resistant commensal organisms are also a 
food safety hazard. Although the magnitude of this risk is undefined, resistance genes may 
spread to other bacteria in the human gastrointestinal tract (6,10,19-21). Furthermore, 
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commensal bacteria reflect the selective pressures for resistance to develop in the normal 
intestinal flora (6,22). Research projects and surveillance programs often use generic Escherichia 
coli as a model for AMR in gram-negative commensals (8,9,22-25). The ubiquity of E. coli 
allows AMR to be compared between populations of healthy animals (6,22). 
 
Experimentally, antimicrobial exposure increases the prevalence of resistant E. coli in 
healthy pigs (7,8,26). On-farm studies have also shown antimicrobial use is associated with E. 
coli AMR (9,27,28). Observational studies are ideal for investigating complex problems with 
many causes or hypotheses (29). These studies can consider numerous drug exposures and 
various resistances simultaneously. To date, observational investigations have not considered the 
extent of antimicrobial exposure within herds (9,27). Therefore, the objective of this project was 
to investigate the dose response relationships between on-farm antimicrobial use and AMR in E. 
coli from grow-finish pigs.  
 
7.2 Materials and Methods 
7.2.1 Herd enrollment, sample collection and laboratory methods 
A convenience sample of 20 herds was allocated to eight swine veterinarians in 
Saskatchewan (thirteen herds) and Alberta (seven herds). Herds were selected by the 
veterinarians and met the inclusion criteria of having more than 100 sows and participation in the 
Canadian Quality Assurance® (CQA®) Program (30). Each veterinarian enrolled two to four 
herds. Study herds were visited once between May and September of 2004. Antimicrobial use 
data and information on inventory and production practices were collected during herds visits 
(Table 7.1). As previously described, pen-level fecal samples collected from healthy grow-finish 
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pigs were cultured for E. coli. Harvested isolates were tested for susceptibility to sixteen 
antimicrobials (Chapter 5).  
 
7.2.2 Antimicrobial use data collection – Exposure through feed and water 
Data collection of antimicrobial use through feed and water was described in detail 
(Chapter 3). Briefly, each herd owner or manager used existing records to complete surveys on 
antimicrobial use through feed and water (Appendix A). Data for each exposure of suckling, 
nursery, grow-finish pig, or sows in the previous 12 months included the product used, number 
of pigs exposed, and duration of exposure. Antimicrobial use was described as the incidence per 
pig-day and scaled by 1,000 or 100,000 to facilitate interpretation (Equation 1). Pigs could be 
exposed more than once per day, either through products in both feed and water, or through 
products containing multiple antimicrobials. 
  
Equation 1. Formula for Antimicrobial Exposure Incidence (AEI) 
AEI = [Pigs E* Days E] / [Pigs R * Days R] 
E = exposed 
R = at risk 
 
7.2.3 Statistical analysis 
Antimicrobial exposure and susceptibility data were maintained in a relational database 
(Microsoft Access, Microsoft Corporation, Redmond, Washington, USA). Descriptive statistics 
were calculated using commercially available software (Microsoft Excel, Microsoft Corporation, 
Redmond, Washington, USA). Intermediate MIC values were classified as susceptible for all 
analyses. Statistical models, adjusted for herd-level clustering using generalized estimating 
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equations (GEE) (PROC GENMOD, SAS version 9.1, SAS Institute Inc., Cary, North Carolina), 
had a logit-link function, binomial distribution, and an exchangeable correlation structure. When 
necessary, extra-binomial variation was allowed by a scale parameter equal to the square root of 
the Pearson’s Chi-Square divided by the degrees of freedom in the model.  
 
The prevalence of resistance to each antimicrobial was calculated using the intercept (β0) 
and 95% confidence intervals (CI) from a null binomial response model in 1/ [1 + exp(-β0)] (29). 
A risk factor model was developed for each resistance that was observed in more than 5% of the 
isolates. Models were restricted to these drug resistances to avoid problems with power, model 
stability and convergence associated with infrequent outcomes.  
 
In contrast to AMR, which was described for individual drugs, antimicrobial exposures 
were described by class: The number of farms using each antimicrobial was insufficient to 
evaluate the dose response relationship between individual drugs and resistance while sufficient 
between-farm variability occurred when antimicrobial were grouped by class. An antimicrobial 
class refers to drugs with similar chemical structures and mechanisms of action (31,32). The 
antimicrobials used by study herds were classified as follows: i) aminoglycosides (included 
aminocyclitols) ii) beta-lactams iii) macrolides (included lincosamides and pleuromutilins) iv) 
sulfonamides and v) tetracyclines. Antimicrobial use was further stratified by the production 
phase exposed: suckling, nursery, grow-finish pigs and sows. Antimicrobial use variables used in 
five or more herds were modeled as the exposure incidence (continuous). Antimicrobial use 
variables used in less than five herds were collapsed to ‘any use’ versus ‘no use’ (dichotomous). 
Those used by only one herd were not evaluated.  
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 The outcome of each model was the proportion of isolates from a sample that were 
resistant to the antimicrobial. Each antimicrobial use variable was screened to determine its 
unconditional association with the outcome variable; only those significant at P < 0.2 were 
considered further. For continuous antimicrobial use variables, the effect estimate of each 
quartile was graphed against the log odds of the outcome to assess the relationship for linearity. 
Non-linear associations were addressed by categorizing antimicrobial use as no use, low use (0.1 
to 500 exposures per 1000 pig-days), and high use (>500 exposures per 1000 pig-days) because 
this categorization best fit the variable distribution. Categorical variables were considered further 
if significant at P < 0.2.   
 
All antimicrobial use variables with an unconditional P < 0.2 were included in the full 
model. Manual step-wise backward selection was used to develop a main effects model, 
retaining only antimicrobial use variables significant at P < 0.05. Variables describing exposure 
to the same antimicrobial class as the outcome were retained, regardless of significance, until all 
other non-significant variables were eliminated. For example, when modeling resistance to 
sulfamethoxazole, variables describing sulfonamide use were retained until all non-significant 
variables describing other classes were removed. This modeling decision was based on the 
premise that direct selection and cross-resistance affect resistance rates more strongly than co-
selection.  
 
Variables removed from the full model were re-introduced into the main effects model 
separately to ensure they had not been inappropriately removed because of confounding. Two-
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way interactions were considered between exposures in the same swine production phase. 
Interaction terms, significant at P <0.05, were retained in the final model along with their main 
effects. Production variables were considered as potential confounders (Table 7.1). Those that 
altered a parameter estimate by more than 25% were retained in the final model. Residuals of the 
final models were examined visually for outliers. The association between each variable of 
interest and the outcome was reported as an odds ratio (OR = expβ) with 95% CI (29). 
 
7.3 Results 
Four hundred and five samples were cultured for E. coli. On average, 63 isolates were 
harvested per herd (range, 60 to 88) for a total of 1439 isolates. More than 5% of the E. coli were 
resistant to seven of the sixteen antimicrobials in the panel (Table 7.2). Resistance to ampicillin, 
streptomycin, sulfamethoxazole and tetracycline were each observed in isolates from every herd. 
One herd had no isolates resistant to chloramphenicol, four had no isolates resistant to 
trimethoprim-sulfamethoxazole, and five had no isolates resistant to kanamycin.  
 
In every herd, antimicrobials had been used in feed or water in the previous 12 months. 
Nursery pigs were exposed to antimicrobials most frequently while sows were exposed least 
frequently (Table 7.3). Macrolides were used in 18 of 20 herds, tetracyclines in 15, 
aminoglycosides in 9, beta-lactams in 9, and sulfonamides in 7 (Table 7.4).  
 
Seven E. coli resistance outcomes were modeled against antimicrobial exposures through 
feed and water (Table 7.2). Of these seven antimicrobials, tetracycline was the only antimicrobial 
that was both considered as a resistance outcome and was used in feed or water in study herds. 
Other tetracycline exposures included oxytetracycline and chlortetracycline. Resistance to 
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sulfamethoxazole was also modeled; because the sulfonamide derivative was not always reported 
we cannot definitively state this drug was not used in study herds. However, sulfamethoxazole is 
not licensed for use in Canadian pigs while the following sulfonamides are licensed for 
administration through feed or water: sulfadoxine, sulfaguanidine, sulfamerazine, 
sulfamethazine, sulfanilamide, sulfapyridine and sulfathiazole (33). Sulfonamide exposures were 
likely a mixture of these. Resistance to two aminoglycosides, kanamycin and streptomycin, were 
modeled. Neither of these drugs were used in study herds but another aminoglycoside 
(neomycin) and an aminocyclitol (spectinomycin) were used. Two of the antimicrobials to which 
resistance was modeled were administered parenterally but not in feed or water. Trimethoprim, 
in combination with sulfadoxine, was used as an injectable product and thus was not captured by 
any of the antimicrobial exposure variables. Similarly, ampicillin was also only used as an 
injectable drug. Beta-lactam use was predominantly penicillin G, although nursery pigs received 
amoxicillin through water in one herd. Resistance to chloramphenicol was the only outcome 
where no product from its antimicrobial class was used in study herds. In contrast, macrolides 
were used extensively but had no resistance outcomes tested. Macrolide exposure included 
tylosin and tilmicosin, tiamulin, and lincomycin. 
 
Six of the seven antimicrobial resistance outcomes had significant antimicrobial use risk 
factors (Table 7.5). Five resistance outcomes were associated with exposure to drugs in the same 
antimicrobial class. Resistance to tetracycline was only associated with exposure to tetracyclines 
in nursery pigs (Figure 1), while resistance to ampicillin was only associated with beta-lactam 
use in grow-finish pigs (Table 7.5). In contrast, E. coli resistance to kanamycin and streptomycin 
were not associated with aminoglycoside exposure. Resistance to streptomycin was predicted by 
172 
macrolide exposure in grow-finish pigs (Figure 2), (Table 7.5). Resistance to kanamycin was the 
only outcome with no significant antimicrobial use risk factors.  
 
Resistance to sulfamethoxazole was linearly associated with sulfonamide and 
aminoglycoside exposure in nursery pigs. Resistance to sulfamethoxazole was also predicted by 
macrolide use in grow-finish pigs; E. coli from herds using a high rate had 3.4 times higher odds 
(95% CI, 1.9 to 6.1; P <0.0001) of resistance than isolates from herds using a low rate, and 6.4 
times (P <0.0001) higher odds of resistance than E. coli from herds using none. The odds of 
resistance to sulfamethoxazole did not differ significantly between isolates from herds using a 
low rate of macrolides in grow-finish pigs compared to herds with no use (P = 0.07).  
 
The odds of trimethoprim-sulfamethoxazole resistance increased with four antimicrobial 
use variables, including sulfonamide use in nursery pigs (Table 7.5). In contrast, nursery pig 
exposure to tetracycline was associated with decreased odds of resistance. Resistance to 
trimethoprim-sulfamethoxazole was the only outcome associated with antimicrobial use in sows. 
It was also the only model with an important confounder; E. coli from herds selling breeding 
stock were more likely to be resistant to trimethoprim-sulfamethoxazole than isolates from herds 
that only sold pigs for consumption.  
 
The odds of E. coli resistance to chloramphenicol increased with aminoglycoside 
exposure and decreased with tetracycline exposure in suckling pigs (Table 7.5). Macrolide use in 
grow-finish pigs was also significant; the odds of chloramphenicol resistance were 4.1 times 
higher (95% CI, 2.2 to 7.6; P <0.0001) in isolates from herds with high exposure compared to 
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low exposure, and 5.9 times higher (P = .0006) in isolates from herds with high exposure 
compared to no exposure. The odds of resistance to chloramphenicol were not significantly 
different between E. coli from herds with low macrolide exposure compared to those with no 
exposure (P = 0.4).  
 
7.4 Discussion 
Antimicrobial resistance is a natural consequence of drug selective pressures. In swine 
herds, these pressures may be intensified because of long-term antimicrobial exposure through 
water and feed (34). Therefore, this study investigated the link between herd level antimicrobial 
use, through feed and water, and resistance of E. coli. Although this study considered E. coli 
from grow-finish pigs only, AMR was associated with antimicrobial use in all production phases. 
This indicates that antimicrobial use in pigs distant from market may have food safety 
repercussions. Four of the resistance outcomes were associated with exposure to unrelated drugs, 
indicating co-selection (11,12). While co-selection is familiar to scientists, producers and 
veterinarians need to understand this phenomenon before AMR can be addressed at the herd-
level. 
 
In general, the statistical models generated by this study indicate that antimicrobial 
exposure provides a competitive advantage to resistant E. coli. Three aspects of acquired AMR 
guided our interpretation of these models. Direct selection occurs when exposure to a drug 
results in increased resistance to the same drug. Cross-resistance occurs when resistance to a 
drug automatically confers resistance to a related drug. Finally, exposure to any drug in a 
multiple drug resistant phenotype creates selective pressure for every resistance in the phenotype 
(co-selection) (11,12). The association between tetracycline resistance and exposure was 
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interpreted as both direct selection and cross selection, while the association between 
sulfamethoxazole resistance and sulfonamide use implied cross selection, and the association 
between chloramphenicol resistance and aminoglycoside exposure suggested co-selection.  
 
Enterobacteriaceae are intrinsically resistant to penicillin G (35). As penicillin G was the 
only beta-lactam used in grow-finish pigs, the association between ampicillin resistance and 
beta-lactam exposure does not fit our understanding of cross selection. From a mechanistic 
perspective, low rates of exposure to a drug that is inactive against E. coli would be unlikely to 
cause this increase in ampicillin resistance. Rather, it seems more plausible that beta-lactam 
exposure was a proxy for a common, undefined risk factor. However, the possibility that 
penicillin G exposure is a true risk factor for ampicillin resistance cannot be discounted; others 
have reported an association between ampicillin resistance in E. coli from grow-finish pigs and 
penicillin G use in lactating sows (9). Investigating this association in more herds with a wider 
range of beta-lactam exposures or in a controlled laboratory experiment might clarify this 
finding.  
 
Neomycin and spectinomycin were used in study herds, yet aminoglycoside use was not 
associated with resistance to kanamycin or streptomycin. This was unexpected because 
resistance genes encoding for both streptomycin and spectinomycin (strA / strB, aadA) have been 
reported in E. coli from Canadian pigs (36,37). Thus, assuming spectinomycin directly selects 
for resistance, it should also select for resistance to streptomycin. Such a relationship between 
spectinomycin use and streptomycin resistance has been previously reported (27). A similar 
relationship exists between kanamycin and neomycin; resistance to both drugs is encoded by 
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aac(3)IV and aph(3’)-Ia genes, which have been identified in E. coli from Canadian pigs (36,37). 
This study’s design might explain the failure to identify associations between aminoglycoside 
resistance and exposure. Aminoglycosides were only used in suckling and nursery pigs while E. 
coli were from grow-finish pigs. Other researchers have observed that E. coli resistance to 
apramycin declines rapidly following the removal of apramycin from feed. Thus, if 
aminoglycoside use had an effect on resistance, it may have dissipated before isolate collection 
in this study (8,38). 
 
Finding chloramphenicol resistance in these E. coli demonstrates that antimicrobial 
resistance can persist without direct selection. Canadian authorities banned chloramphenicol use 
in food animals in 1985 and no study herds reported its use or use of the related approved drug 
florfenicol (39). Antimicrobial exposure can increase resistance to unrelated drugs by selecting 
for multiple resistant organisms (12,14). Others have reported physical linkages and statistical 
associations between chloramphenicol and aminoglycoside resistance genes. This supports the 
conclusion that chloramphenicol resistance might be persisting because of aminoglycoside use in 
suckling piglets and macrolide use in grow-finish pigs (40,41). A report of increased odds of 
chloramphenicol resistance in herds adding tylosin to finisher diets further supports this 
statement (27).  
 
Identifying macrolide use as a risk factor for four different resistance outcomes was 
striking because E. coli are intrinsically resistant to macrolides (42,43). However, another report 
also found macrolide use to be a risk factor for various E. coli resistances (27). In humans, when 
erythromycin is administered orally, the intestinal concentration overcomes the intrinsic 
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resistance of E. coli (42,44). This suppresses the aerobic gram-negative intestinal flora and 
selects for erythromycin resistance (42,44). Escherichia coli, isolated from people receiving 
erythromycin, can carry transmissible plasmids with linked erythromycin, ampicillin, gentamicin 
and streptomycin resistance genes (42,44). In pigs, E. coli MICs to tylosin, tilmicosin, 
lincomycin and tiamulin have not been investigated. The intestinal and colonic concentrations of 
these antimicrobials have only been estimated (45). Considering the situation in humans, it is 
plausible that macrolide resistant E. coli exist in pigs. Investigation into macrolide use and 
resistance in E. coli from pigs is urgently needed considering tylosin is among the most 
commonly used antimicrobials in grow-finish pigs and use of this antimicrobial is considered 
critically important in some classification schemes (32,34,46-48). 
 
Similar to other observational studies, antimicrobial use in other production phases was 
associated with E. coli AMR in grow-finish pigs in this study (9,27,49). These findings have 
been supported experimentally; offspring from sows receiving oxytetracycline in feed pre-
farrowing had increased oxytetracycline resistance compared to control piglets (8). Thus, AMR 
studies should consider antimicrobial use in the entire herd as potential risk factors. Equally 
important, antimicrobials should always be used sparingly in all ages of pigs.  
 
Two of our statistical models identified decreased odds of resistance with increased 
antimicrobial exposure. Similar to this study, Akwar reported tetracycline exposure was 
protective for chloramphenicol resistance (27). Finding decreasing resistance with increased 
antimicrobial use is counter-intuitive. When statistical models identify counter-intuitive 
associations, they may be discounted as spurious. In our case, corroborating findings between 
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studies strengthens the premise that the statistical associations reflect biological reality and 
underlines the importance of heeding unexpected or conflicting results. As recommended in 
Chapter 6, the chloramphenicol resistance genes in these isolates require further description. 
Others have reported negative associations between catA1 and tetB (40). Further investigation in 
these isolates might also demonstrate incompatible tetracycline and chloramphenicol resistance 
genes. 
 
The frequency of AMR in these E. coli was similar to surveillance reports from abattoirs 
and swine herds in North America (9,23,24,27). Although descriptions of antimicrobial use in 
North American pigs are scarce, the number of herds using group medications and the types of 
drugs used in the current study were comparable to available data (34,47,50). The similarity of 
the antimicrobial use and resistance between this and other reports, and the infrequent 
confounding by management variables, suggests that these findings are relevant to many swine 
farms in North America.  
 
Reporting relationships between AMR and antimicrobial exposure incidence through 
feed and water is unique. Previous risk factor studies have described antimicrobial use in feed 
and water qualitatively, while we described the rate of exposure (9,27). Assuming a causal 
relationship, long term antimicrobial use in pigs affects AMR more than targeted use. Despite 
this strength, our description of antimicrobial use was also a primary weakness of this study. 
Describing antimicrobial exposure by class allowed consideration of dose-response relationships 
but may have biased associations towards the null. Pharmacokinetic characteristics, such as the 
rate of absorption, and physical characteristics, such as stability in gastric acid, can differ 
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between drugs within a class (31). If the selective pressure for resistance differed markedly 
between drugs within a class, this study may have missed significant associations because 
exposure was defined by antimicrobial class. Future studies will need to enroll more herds or 
purposively select herds based on antimicrobial use to evaluate individual drugs as risk factors. 
 
Administering antimicrobials to pigs is a risk factor for antimicrobial resistance. 
However, the human health risks from resistant porcine E. coli are unquantified and the risk 
factors for many resistances are unknown. Until more data are available, the swine industry faces 
the conundrum of knowing that antimicrobial use can select for resistance without knowing 
which antimicrobials might pose lower risks to consumers (32,51). Until such knowledge is 
generated, swine producers should use antimicrobials judiciously to mitigate the potential effects 
of resistance. These findings emphasize the importance of co-selection and minimizing drug use 
to decrease selective pressures for multiple drug resistances.  
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Table 7.1 Study herd (n = 20), grow-finish production phase (n = 20) and sampled pen (n = 405) 
characteristics: frequency, or mean and standard deviation (S). 
 
Level Characteristic   Description 
Herd    
 Number of sows in herds (median and IQR)a  456 (274 - 1042) 
    
 Days in each production phase Suckling 21 (1.8) 
  Nursery  46 (15.7) 
  Grow-finish 112 (27.1) 
    
 Purpose for which animals were sold* Breeding stock 7 
  Slaughter only 13 
    
 Number of sites farrow-to-finish herd located on* one 15 
  two 2 
  three 3 
   
Grow-Finish Phase    
 All-in-all-out by room or barn* yes 9 
  no 11 
    
 Pens emptied between batches* yes 12 
  no 8 
    
 Manure removed between batches* yes 10 
  no 10 
    
 Pens washed and disinfected between batches* yes 8 
  no 12 
   
 Times barn was washed in previous 12 months* 3 (3.7) 
    
 Days pens empty between batches* 1 (1.7) 
    
Pen    
 Sex b, * Boar 20 
  Gilt 167 
  Barrow 134 
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Level Characteristic   Description 
  Mixed 80 
    
 Flooring type* Full slat 102 
  Partial slat 299 
  Solid 4 
    
 Feed presentation* Feeder 362 
  Floor 43 
    
 Weeks pigs had been in pen at sampling* 5.9 (4.1) 
    
 Pen density (pigs per m2)*  1.7 (0.8) 
a: non-normally distributed 
b: data missing for four pens 
* considered as potential confounders  
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Table 7.2 Population average prevalence of resistance in E. coli (n = 1439), 95% confidence 
intervals (CI), dilution range tested and resistance breakpoint (resistant if ≥ MIC).  
 
Antimicrobial Prevalence
95% confidence 
interval Dilution range 
Resistant 
MIC  
Tetracycline* 66.8 57.9 - 74.7 4 - 32 16 
Sulfamethoxazole* 46.0 36.4 - 56.0 16 - 512 512 
Streptomycin* 33.4 27.8 - 39.5 32 - 64 64 
Ampicillin* 18.6 17.9 - 19.2 1 - 32 32 
Chloramphenicol* 17.3 10.7 - 26.7 2 - 32 32 
Kanamycin* 9.3 4.6 - 18.0 8-64 64 
Trimethoprim-
Sulfamethoxazole* 7.4 5.1 - 10.5 
0.12 / 2.38 - 
4 / 76 4 / 76 
Cephalothin 3.8 2.2 - 6.6 2 - 32 32 
Gentamicin 0.8 0.4 - 1.8 0.25 - 16 16 
Cefoxitin 0.6 0.2 - 1.6 0.5 - 16 32 
Amoxicillin-Clavulanic Acid 0.4 0.1 - 1.3 1 / .05 - 32 / 16 32 / 16 
Ceftiofur 0.1 0.0 - 0.5 0.12 - 8 8 
Nalidixic Acid 0.1 0.0 - 0.5 0.5 - 32 32 
Amikacin 0.0 0.0 - 0.2 0.5 - 4 64 
Ceftriaxone 0.0 0.0 - 0.2 0.25 - 64 64 
Ciprofloxacin 0.0 0.0 - 0.2 0.015 - 4 4 
* risk factor models developed for resistance phenotypes observed in more than 5% of the 
isolates 
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Table 7.3 Antimicrobial exposure incidence per 1000 pig-days for all antimicrobial classes 
combined. Incidence in all herds (n = 20) and in herds with an exposure incidence greater than 
zero. 
 
Production AEI of all herds AEI in herds with incidence > 0  
Phase Median  IQR Herds Median IQR 
Suckling 3 0 - 750 10 833 552 - 1056 
Nursery 929 663 - 1230 20 929 663 - 1230 
Grow-finish 301 16 - 965 15 715 160 - 1000 
Sow 0  0 - 20 8 49 15 - 199 
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Table 7.4 Frequency of antimicrobial use by class and production phase, (n = 20 herds) and 
description of exposure incidence per 1,000 pig-days in herds with an exposure incidence greater 
than zero.  
 
Antimicrobial Production   Herds reporting AEI > 0 
class phase N Median IQRa 
Aminoglycosides Suckling  3 700 517 739 
 Nursery 8 272 137 501 
 Grow-finish 0 - - - 
 Sow 0 - - - 
      
Beta-lactams Suckling  3 286 238 310 
 Nursery 8 210 176 291 
 Grow-finish 3 11 6 17 
 Sow 1 64 - - 
      
Macrolides Suckling 8 310 228 572 
 Nursery 17 528 411 974 
 Grow-finish 15 714 160 977 
 Sow 3 34 18 167 
      
Sulfonamides Suckling 3 286 238 310 
 Nursery 6 143 126 191 
 Grow-finish 1 24 - - 
 Sow 0 -   
      
Tetracyclines Suckling 5 333 273 381 
 Nursery 13 226 220 508 
 Grow-finish 1 725 - - 
  Sow 5 37 16 185 
a: IQR = Inter-quartile range is presented for herds with exposure incidence > 0
Table 7.5 Final logistic regression models for E. coli resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, 
tetracycline and trimethoprim-sulfamethoxazole (n = 1439 isolates, n = 405 pens).  
 
 
Resistance 
outcome Antimicrobial Use Risk Factor Odds Ratio 
95% confidence 
interval P 
Ampicillin Grow-finish Beta-lactam any use 2.8 1.6 - 5.0 0.0005 
   no use reference   
       
Chloramphenicol Suckling Aminoglycoside any use 2.3 1.2 - 4.6 0.02 
   no use reference   
       
 Grow-finish Macrolide high  5.9 2.2 - 16.0 0.04 
   low 1.4 0.6 - 3.4  
   no use reference   
       
 Suckling Tetracycline 100,000 pig-days 0.8 0.6 - 0.97 0.02 
       
Streptomycin Grow-finish Macrolide 100,000 pig-days 1.07 1.01 - 1.1 0.02 
       
Sulfamethoxazole Nursery Aminoglycoside 100,000 pig-days 1.1 1.02 - 1.3 0.02 
       
 Grow-finish Macrolide high 6.4 3.3 - 12.2 0.004 
   low 1.9 1.0 - 3.7  
   no use reference   
       
 Nursery Sulfonamide 100,000 pig-days 2.0 1.4 - 2.9 0.0001 
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Resistance 
outcome Antimicrobial Use Risk Factor Odds Ratio 
95% confidence 
interval P 
Tetracycline Nursery Tetracycline 100,000 pig-days 1.3 1.1 - 1.5 0.0004 
       
Nursery Sulfonamide any use 4.6 2.0 - 10.5 0.0004 Trimethoprim- 
sulfamethoxazole   no use reference   
       
 Sow Macrolide any use 3.9 1.6 - 9.6 0.003 
   no use reference   
       
 Nursery Tetracycline 100,000 pig-days 0.9 0.8 - 1.0 0.047 
       
 Sow Tetracycline 100,000 pig-days 1.6 1.1 - 2.3 0.008 
       
 Grow-finish Beta-lactam any use 7.9 2.8 - 21 <.0001 
   no use reference   
      
 Herd type Commercial 2.6 1.5 - 4.9 0.004 
   Breeding stock   reference     
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Figure 7.1 Relationship between tetracycline use in nursery pigs and tetracycline resistance in E. 
coli from grow-finish pigs 
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Figure 7.2 Relationship between macrolide use in grow-finish pigs and streptomycin resistance 
in E. coli from grow-finish pigs 
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CHAPTER 8 
ASSOCIATIONS BETWEEN ANTIMICROBIAL EXPOSURE AND RESISTANCE IN 
FECAL CAMPYLOBACTER SPP. FROM GROW-FINISH PIGS ON-FARM IN ALBERTA 
AND SASKATCHEWAN CANADA 
8.1 Introduction 
Campylobacter species are a leading cause of bacterial enteritis for people in many 
counties, including Canada (1,2). Campylobacter jejuni are responsible for 80 to 90% of clinical 
disease, while Campylobacter coli cause 5 to 10% of cases (2,3). Although most enteric 
Campylobacter infections are self-limiting, people requiring antimicrobial therapy are often 
treated with a fluoroquinolone or macrolide. Hence, the growing resistance to these drugs is a 
serious public health problem (4-7). This problem may be linked to antimicrobial use in food 
animals because Campylobacter infections are primarily foodborne (1,5).  
 
Pigs are an important reservoir for C. coli; most swine herds are Campylobacter spp. 
positive and the prevalence in slaughter age pigs ranges between 53 and 85% (8,9). 
Campylobacter coli from pigs are commonly resistant to macrolides (erythromycin and 
azithromycin, 43 to 81%) while resistance to quinolones is more variable (ciprofloxacin, 3 to 
100%; nalidixic acid, 5 to 100%) (10-17). In North America, swine producers use antimicrobials 
to treat and prevent disease and to improve growth performance (18,19). Despite this, the 
relationship between antimicrobial use and resistance in Campylobacter spp. has not been 
described on swine farms. Furthermore, antimicrobial resistance in Campylobacter from pigs on 
Canadian farms has not been described to date. This study's primarily objective was to describe 
antimicrobial resistance (AMR) in Campylobacter spp. from grow-finish pigs on western 
194 
Canadian farms (Alberta and Saskatchewan). Additional objectives were to evaluate 
antimicrobial use as a risk factor for resistance to macrolides and quinolones, and to estimate the 
variability in resistance within herds. Clustering within herds indicates the potential for herd 
level interventions to control AMR (20,21).  
 
8.2 Materials and Methods 
8.2.1 Herd selection and data collection 
The number of herds enrolled, and samples analyzed, were subject to practical and 
financial constraints. Eight swine veterinarians each recruited two to four study herds. Thirteen 
herds were in Saskatchewan and seven in Alberta. Herd inclusion criteria included a minimum of 
100 sows and enrollment in the Canadian Quality Assurance® (CQA®) Program (22). At 
selection, the researchers were blind to antimicrobial use practices in the herds.  
 
Each herd was visited between May and September of 2004. During this visit, 20 to 25 
pens of apparently healthy grow-finish pigs were identified using a random numbers table. One 
composite sample, consisting of feces from five pigs, was collected from each of these pens. The 
herd owner or manager used existing records to complete a survey describing antimicrobial use 
through feed and water at the production phase level. For every exposure of suckling, nursery, 
grow-finish pigs and sows in the previous 12 months, the product used, number of pigs, and 
number of days was recorded. Inventory and management data were also collected (Table 8.1). 
Antimicrobial use was quantified as the antimicrobial exposure incidence (AEI) and reported for 
1,000 or 100,000 pig-days at risk to facilitate interpretation (Equation 1).  
 
Equation 1. Formula for Antimicrobial Exposure Incidence (AEI) 
195 
AEI = [Pigs E* Days E] / [Pigs R * Days R] 
E = exposed 
R = at risk 
 
8.2.2 Isolation and identification 
Samples were sent on ice to the Laboratory Services Division, University of Guelph, 
Guelph, Ontario for Campylobacter isolation within 24 h of collection. The isolation protocol 
was based on two previously reported methods (23,24). From each sample, a 25 g fecal aliquot 
was homogenated in 225 ml of Rosef’s broth. The Rosef’s broth contained 10 g Peptone (BD), 8 
g lab Lemco powder (Oxoid), 1 g yeast extract (BD), 5 g NaCl (Fisher), 16 ml of Resazurin 
solution (25 mg of Resazurin (Difco) in 100 ml distilled water) and 984 ml of distilled water. 
One swab of the homogenated mixture was streaked onto Charcoal Selective Media (CSM; 
OXOID CM0739 with supplement OXOID SR155) and incubated at 43° C for 48 to 72 h. 
Selective enrichment was also performed; 625 µl of FBP solution (equal volume mixture of: 
10% ferrous sulfate, 10% sodium metabisulfite and 10% sodium pyruvate) was added to the 
Rosef’s broth and incubated at 30° C for 4 h. Following this, 1.0 ml of cefoperazone (Sigma 
C4292), 1.0 ml of cycloheximide (HP Biomedicals 100183), and 5.0 ml of VTP [0.5 g 
vancomycin (Sigma V2002), 0.25g trimethoprim (Sigma T0667), 0.035 g polymyxin B sulfate 
(Sigma P1004) in 1 L distilled water] were added and the broth was re-incubated at 37° C for 2 h 
followed by 43° C for 44 h. A swab of the enriched broth was streaked onto Mueller-Hinton 
Blood Agar (MHBA) plates that contained the same antibiotics as above. The MHBA plates 
were incubated at 43° C for 48 to 72 h. Positive control of Campylobacter jejuni ATCC 33560 
and negative control of Escherichia coli ATCC 25922 were run concurrently. All incubations 
occurred under microaerophilic conditions (85% nitrogen, 10% carbon dioxide and 5% oxygen).  
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 Typical colonies were selected from the CSM and MHBA plates for darkfield 
microscopy examination using the wet-mount technique. Those with typical corkscrew motility 
were subcultured onto MHBA plates and incubated at 35° C for 24 to 48 h to obtain pure 
cultures. Campylobacter identification was based on colonies being Gram-negative, catalase 
positive, oxidase positive and having a spiral S-shape or sea gull-wing morphology. The 
Campylobacter species was identified through indoxyl acetate and hippurate hydrolysis (25,26). 
A swab of growth from the MHBA plate was mixed in glycerol peptone (250 ml Glycerol 
(Neutral) (Sigma), 10g Neo-peptone (BD), 5g NaCl (Fisher S671) and 750 ml distilled water) to 
create a turbid suspension. Growth from the same plate was collected and inoculated into a 
cryovial with beads. The glycerol peptone culture and cryovial were stored at minus 80° C.  
 
8.2.3 Antimicrobial susceptibility testing  
Antimicrobial susceptibility testing was performed by the Laboratory for Foodborne 
Zoonoses, Guelph, Ontario using the Etest® (AB Biodisk) according to the manufacturer’s 
instructions. Briefly, Campylobacter isolates were subcultured onto MHBA plates and incubated 
overnight at 42° C. All incubations were under microaerophilic conditions (85% nitrogen, 10% 
carbon dioxide and 5% oxygen). Colonies were suspended in 2 ml of Mueller-Hinton broth to 
obtain turbidity equivalent to a 0.5 McFarland standard using a MicroScan turbidity meter (Dade 
Behring Inc., West Sacramento CA). The suspensions were streaked onto Mueller-Hinton Agar 
plates supplemented with 5% laked horse blood with a sterile swab to create a lawn growth over 
the entire plate. Pairs of Etest® strips containing ampicillin, azithromycin, chloramphenicol, 
ciprofloxacin, clindamycin, erythromycin, gentamicin, nalidixic acid, spectinomycin, or 
tetracycline, were applied in antiparallel fashion onto each plate and incubated in a 
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microaerophilic environment at 37° C for 48 h. Bactericidal antibiotic Etest® strips were read 
where 100% inhibition intersected with the strip (Table 8.2). If this occurred between marks on 
the strip, the minimum inhibitory concentration (MIC) was rounded up to the next gradient 
marking. Bacteriostatic antibiotic strips were read at 80% inhibition / 20% growth (Table 8.2). If 
this occurred between markings on the strip, the MIC was rounded down. Breakpoints used by 
the National Antimicrobial Resistance Monitoring System (NARMS) and Canadian Integrated 
Program for Antimicrobial Resistance Surveillance (Dutil, personal communication), based on 
the Clinical and Laboratory Standards Institute (CLSI) recommendations for Enterobacteriaceae, 
were used (27-30). Specifically the resistance breakpoints were as follows: ampicillin ≥32, 
azithromycin ≥8, chloramphenicol ≥32, ciprofloxacin ≥4, clindamycin ≥8, erythromycin ≥32, 
gentamicin ≥8, nalidixic acid ≥64, spectinomycin ≥32 and tetracycline ≥16. Spectinomycin 
breakpoints were based on those previously used in Denmark because CIPARS and NARMS 
have no established breakpoint (16). Quality control organisms included Escherichia coli ATCC 
25922, Staphylococcus aureus ATCC 29213, Campylobacter jejuni ATCC 33560 and 
Campylobacter coli ATCC 33559. Quality control was ensured by incubating these, and a blank 
control, at 37° C under microaerophilic conditions for 48 h. The Escherichia coli ATCC 25922, 
Staphylococcus aureus ATCC 29213, and blank control were also incubated at 37° C under 
aerobic conditions for 24 h.  
 
8.2.4 Statistical analysis 
As defined by the World Health Organization (WHO), an antimicrobial class refers to 
“agents with similar chemical structures that exert an effect on the same target in bacteria and 
may be affected by the same mechanism of resistance” (7). Five classes were represented by a 
single antimicrobial: ampicillin, chloramphenicol, gentamicin, spectinomycin, and tetracycline. 
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Two classes had more than one antimicrobial considered because of their importance to human 
medicine. An isolate was considered resistant to quinolones if resistant to ciprofloxacin or 
nalidixic acid, and resistant to macrolides if resistant to azithromycin (an azalide), or 
clindamycin (a lincosamide), or erythromycin (a macrolide).  
 
Data were stored and organized using Microsoft Access (Microsoft Corporation, USA) 
and descriptive statistics were calculated using Microsoft Excel (Microsoft Corporation, USA). 
Generalized estimating equations (PROC GENMOD, SAS for Windows version 9.1, SAS 
Institute Inc., Cary, North Carolina) were used to estimate the prevalence of AMR and examine 
the association between antimicrobial use and AMR. All models had a binomial distribution, 
logit link function and adjusted for clustering within herds using an exchangeable correlation 
structure (20). When necessary, extra-binomial variation was permitted by a scale parameter 
equal to the square root of the Pearson’s Chi-Square divided by the degrees of freedom in the 
model. Population-average prevalence estimates for resistance to each antimicrobial, and each 
drug class, were calculated from the intercept (β0) and 95% confidence intervals (CI) of the null 
models using the formula 1/[1 + exp(-β0)] (20). Susceptibility results were not stratified by 
Campylobacter species as biochemical speciation is imperfect, and isolates were predominantly 
C. coli (31).  
 
Antimicrobial use variables were investigated as potential risk factors for resistance to 
macrolides and quinolones, important therapeutic drugs for human campylobacteriosis. 
Antimicrobial use was categorized into five classes: i) aminoglycosides (including 
aminocyclitols), ii) beta-lactams, iii) macrolides (including lincosamides and pleuromutilins), iv) 
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sulfonamides, and v) tetracyclines (7,32). Antimicrobial use was then stratified by the production 
phase exposed. 
 
The following model building strategy was used for each resistance outcome. The 
unconditional association between each antimicrobial use variable and resistance was 
determined. Outcomes were modeled using the number of resistant isolates in the herd 
(numerator) over the number of isolates tested in the herd (denominator). Predictor variables 
were modeled as continuous if the AEI was greater than zero in five or more herds. The 
associations between antimicrobial use, measured as a continuous variable, and resistance were 
examined for linearity by graphically assessing the effect estimate for each quartile against the 
log odds of the outcome. Antimicrobial use variables associated with the outcome in a non-linear 
manner were categorized as no use, low use (0.1 to 500 treatments per 1000 pig-days) and high 
use (>500 treatments per 1000 pig-days) because this categorization best fit the data. Variables 
used in less than five herds were collapsed to ‘any use’ versus ‘no use’ (dichotomous). Variables 
reported in only one herd were not examined.  
 
Antimicrobial use variables with an unconditional P < 0.2 were included in the full 
model. Manual step-wise backward selection was used to develop a main effects model, 
retaining only variables significant at P < 0.05. Variables removed from the full model were re-
introduced into the main effects model individually; this prevented inappropriate removal due to 
confounding. Two-way interactions were considered between significant variables within a 
production phase and were retained, along with their main effects, if P < 0.05. Eight 
management variables were examined for potential confounding (Table 8.1). These were 
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retained, along with their main effects, if their inclusion altered a parameter estimate by more 
than 25%. Residuals of the final models were examined visually for outliers (20). The 
association between each variable of interest and the outcome was reported as an odds ratio 
(OR=expβ) with 95% CI (20). 
 
A second modeling approach estimated the extent AMR clustered within herds. The 
variance at the herd level was determined using restricted maximum likelihood estimation. 
Models had a binomial distribution, logit link function and modeled the outcome as the 
proportion of resistant isolates in a herd in the numerator and number of isolates tested in the 
denominator. Under-dispersion was accounted for by allowing random variation at the lowest 
level (21). The restricted generalized iterative least-squares (RIGLS) algorithm (MLwiN version 
2.0r, Centre for Multilevel Modelling, Institute of Education, University of London, London, 
England) was used and second-order penalized quasi-likelihood (PQL-2) estimates were reported 
(21,33). Intra-class correlation coefficients (ICC) were approximated by the latent variable 
approach (20,21,33). Specifically, the herd variance was divided by the total variance after fixing 
the error variance at π2/3.  
  
8.3 Results 
8.3.1 Prevalence of Campylobacter spp. and antimicrobial susceptibility  
Campylobacter were isolated from 438 of 444 pooled fecal samples. Of the positive 
samples, 86.5% were C. coli (379), 2.3% were C. jejuni (10), 0.9% were C. lari (4) and 10.3% 
(45) could not be speciated because the lawn growth was too weak to perform hippurate 
hydrolysis and indoxyl acetate tests. Antimicrobial susceptibility testing was performed on 405 
isolates (average; 20 per herd). These included all of the C. coli, C. jejuni and C. lari and 12 
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unspeciated isolates. The remaining 33 unspeciated samples also had lawn growth too weak for 
susceptibility testing.  
 
The prevalence of resistance to individual drugs ranged from 0 to 71% (Table 8.2). The 
highest prevalence of resistance was to clindamycin followed by azithromycin and erythromycin 
(Table 8.2). Concurrent resistance to these three drugs was the most common pattern identified 
(Table 8.3). With the exception of three isolates, which were resistant to clindamycin but 
susceptible to erythromycin and azithromycin, isolates resistant to any one of these drugs were 
resistant to all three. Therefore, although the WHO classifies clindamycin separately from the 
macrolides, these drugs were grouped as one resistance class for the purpose of this study. Cross-
resistance was not complete between ciprofloxacin and nalidixic acid. Thirty-five isolates were 
resistant to both drugs, two were resistant to ciprofloxacin only, and eleven were resistant to 
nalidixic acid only. Hence, 14.8% (95% CI, 6.5 to 30.2) of the isolates were classified as 
quinolone resistant. Twelve percent (95% CI, 5.5 to 24.0) of the isolates were susceptible to all 
drugs while 64.0% (95% CI, 47.1 to 78.0) were resistant to drugs in two or more classes. Three 
percent (12) of the Campylobacter spp. were resistant to drugs in four of the seven antimicrobial 
classes.  
 
8.3.2 Antimicrobial use and resistance 
In every herd, antimicrobials were administered through feed and/or water to groups of 
pigs in the previous 12 months. Suckling pigs were exposed to antimicrobials in 10 herds, 
nursery pigs in all 20 herds, grow-finish pigs in 15 herds, and sows in 8 herds. Seven producers 
used sulfonamides, 9 used aminoglycosides, 9 used beta-lactams, 15 used tetracyclines and 18 
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used macrolides (Table 8.4). No producers reported using quinolones, chloramphenicol or 
florfenicol.  
  
Campylobacter spp. resistance to macrolides and quinolones were each associated with 
one antimicrobial use variable. The odds of resistance to a macrolide increased 1.3 times (95% 
CI, 1.0 to 1.6; P = 0.049) for every 100,000 pig days macrolides were administered to nursery 
pigs. In contrast, the odds of resistance to a quinolone were 8.9 times higher (95% CI, 1.3 to 
61.9; P = 0.03) in Campylobacter spp. from herds with no beta-lactam use in grow-finish pigs 
compared to Campylobacter spp. from herds with exposure. Management variables were not 
important confounders in either relationship (Table 8.1).  
 
8.3.3 Within herd variability in antimicrobial resistance 
All of the isolates from individual herds were often either susceptible or resistant to a 
drug class, providing evidence that AMR clustered within herds (Table 8.5). This was most 
notable for macrolide resistance as only six herds had a mixture of susceptible and resistant 
isolates. The extremely high intra-class correlations (ICC) described just how similar the AMR 
was for isolates from the same herd (Table 8.5). Even tetracycline, the resistance with the lowest 
ICC, showed very strong clustering within herds.  
 
8.4 Discussion 
Many of these Campylobacter spp., isolated from grow-finish pigs on farms in western 
Canada were resistant to macrolides and quinolones. To date, the role of pork in foodborne 
campylobacteriosis is unclear because the source of human infections is rarely identified and risk 
factor studies seldom consider C. coli independently (6,34,35). Similarly, the public health 
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significance of AMR is also unmeasured because tracing resistance in animals to disease in 
people is difficult (6,35,36). However, C. coli can rank among the top four causes of human 
enteric infections (37). When treatment is required, macrolides and quinolones are first-line 
therapies (5-7). Thus given Campylobacter’s zoonotic potential, the frequency of resistance in 
these isolates is concerning.  
 
It is also concerning that only 12% of these isolates were susceptible to all ten drugs 
tested. Resistance was largely attributable to the macrolides and our findings are consistent with 
other North American and European reports (10-17). Campylobacter coli, and particularly C. 
coli from pigs, typically have a higher prevalence of resistance to macrolides than C. jejuni (12-
16,38). Although the reasons for this remain speculative, it is notable that macrolides are used 
extensively in pigs (18,19,39). 
 
The 10% observed resistance to ciprofloxacin was interesting considering no study herds 
reportedly used quinolones. The frequency of resistance was similar to other North America 
findings (1 to 11%) (15,17,38,40) and lower than reported in Europe (28 to 100%) (10,12-14). 
These isolates’ susceptibility to chloramphenicol and gentamicin also corresponded with 
previous North American reports (0 to <5%) (9,15,17). To date, only European studies have 
considered spectinomycin resistance and our data fell in the middle of these previous reports (4 
and 94%) (10,16). Although considerably more ampicillin resistance has been described in Spain 
(66%), our findings were similar to other Canadian and European studies (6 to 20%) (11,13-16). 
Ampicillin and spectinomycin resistance were of interest because beta-lactams and 
spectinomycin are used in Canadian pigs (18,39). Finally, the frequency of resistance to 
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tetracycline was lower than other North American reports (68 to 71%) (15,17). Interestingly, it 
was also lower than that reported from antibiotic-free farms in the United States (56%) (9).  
 
Resistance to multiple antimicrobial classes was described, rather than resistance to 
multiple drugs. This more accurately depicted the extent of multiresistance because isolates had 
almost complete cross-resistance within the macrolide and quinolone classes. Comparing the 
level of multiresistance between studies is hindered by differences in the antimicrobials tested. 
However, the 64% resistance to two or more drug classes was much closer to the level of 
multiresistance described in France and Belgium than the 4% resistance to three or more drugs 
reported from antibiotic-free swine herds in the United States (11,14,41). Campylobacter from 
conventional swine herds have shown significantly more multiple resistance than those from 
herds with antibiotic free production (9). Likewise, Campylobacter spp. from herds with lame 
and ill-thrift pigs (where herd health variables reflected antimicrobial use) had substantially 
higher odds of being multiple resistant (42). Considering these previous reports, it was important 
to consider antimicrobial exposures as risk factors for resistance. 
 
High level Campylobacter resistance to erythromycin, as seen in these isolates, is 
predominantly due to a mutation in the 23S rRNA gene (43,44). Thus, the association between 
macrolide use and resistance suggests macrolide exposure selected for mutated bacteria. 
Although these Campylobacter spp. were from grow-finish pigs, antimicrobial exposure in 
nursery pigs was the significant risk factor. Observational and experimental studies support that 
antimicrobial use in one production phase can affect AMR in pigs from another phase (45-47). 
This finding may be of great clinical importance because macrolides are used extensively in 
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Canadian pigs (18,19). We feel it is crucial that swine producers and veterinarians know 
antimicrobial exposure in young pigs may have food safety repercussions. 
 
Enrofloxacin exposure can increase C. coli resistance to quinolones (48). However, direct 
selection does not explain these isolates’ resistance because study herds reported no quinolone 
exposure. Others have also found ciprofloxacin resistant Campylobacter in swine herds without 
quinolone exposure, and even in herds raising antibiotic-free pigs (9,41,42). This project 
identified one antimicrobial use risk-factor for quinolone resistance; administering beta-lactams 
to grow-finish pigs appeared protective. We propose three possible explanations for this finding. 
First, it may be a true association reflecting an undefined, antagonistic relationship between 
quinolone and beta-lactam resistance genes. Second, considering the strong association and the 
low exposure incidence in the herds with grow-finish beta-lactam exposure, this variable may 
have acted as a proxy for another common, but undefined, risk factor. Third, the association 
could be spurious. Although this seems unlikely given the bounds of the confidence interval, 
future studies should re-investigate this relationship.  
 
Strong similarities were found between individual drug resistances within herds. This 
could indicate two things: risk factors for resistance may have been present and pervasive in 
some herds but not present in others or clustering could be due to resistant clones. The clonal 
hypothesis is unlikely considering resistance phenotypes varied within herds (data not shown). 
For example, although macrolide resistance was highly similar within a herd the macrolide 
resistant isolates carried different additional resistances. Additionally, others have found 
extensive genetic diversity in resistant Campylobacter in swine herds (49,50). Future on-farm 
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studies might attempt to explain this uniformity within herds. Meanwhile, clustering must be 
considered in study design and statistical analyses.  
 
This study’s primary weakness was the small number of herds in this convenience 
sample; a limitation common to pilot studies. The authors had no knowledge of the antimicrobial 
use practices in herds at the time of enrollment. However, to ensure adequate antimicrobial use 
records, herds had to be enrolled in the CQA® program (22). Although this could have 
influenced antimicrobial use practices, it is unlikely to have biased results because at the time of 
the study more than 98% of herds in Alberta and Saskatchewan participated in this program 
(personal communication Sarah Turner, Alberta Pork and Harvey Wagner, Sask Pork). 
Repeating this study in a larger number of randomly selected herds would improve the ability to 
extrapolate prevalence results. It would also make risk factor estimates more precise and might 
allow consideration of individual drugs rather than antimicrobial classes. 
 
Extrapolating these data beyond the study herds should be done with caution. Likewise, 
comparing these data to other publications should be done cautiously because isolation 
techniques, antimicrobial susceptibility testing methods and breakpoints can affect results (51). 
Presenting our data with other North American reports provides a regional context 
(9,15,17,38,41). European studies were referred to because of extensive reporting on 
Campylobacter AMR (10-14,16). However, we do not suggest that differences in AMR are soley 
due to variations in antimicrobial use because geography, temporality, seasonality and husbandry 
were not considered. 
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This project described the prevalence of antimicrobial resistant Campylobacter spp. from 
20 swine herds in Alberta and Saskatchewan, Canada. It identified a dose-response relationship 
between macrolide use and resistance. This study was cross sectional and could not definitively 
prove that antimicrobial use caused the observed resistance. However, in light of previous 
evidence, the study findings support a causal link between antimicrobial exposure and resistance 
in pigs (47,48,52). Continued research may generate sufficient knowledge to control AMR on-
farm. As this would ultimately mitigate concerns about food safety from antimicrobial resistance 
in pork, we strongly advocate for continued on-farm AMR research.  
 
208 
8.5. References  
1. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe R. Food-
Related Illness and Death in the United States. Emerg Infect Dis 1999;5:607-625. 
2. Government of Canada. Canadian Integrated Surveillance Report Salmonella, Campylobacter, 
pathogenic E. coli and Shigella, from 1996 to 1999. Canada Communicable Disease Report. 
Ottawa, Ontario: Division of Enteric, Foodborne and Waterborne Diseases, Centre for Infectious 
Disease Prevention and Control, Public Health Agency of Canada, Health Canada, 2003. 
Accessed March 1, 2007. http://www.phac-aspc.gc.ca/publicat/ccdr-
rmtc/03vol29/29s1/index.html 
3. Nachamkin I, Engberg J, Aarestrup FM. Diagnosis and Antimicrobial Susceptibility of 
Campylobacter Species. In: Nachamkin I Blaser MJ eds. Campylobacter.Second Edition. Second 
edition. Washington D.C.: ASM Press, 2000:45-66. 
4. Aarestrup FM, Engberg J. Antimicrobial resistance of thermophilic Campylobacter. Vet Res 
2001;32:311-321. 
5. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and 
Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends 
in Human Isolates. Emerg Infect Dis 2001;7:24-24. 
6. Smith KE, Bender JB, Osterholm MT. Antimicrobial resistance in animals and relevance to 
human infections. In: Nachamkin I Blaser MJ eds. Campylobacter.Second Edition. Second 
edition. Washington DC: ASM Press, 2000:483-495. 
7. World Health Organization. Critically Important Antibacterial Agents for Human Medicine 
for Risk Management Strategies of Non-Human Use: report of a WHO working group 
consultation. Canberra, Australia: 2005. Accessed March 17, 2007. 
http://www.who.int/foodborne_disease/resistance/amr_feb2005.pdf 
8. Weijtens MJBM, Bijker PGH, Van der Plas J, Urlings HAP, Biesheuvel MH. Prevalence of 
Campylobacter in Pigs During Fattening; An Epidemiological Study. Vet Quart 1993;15:138-
143. 
9. Thakur S, Gebreyes WA. Prevalence and antimicrobial resistance of Campylobacter in 
antimicrobial-free and conventional pig production systems. J Food Prot 2005;68:2402-2410. 
10. Lucey B, Feurer C, Greer P, Moloney P, Cryan B, Fanning S. Antimicrobial resistance 
profiling and DNA Amplification Fingerprinting (DAF) of thermophilic Campylobacter spp. in 
human, poultry and porcine samples from the Cork region of Ireland. J Appl Microbiol 
2000;89:727-734. 
11. Payot S, Dridi S, Laroche M, Federighi M, Magras C. Prevalence and antimicrobial 
resistance of Campylobacter coli isolated from fattening pigs in France. Vet Microbiol 
2004;101:91-99. 
209 
12. Pezzotti G, Serafin A, Luzzi I, Mioni R, Milan M, Perin R. Occurrence and resistance to 
antibiotics of Campylobacter jejuni and Campylobacter coli in animals and meat in northeastern 
Italy. Int J Food Microbiol 2003;82:281-287. 
13. Sáenz Y, Zarazaga M, Lantero M, Gastañares MJ, Baquero F, Torres C. Antibiotic 
Resistance in Campylobacter Strains Isolated from Animals, Foods, and Humans in Spain in 
1997-1998. Antimicrob Agents Chemother 2000;44:267-271. 
14. Van Looveren M, Daube G, De Zutter L, Dumont JM, Lammens C, Wijdooghe M, 
Vandamme P, Jouret M, Cornelis M, Goossens H. Antimicrobial susceptibilities of 
Campylobacter strains isolated from food animals in Belgium. J Antimicrob Chemother 
2001;48:235-240. 
15. Guévremont E, Nadeau É, Sirois M, Quessy S. Antimicrobial susceptibilities of thermophilic 
Campylobacter from humans, swine and chicken broilers. Can J Vet Res 2006;70:81-86. 
16. Aarestrup FM, Nielsen EM, Madsen M, Engberg J. Antimicrobial Susceptibility Patterns of 
Thermophilic Campylobacter spp. from Humans, Pigs, Cattle, and Broilers in Denmark. 
Antimicrob Agents Chemother 1997;41:2244-2250. 
17. United States Department of Agriculture. Collaboration in Animal Health and Food Safety 
Epidemiology (CAHFSE) Annual Report, July 2003 - June 2004. 2004. Accessed 
http://www.aphis.usda.gov/cahfse/index.htm 
18. Rajic A, Reid-Smith R, Deckert AE, Dewey CE, McEwen SA. Reported antibiotic use in 90 
swine farms in Alberta. Can Vet J 2006;47:446-452. 
19. Dunlop RH, McEwen SA, Meek AH, Friendship RA, Clarke RC, Black WD. Antimicrobial 
drug use and related management practices among Ontario swine producers. Can Vet J 
1998;39:87-96. 
20. Dohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research. Charlottetown, PEI: 
AVC Inc., 2003.  
21. Browne WJ, Subramanian SV, Jones K, Goldstein H. Variance partitioning in multilevel 
logistic models that exhibit overdispersion. J R Statist Soc A 2005;168:599-613. 
22. Canadian Pork Council. Canadian Quality Assurance Producer Materials. CQA For Canadian 
Hog Producers. Accessed March 17, 2007, Last Updated 2007. http://www.cqa-
aqc.ca/home_e.cfm 
23. Garcia MM, Lammerding AM: Isolation of Thermophilic Campylobacters from Fresh Pork, 
Beef, Veal, Poultry and Ready-to-Eat Meat Products, version 4.0, in Animal and Plant Health 
Directorate Official Protocol, Meat Safety Laboratory Procedures ManualAgriculture Canada, 
1993. 
24. Ransom GM, Rose BE. Isolation, Identification, and Enumeration of Campylobacter 
jejuni/coli from Meat and Poultry Products. In: United States Department of Agriculture Food 
210 
Safety and Inspection Servise (USDA / FSIS) eds. Microbiology Laboratory Guidebook.Third 
edition. Washington, D.C.: 1998: 
25. Loir H. New, Extended Biotyping Scheme for Campylobacter jejuni, Campylobacter coli, 
and Campylobacter laridis. J Clin Microbiol 1984;20:636-640. 
26. Hodge DS, Borczyk A, Wat L-L. Evaluation of the Indoxyl Acetate Hydrolysis Test for the 
Differentiation of Campylobacters. Journal of Clinical Microbiology 1990;28:1482-1483. 
27. Clinical and Laboratory Standards Institute: Performance standards for Antimicrobial Disk 
and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Informational Supplement: 
Updated tables for the NCCLS antimicrobial susceptibility testing standard M31-A2, in 
CLSI2004. 
28. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial 
Susceptibility Testing; Fifteenth Informational Supplement M100-S15, in CLSI2005, pp 102-
106. 
29. Government of Canada. Canadian Integrated Program for Antimicrobial Resistance 
Surveillance (CIPARS) 2005 Preliminary Results. Guelph, ON: Public Health Agency of 
Canada, 2007. Accessed March 17, 2007. http://www.phac-aspc.gc.ca/cipars-
picra/2005_pr_e.html 
30. United States Department of Agriculture. National Antimicrobial Resistance Monitoring 
System, MIC Distributions and Percent Resistance among Campylobacter coli and 
Campylobacter jejuni isolates from poultry for 2006. Campbell JR Bacterial Epidemiology 
Antimicrobial Resistance. Accessed August 25, 2007, Last Updated April 13, 2007. 
http://ars.usda.gov/Main/docs.htm?docid=6750 
31. Vandamme P. Taxonomy of the Family Campylobacteraceae. In: Nachamkin I Blaser MJ 
eds. Campylobacter, 2nd Edition.Washington, D. C.: ASM Press, 2000:3 - 44. 
32. Prescott JF, Baggot JD, Walker RD. Antimicrobial Therapy in Veterinary Medicine. 3rd. 
Ames, Iowa: Iowa State University Press, 2000.  
33. Rasbach J, Steele F, Browne W, Prosser B. A User's Guide to MLwiN Version 2.0. United 
Kingdom: Centre for Multilevel Modelling, Institute of Education, University of London, 2004.  
34. Gillespie IA, O'Brien SJ, Frost JA, Adak GK, Horby P, Swan AV, Painter MJ, Neal KR, the 
Campylobacter Sentinel Surveillance Scheme Collaborators. A Case-Case Comparison of 
Campylobacter coli and Campylobacter jejuni Infection: A Tool for Generating Hypotheses. 
Emerg Infect Dis 2002;8:937-942. 
35. Siemer BL, Nielsen EM, On SLW. Identification and Molecular Epidemiology of 
Campylobacter coli Isolates from Human Gastroenteritis, Food, and Animal Sources by 
Amplified Fragment Length Polymorphism Analysis and Penner Serotyping. Appl Environ 
Micro 2005;71:1953-1958. 
211 
36. Guévremont E, Higgins R, Quessy S. Characterization of Campylobacter Isolates Recovered 
from Clinically Healthy Pigs and from Sporadic Cases of Campylobacteriosis in Humans. J Food 
Prot 2004;67:228-234. 
37. Tam CC, O'Brien SJ, Adak GK, Meakins SM, Frost JA. Campylobacter coli - an important 
foodborne pathogen. J Infect 2003;47:28-32. 
38. Larkin C, van Donkersgoed C, Mahdi A, Johnson P, McNab B, Odumeru J. Antibiotic 
Resistance of Campylobacter jejuni and Campylobacter coli Isolated from Hog, Beef, and 
Chicken Carcass Samples from Provincially Inspected Abattoirs in Ontario. J Food Prot 
2006;69:22-26. 
39. Bush EJ, Biehl LG. Use of antibiotics and feed additives in weaned market pigs by U.S. pork 
producers. Proceedings of American Association of Swine Veterinarians 2002. 329-331. 
40. United States Department of Agriculture. Collaboration in Animal Health and Food Safety 
Epidemiology (CAHFSE) Annual Report, July 2004 - June 2005. 2005. Accessed May 1, 2007. 
http://www.aphis.usda.gov/cahfse/index.htm 
41. Gebreyes WA, Thakur S, Morrow WEM. Campylobacter coli: prevalence and antimicrobial 
resistance in antimicrobial-free (ABF) swine production systems. J Antimicrob Chemother 
2005;56:765-768. 
42. Schuppers ME, Stephan R, Ledergerber U, Danuser J, Bissig-Choisat B, Stärk KDC, Regula 
G. Clinical herd health, farm management and antimicrobial resistance in Campylobacter coli on 
finishing pig farms in Switzerland. Prev Vet Med 2005;69:189-202. 
43. Payot S, Avrain L, Magras C, Praud K, Cloeckaert A, Chaslus-Dancla E. Relative 
contribution of target gene mutation and efflux to fluoroquinolone and erythromycin resistance, 
in French poultry and pig isolates of Campylobacter coli. Int J Antimicrob Agents 2004;23:468-
472. 
44. Kim J-S, Carver DK, Kathariou S. Natural Transformation-Mediated Transfer of 
Erythromycin Resistance in Campylobacter coli Strains from Turkeys and Swine. Appl Environ 
Microbiol 2006;72:1316-1321. 
45. Dunlop RH, McEwen SA, Meek AH, Clarke RC, Black WD, Friendship RM. Associations 
among antimicrobial drug treatments and antimicrobial resistance of fecal Escherichia coli of 
swine on 34 farrow-to-finish farms in Ontario, Canada. Prev Vet Med 1998;34:283-305. 
46. Akwar TH. Prevalence and risk factors of antimicrobial resistance of fecal Escherichia coli 
and Enterococci of pigs and farm residents [PhD dissertation]. Guelph, Ontario: University of 
Guelph, 2003. 287 p. 
47. Mathew AG, Garner KN, Ebner PD, Saxton AM, Clift RE, Liamthong S. Effects of 
Antibiotic Use in Sows on Resistance of E. coli and Salmonella enterica Typhimurium in Their 
Offspring. Food Path Dis 2005;2:212-220. 
212 
48. Delsol AA, Sunderland J, Woodward MJ, Pumbwe L, Piddock LJV, Roe JM. Emergence of 
fluoroquinolone resistance in the native Campylobacter coli population of pigs exposed to 
enrofloxacin. J Antimicrob Chemother 2004;53:872-874. 
49. Thakur S, Morrow WEM, Funk JA, Bahnson PB, Gebreyes WA. Molecular Epidemiologic 
Investigation of Campylobacter coli in Swine Production Systems, Using Multilocus Sequence 
Typing. Appl Environ Microbiol 2006;72:5666-5669. 
50. Keller J, Perreten V. Genetic diversity in fluoroquinolone and macrolide-resistant 
Campylobacter coli from pigs. Vet Microbiol 2006;113:103-108. 
51. Silley P. Campylobacter and fluoroquinolones: a bias data set? Environ Micro 2003;5:219-
230. 
52. Funk JA, LeJeune JT, Wittum TE, Rajala-Schultz PJ. The Effect of Subtherapeutic 
Chlortetracycline on Antimicrobial Resistance in the Fecal Flora of Swine. Microb Drug Resist 
2006;12:210-218. 
 
213 
Table 8.1 Management variables considered as potential confounders of the relationship between 
antimicrobial use and resistance (N=20 herds). 
  
Level Variable  Herds 
Herd Purpose for which animals were sold breeding stock 7 
  slaughter only 13 
 Sites farrow-to-finish herd located on one 15 
  two 2 
  three 3 
Grow-finish  All-in-all-out by room or barn yes 9 
  no 11 
 Pens emptied between batches yes 12 
  no 8 
 Manure removed between batches yes 10 
  no 10 
 Pens washed and disinfected between batches yes 8 
  no 12 
 Times barn washed in previous 12 months mean (S)a 3 (3.7) 
 Days pens empty between batches mean (S) 1 (1.7) 
a: S represents standard deviation 
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Table 8.2 Frequency of resistant Campylobacter spp., percent prevalence of resistance adjusted 
for herd-level clustering with 95% confidence intervals, and MIC50 and MIC90 (n = 405). 
 
Antimicrobial a Frequency Prevalence 95% CI MIC50 MIC90 
Clindamycin s 300 71.3 51.6 - 85.3 256 256 
Azithromycin s 297 70.5 50.8 - 84.7 256 256 
Erythromycins 297 70.5 50.8 - 84.7 256 256 
Spectinomycin s 190 45.6 28.6 - 63.7 8 1024 
Tetracyclines 145 35.1 23.7 - 48.5 0.75 256 
Ampicillin s 57 14.8 7.5 - 27.2 6 32 
Nalidixic Acid c 46 14.3 6.2 - 29.8 8 256 
Ciprofloxacin c 37 10.1 3.3 - 26.6 0.125 2 
Chloramphenicol s 7 1.9 0.3 - 12.2 3 16 
Gentamicin c 0 0 0.0 - 0.0 0.5 0.75 
a: Superscript ‘s’ denotes bacteriostatic antimicrobials and ‘c’ denotes bacteriocidal. 
MIC (µg/ml); MIC50 and MIC90indicates the MIC at which 50% and 90% of the isolates were 
inhibited respectively  
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Table 8.3 Frequency of the ten most common antimicrobial resistance phenotypes observed in 
Campylobacter spp. isolated from grow-finish pigs (n = 405). 
 
Resistance phenotype Frequency Percent 
AZM-CLI-ERY 71 17.5 
AZM-CLI-ERY-SPT 69 17.0 
AZM-CLI-ERY-TET 51 12.6 
AZM-CLI-ERY-SPT-TET 46 11.4 
AMP-AZM-CLI-ERY-SPT 26 6.4 
TET 15 3.7 
CIP-NAL 13 3.2 
AZM-CIP-CLI-ERY-NAL-SPT 12 3.0 
AMP-SPT-TET 7 1.7 
AMP-AZM-CIP-CLI-ERY-NAL-SPT 6 1.5 
AMP, ampicillin; AZM, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CLI, 
clindamycin; ERY, erythromycin; NAL, nalidixic acid; SPT, spectinomycin; TET, tetracycline  
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Table 8.4 Frequency of herds administering antimicrobials to each production phase (N = 20 
herds), and antimicrobial exposure incidence per 1000 pig-days in herds reporting an exposure 
incidence greater than zero. 
 
 Antimicrobial Production  # of Herds  AEI in herds with any use 
Class phase reporting use Median IQRa 
Aminoglycosides Suckling 3 700 517 - 850 
 Nursery 8 272 137 - 501 
 Grow-finish 0 - -  
 Sow 0 - - 
      
Beta-lactams Suckling 3 286 238 - 310 
 Nursery 8 210 176 - 291 
 Grow-finish 3 11 6 - 17 
 Sow 1 64 - 
      
Macrolides Suckling 8 310 228 - 572 
 Nursery 17 528 411 - 974 
 Grow-finish 15 714 160 - 977 
 Sow 3 34 18 - 167 
      
Sulfonamides Suckling 3 286 238 - 310 
 Nursery 6 143 126 - 191 
 Grow-finish 1 24 -  
 Sow 0 -  -  
      
Tetracyclines Suckling 5 333 273 - 381 
 Nursery 13 226 220 - 508 
 Grow-finish 1 725 -  
  Sow 5 37 16 - 185 
a: IQR = Interquartile range presented for herds with treatment incidence > 0 
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Table 8.5 Distribution of Campylobacter spp. resistance to each antimicrobial class within herds, 
herd variance and intra-class correlation between isolates within herds (N = 20 herds, n = 405 
isolates). 
 
Number of herds Representative of 
Antimicrobial 
Class* 
Completely 
susceptible 
Completely 
resistant 
Herd 
Variance 
(SE) a 
Intra-class 
Correlation  
Ampicillin 9 0 6.8 (3.5) 0.67 
Chloramphenicol 19 0 - - 
Gentamicin 20 0 - - 
Macrolides 4 10 14.9 (11.8) 0.82 
Quinolones 8 1 12.4 (9.1) 0.79 
Spectinomycin 6 3 8.5 (4.0) 0.72 
Tetracycline 6 0 3.8 (1.4) 0.53 
* Variance and ICC only estimated for Campylobacter resistances observed at >5% prevalence 
to ensure convergence in RIGLS PQL-2 
a: Standard errors of estimate in parenthesis 
CHAPTER 9 
CONCLUSIONS 
This thesis described the antimicrobial resistance (AMR) of gram negative enteric 
bacteria from healthy pigs and investigated the relationship between resistance in E. coli 
and Campylobacter and antimicrobial exposure in swine herds. Antimicrobial resistant 
bacteria from livestock are a food safety hazard; resistant bacteria from animals can pass 
through the food processing chain and infect consumers (1-5). Pigs commonly receive 
antimicrobials and these exposures contribute to antimicrobial resistance (AMR). 
However, the extent of antimicrobial use and the relationship between antimicrobial 
exposure and resistance had not previously been described in western Canadian swine 
herds. This study was conducted in Alberta and Saskatchewan as together, these 
provinces produce 20% of Canada’s market hogs (6). Despite this sizable industry, on-
farm AMR had only been described in Salmonella from grow-finish pigs (7). In this 
concluding chapter, the key findings of this thesis are presented and the strengths and 
limitations of the project are considered. As is often the case in research, our finding 
generated many new questions. Therefore, future research directions are also presented.  
 
To address the objectives of this thesis, a cross-sectional study was conducted in a 
convenience sample of 20 swine herds. The antimicrobial exposure incidence in each 
herd was described from existing records and fresh fecal samples were collected from 
pens of healthy grow-finish pigs. In half of the herds, additional samples were collected 
from nursery pigs and sows. This allowed AMR in Salmonella to be compared across 
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production phases. The AMR phenotypes of Salmonella, Escherichia coli, and 
Campylobacter were described and a subset of E. coli was tested for resistance genes and 
virulence factors.  
 
Chapter 3 described antimicrobial use in study herds. This project differed from 
previous descriptions of antimicrobial use in Canadian pigs because the antimicrobial 
exposure incidence (AEI) per pig-day was estimated from existing on-farm records. The 
AEI through feed, water and injection of pigs in the suckling, nursery, grow-finish and 
sow production phases was described for a 12 month-period. Previously, this measure 
had only been used to estimate the injectable exposure incidence from prospectively 
maintained records (8).  
 
These study herds used similar antimicrobials and routes of administration as 
herds in Alberta, British Columbia, Ontario and the United States (8-12). Almost all 
herds used antimicrobials in feed, approximately half used water medications, and 
nursery pigs were the most commonly medicated production phase. On any day, the 
probability of in-feed exposure was 0.8 for a nursery pig and 0.3 for a grow-finish pig. 
Describing antimicrobial use as an incidence showed the extent that exposure varied 
among herds. Most notably, in-feed medication of grow-finish pigs varied from 0 to 1000 
exposures per 1000 pig-days. Although different disease pressures explained some of this 
variation, much was for growth promotion. This may be a target for judicious use 
campaigns: Grow benefits decline as pigs age and Scandinavian producers experienced 
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minimal disease problems in grower and finisher pigs following bans of growth 
promotion drugs (13-15).  
 
This study demonstrated that on-farm records maintained by producers enrolled in 
the CQA® program provided sufficient information to describe the AEI of groups of pigs. 
Exposure incidences allow relatively small changes in antimicrobial use, such as targeted 
medication at high risk groups, or shortened exposure durations, to be recognized. If 
future studies and monitoring programs report antimicrobial exposure incidences, rather 
than qualitative data, subtle decreases in drug use will be captured. Future research into 
management practices on farms with minimal drug use might identify strategies that 
eliminate unnecessary antimicrobial exposures. Widespread implementation of such 
strategies could decrease antimicrobial use in Canadian pigs while potentially improving 
profits of swine producers.  
 
In the fourth chapter, the frequency and patterns of AMR in Salmonella spp. were 
described. This thesis expanded our knowledge of on-farm AMR by testing Salmonella 
from apparently healthy grow-finish pigs in all herds, plus sows and nursery pigs in half 
of the study herds. Few studies have collected resistance data from animals distant from 
market; a study in North Carolina collected samples from multiple phases but did not 
compare resistance across phases, while another study compared resistance across phases 
but only studied three herds (16,17). Thus, describing AMR resistance in nursery pigs, 
grow-finish pigs and sows was novel. The differences observed between production 
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phases indicate there is much to learn about the development, persistence and spread of 
resistance within modern swine barns.  
 
The overall, or pooled, frequencies of resistance in these Salmonella isolates were 
similar to previous reports from healthy grow-finish pigs on farms in Alberta and from 
pigs sampled at abattoirs across Canada (9,18). However, differences were found 
between phases. Salmonella isolates from sows had less resistance to individual 
antimicrobials, and were more likely to be pansusceptible, than the isolates from the other 
phases. In contrast, Salmonella spp. from nursery pigs had more resistance to most of the 
antimicrobials tested, and were more likely to be multiresistant than isolates from the 
other phases. A tendency for young pigs to have increased rates of resistance has been 
reported in E. coli, but has not been well described in Salmonella (19,20). Others have 
speculated resistance may be increased due to physiological differences in the gut flora 
but increased resistance from antimicrobial use is also plausible considering the high 
exposure rates in these nursery pigs. Future studies should aim for sufficient power to 
account for confounding by serotype and evaluate on farm risk factors, particularly 
antimicrobial use. This would enable researchers to distinguish between normal gut 
ecology and on-farm management practices as causes for increased AMR in young pigs.  
 
Describing different resistance rates in each production phase has implications for 
mitigating resistance in pigs. Identifying less resistance in sows is encouraging because 
suckling piglets should be exposed to less resistant bacteria. The increased resistance in 
nursery pigs suggests the nursery phase may be a target for control measures. Finally, 
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finding lower resistance in grow-finish pigs compared to nursery animals confirms that 
resistance is dynamic within barns; future research should seek to identify and exploit the 
factors that cause any decreases in resistance. Future studies will need to investigate not 
only what but when interventions to control AMR are most effective.  
 
Understanding Salmonella AMR on farms is complicated by the relationship 
between serovar and resistance (17,21). Our study found certain resistance phenotypes 
occurred only in certain serovars and those serovars appeared linked to farm. Molecular 
studies could clarify the clonal relatedness between isolates within herds; these studies 
would be valuable as interventions to prevent the spread and persistence of clones may 
differ from those aimed to prevent the development of resistance. Studies investigating 
risk factors for Salmonella AMR require many isolates from numerous herds to 
differentiate potential herd and serovar effects. The relatively low number of isolates and 
herds in this study precluded antimicrobial exposure risk factor analyses. 
 
Antimicrobial resistance in E. coli was the principal focus of this thesis; three 
chapters were devoted to E. coli antimicrobial resistance phenotypes, genotypes and risk 
factors. Escherichia coli AMR phenotypes were described as the prevalence of resistance 
to each drug and multiple drug resistance patterns, as well as by estimating odds ratios 
between resistances. Overall, the frequency of pansusceptible isolates (21%) was similar 
to other on-farm studies in Canada (11,22). Encouragingly, all isolates were susceptible 
to ciprofloxacin and ceftriaxone. These drugs are considered of critical importance to 
human health due to the consequences of resistant human pathogens (23-25). Of concern, 
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one isolate was resistant to nalidixic acid, an indicator of emerging fluoroquinolone 
resistance (26). Similarly, one isolate was resistant to the third-generation cephalosporin 
ceftiofur. Although infrequent in this study, on-farm monitoring in the United States has 
found 1.5% of E. coli were resistant to ceftiofur (27,28). Thus, a low prevalence of 
ceftiofur resistant E. coli and more common ceftiofur resistant Salmonella from United 
States farms should remind Canadian authorities to be vigilant for emerging resistance to 
this drug (28). 
 
As found in the Salmonella isolates, the E. coli isolates were most commonly 
resistant to tetracycline, sulfamethoxazole and streptomycin. North American 
surveillance programs have also found the ranking of resistances to be similar between 
these two Enterobacteriaceae (28). Considering that these bacterial species can share 
resistance genes, the herd-level prevalence of resistance in E. coli might predict 
resistance in Salmonella (29,30). Resistance to seven different drugs was considered but 
only two associations were significant. Thus, E. coli was not a very effective on-farm 
sentinel for Salmonella AMR in this study population. Considering that E. coli has 
multiple resistance genes for each of the considered resistance phenotypes, it is still 
possible the prevalence of AMR genes in E. coli could predict AMR genes in Salmonella. 
Conversely, if serotype and resistant clones in Salmonella were accounted for, 
phenotypic resistance in E. coli could yet prove to be a useful sentinel for AMR in 
Salmonella in swine farms.    
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Most parametric statistical tests assume data are independent (31). However, E. 
coli from one herd could be more similar than E. coli from different farms because pig-
to-pig contact facilitates AMR gene transmission, animals have similar antimicrobial 
exposures, and herd-mates are raised under the same barn design, hygiene and 
management. Failure to account for clustering can result in type I error (31). So multi-
level models are used to provide accurate assessments of confidence levels and statistical 
significance. Additionally, these models indicate where unexplained variability remains 
in hierarchical datasets. Interventions aimed at hierarchal levels with more variation are 
more likely to be effective (31,32). The similarity in resistance within herds suggests 
farm-level interventions could help manage AMR in E. coli. Although based on a small 
dataset, we found little clustering at the veterinarian level. This suggests that 
interventions targeted at swine veterinarians would be markedly less effective. 
 
The molecular basis for multiple drug resistance and co-selection in bacteria are 
well understood. Yet in reality, it is difficult to predict if a given antimicrobial exposure 
will select for unrelated, but linked, AMR genes under field conditions. To provide 
insight to this problem, we investigated which resistance-phenotypes were more likely to 
occur together. In these isolates, every drug-resistance phenotype was significantly 
associated with at least two other drug-resistances. Remarkably, the odds of 
sulfamethoxazole resistance increased significantly in the presence of every drug-
resistance that we considered. This is of immediate importance to the swine industry 
because the widespread use of sulfonamides could select for resistance to many unrelated 
drugs. The numerous associations between resistance phenotypes in this study re-
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enforces the take-home message of this thesis: using drugs considered ‘older’ or ‘of 
lesser importance’ to human medicine is not a risk free practice (23-25). For example, 
penicillin use in grow-finish pigs was associated with increased odds of trimethoprim-
sulfamethoxazole resistance in E. coli.  
 
Chapter 6 described the diversity of genes carried by a subset of the E. coli 
described in Chapter 3. Prior to this study, the AMR genes carried by porcine commensal 
E. coli had only been described in isolates from Ontario. The isolate selection was 
purposive; isolates were chosen to avoid clustering within pens and ensure a minimum 
number of isolates showed phenotypic resistance to seven antimicrobials. This improved 
the power of the numerous univariate analyses but meant the frequency of AMR genes 
did not accurately reflect the prevalence of resistance genes in these herds. Despite this 
limitation, identifying sul3 as the most common sulfonamide resistance gene was notable. 
The sul3 gene was first described in pigs from Switzerland in 2003 (33). Although this 
gene is recently emerged, it has since been reported in many European countries as well 
as the United States, Ontario, and now Alberta and Saskatchewan (34-38). Such rapid 
emergence and spread demonstrates the global nature of antimicrobial resistance.  
 
No chloramphenicol resistance genes were identified in this study. The absence of 
cmlA, floR and cat1 in these isolates indicates that the chloramphenicol resistance in this 
population differs from porcine E. coli in Ontario and Oklahoma (39,40). This 
unexpected finding illustrates the value of describing AMR by both phenotype and 
genotype. Although phenotype reflects the risk posed by resistant bacteria on-farms, and 
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the expected impact of antimicrobial exposure on bacteria, the resistance genotype can 
distinguish between apparently equivalent resistances in different regions, farms or 
animals. This information can then provide insight into the evolution of resistance. 
Chloramphenicol was banned in Canadian livestock in 1985, and so resistance 
presumably persists due to co-selection with other resistance and virulence genes (34,39-
42). If the chloramphenicol genes and their linkages were described in E. coli from 
western Canadian pigs, it might clarify how chloramphenicol resistance in persisting in E. 
coli in western Canadian pigs.  
 
The associations between AMR genes generated hypotheses about gene-linkages. 
Two sets of genes were interrelated: one set contained aadA1, sul1, and tetA and the other 
consisted of blaTEM, strA – strB, sul2 and tetB. Interestingly, each set contained a 
streptomycin, sulfamethoxazole and tetracycline resistance gene. So theoretically, 
amoxicillin use would select for streptomycin, sulfamethoxazole and tetracycline 
resistance in E. coli carrying the second set of genes but not the first. The associations 
between AMR genes matched associations between the phenotypes for each of the genes. 
As odds ratios between AMR genes can predict gene linkages (39), this suggests the odds 
ratios between AMR phenotypes could predict co-selection. If this approach is validated, 
analysis of nationally representative AMR data might identify antimicrobial exposures 
that are increasing resistance to important, but unrelated, drugs. The potential for this to 
improve our understanding of resistance makes validating this hypothesis among the 
most important research needs identified in this thesis. 
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The associations between AMR genes, and between AMR and virulence genes, 
were substantially different from reports in pathogenic E. coli (35,39,43). This difference 
suggests resistance gene linkages in E. coli are serotype, or pathotype, specific. Although 
the lack of associations between resistance and virulence genes could be due to low study 
power, the relationships could also be specific to certain E. coli pathotypes. So while the 
conclusions of this study cannot be extrapolated to pathogens or specific serotypes of E. 
coli, our findings suggest that antimicrobial use does not select for virulence factors in 
generic E. coli from healthy pigs.  
 
Chapter 7 described the associations between phenotypic AMR in E. coli and 
antimicrobial use through feed and water. Six of the seven resistance outcomes 
considered had at least one significant antimicrobial use predictor. In five, the odds of 
resistance increased per pig-day of exposure. To my knowledge, this description of dose-
response relationships between antimicrobial exposure and resistance is unique. These 
results suggest that if eliminating antimicrobial exposure is undesirable for animal 
welfare reasons, or impractical for financial reasons, decreasing antimicrobial use may be 
still be beneficial. While causal inferences cannot be drawn from cross-sectional studies, 
dose-response relationships support a causal role for antimicrobial use in resistance (31).   
 
Assuming a causal relationship, the findings of this study indicate that three 
biological mechanisms contributed to the associations between antimicrobial use and 
resistance reported in this paper. Direct selection explained associations between 
antimicrobial resistance and exposure to the same drug: an example was tetracycline use 
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(along with oxytetracycline and chlortetracycline) in nursery pigs was a risk factor for 
tetracycline resistance. Cross-resistance best explained associations between a resistance 
phenotype and exposure to a related drug, as occurred with sulfonamide use in nursery 
pigs and sulfamethoxazole resistance (although many sulfonamides are licensed for use 
in Canadian pigs, sulfamethoxazole is not among these) (27). Finally, co-selection was 
the biological explanation for the associations between resistance and exposure to an 
unrelated drug, as occurred in four models. Interestingly, macrolide exposure was a 
significant predictor in all of these models. Macrolides were the most commonly used 
antimicrobial class in these herds. Therefore, communications with the swine industry 
should emphasize the concept of co-selection and the possible implications from 
macrolide use (9,10,12).  
 
Campylobacter is the number one reported cause of foodborne bacterial infection 
in Canadians (44). The final chapter of this thesis described the antimicrobial resistance 
of Campylobacter spp. recovered from grow-finish pigs on the study farms. This was the 
first description of AMR in Campylobacter spp. from pigs on Canadian swine farms, and 
included resistance to the first choice treatments for campylobacteriosis in humans, the 
macrolides and fluoroquinolones. Although these resistances have been reported in other 
regions of North America, no published studies have investigated antimicrobial use risk 
factors (28,45-48).  
 
Campylobacter coli was the predominant Campylobacter species identified on 
these farms, and more than 70% of the isolates were resistant to azithromycin, 
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clindamycin and erythromycin. Campylobacter coli are more commonly resistant to 
macrolides than C. jejuni. Additionally, C. coli from pigs are more commonly resistant to 
macrolides than C. coli from other species (46,47,49-53). This is concerning considering 
the extensive use of macrolides in pigs (9,10,12). In this project, macrolide resistance was 
associated with macrolide exposure of nursery pigs. This finding, in combination with the 
associations between macrolide exposure and AMR in E. coli, re-iterates the need for 
swine producers to eliminate unessential macrolide use. 
 
Fluoroquinolones are a common antimicrobial treatment for undifferentiated 
diarrheas in people, which are often caused by Campylobacter infection (54,55). Despite 
the absence of reported quinolone use in study herds, 15% of isolated Campylobacter 
were resistant to a quinolone. Others have also reported quinolone resistance in herds 
with no quinolone exposure, including herds with no antimicrobial use (48,56). 
Considering these reports, it was imperative that we investigate farm level risk factors for 
this resistance. Interestingly, only one predictor of quinolone resistance was found; beta-
lactam use in grow-finish pigs appeared protective. However, this negative association 
does not give any indication of what is causing quinolone resistance to develop or persist, 
and so this question remains for future studies.  
 
The extreme within-herd similarity in resistance among Campylobacter isolates 
was unforeseen when this project was designed. The intra-class correlations ranged from 
0.5 for tetracycline resistance to 0.8 for macrolide resistance. Such clustering within 
herds indicates great potential for on-farm interventions to mitigate AMR in 
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Campylobacter (31,32). However, it also means the power of our risk-factor analysis was 
diminished because the number of independent observations was closer to 20 (the number 
of herds) than 405 (the number of isolates). Future studies should consider this clustering 
in their sampling strategy and collect samples from as many herds as possible.  
 
This project was initially developed as a pilot for those developing on-going 
monitoring programs for antimicrobial use and resistance on swine farms. As is inherent 
with pilot projects, the number of study herds enrolled, samples collected, and isolates 
tested were limited. The relatively small number of participating herds impeded our 
ability to describe the association between antimicrobial resistance and exposures to 
individual drugs. It also limited the power of the risk-factor analysis for Campylobacter 
resistance. Herds were not randomly selected; rather veterinarians nominated herds based 
on our enrollment criteria, including knowledge of the Salmonella status and willingness 
to participate in on-going research. Thus, the prevalence estimates reported in this thesis 
should not be directly extrapolated to other herds in these provinces. However, there was 
minimal evidence that the herd selection biased our findings; the three factors affected by 
selection, the Salmonella status, herd size, and veterinary practitioner, were rarely 
associated with any resistance outcomes. Finances also limited the number of E. coli 
isolates tested for AMR genes and virulence factors. The purposive isolate selection 
ensured a minimum frequency of resistance to the antimicrobials of interest and thus 
increased the chances of identifying resistance genes. This was a compromise as it 
improved the power of the univariate analyses but precluded estimating the prevalence of 
resistance and virulence genes in the study herds.  
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 The findings of this thesis generated many new research questions, but three 
dominate. First, the differences between antimicrobial resistances in Salmonella from 
nursery pigs, grow-finish pigs and sows raised questions about the dynamics of resistance 
within herds. Longitudinal studies, which follow batches through the production chain, 
might identify times when pigs are at risk for acquiring resistance or practices associated 
with resistance. Just as importantly, management practices associated with declining 
resistance might also be found and lead to interventions. 
 
Secondly, the parallel between significantly associated pairs of resistance genes 
and resistance phenotypes in E. coli was intriguing. Confirming that co-selection can be 
predicted by odds ratios between resistance phenotypes would provide veterinarians with 
a simple tool to consider how their prescribing behavior affects AMR. This could 
immediately influence antimicrobial use in Canadian agriculture. 
 
Finally, on-farm food safety programs rarely consider the cost:benefit ratio of 
their recommendations. Resistance has fallen in Denmark since the ban on growth 
promoters but producers have also experienced an estimated 1.0 € increase in the cost of 
production from birth to slaughter (14). As differences exist between Canadian and 
Danish swine production, future studies must evaluate the economics of metaphylactic 
and prophylactic antimicrobial use in Canadian pork production. This data could then be 
considered in light of predicted benefits from changes in AMU: such change may be 
possible as indicated by the highly variable AMU in these study herds. Odds ratios will 
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never speak to producers with the same intensity as dollars and cents. Veterinary 
epidemiologists should investigate all aspects of appropriate antimicrobial use, including 
economics. Should minimal drug use be shown to be economical, authorities and 
producers would share a common goal. 
 
This thesis adds a few pieces to the complex puzzle of antimicrobial resistance. 
Undoubtedly, it will be years before we will fully understand the food safety risks from 
agricultural antimicrobial use. However considering the dearth of new antimicrobials 
under development for human or veterinary medicine, and the potential for increased 
resistance to those currently used, both the medical and veterinary communities should 
follow John Snow’s bold example and take action before this problem is fully understood 
(57). Swine producers must use be educated about co-selection: Using older 
antimicrobials or drugs unimportant to human medicine is not risk-free. Until science 
defines which antimicrobial use practices create the greatest food-safety risks, 
antimicrobials must be used as judiciously as possible. Not only will this minimize any 
contribution to this public health crisis, it will remove ammunition from calls for 
restrictions or bans of agricultural antimicrobial use.  
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APPENDIX A 
ANTIMICROBIAL USE DATA COLLECTION TOOLS 
 
A.1 Instructions for Antimicrobial Use Data Collection 
1. Overall Antibiotic Use on Farm 
a. Go through form A stressing that you are asking about the last 12 months. 
b. Note any categories that are different from never 
c. For those categories you will need to go to the next level 
 
2. Feed Medication Use 
a. Copy “RATIONS USED ON FARM” from CQA® records for ALL farms 
b. Complete Form B for any farm which answered different from never on form A 
for questions 1, 4, 7, 10, 13, 16 (questions relating to feed medication) 
c. NOTE:  The questions that you can NOT obtain answers from CQA® form are 
italicized. 
d. Ensure data is complete for suckling and nursery animals. 
 
3. Water Medication Use 
a. There is No CQA® record for water medication 
b. Complete Form C for any farm which answered different from never on Form A 
for questions 2,5,8,11,14,17 (questions relating to water medication) 
 
4. Injectable Antibiotic Use 
a. Copy “Pen or Individual Treatment Records For All Pigs Beyond the Weaning 
Phase” CQA® form 
b. Copy “Medication and Vaccine Usage Plan On Farm” CQA® form 
c. Ensure data is complete each production phase. If not, complete form D 
 
5. Numbers of pigs 
a. Complete form E 
 
6. Duration in each production phase and average weight at transfer 
a. Complete form F 
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A.2 Overview of Antimicrobial Use 
 
Herd Id: ________________________________________ 
Date: ___________________________________________ 
 
1 Never 
2 Occasionally 
3 Routinely 
4 Not applicable 
 
For each question below, circle the number to the right that best fits your operation.  Answers 
should be for the 12 months.   
Group medication means >1 pig (this could include treating an entire pen or room).  
Occasionally means treatment has been done in a disease outbreak situation and occurred in less 
than 30% of the pigs produced in the last year.   
 Routinely means treatment is done to prevent disease OR that more than 30% of animals 
produced in the last year have received treatment.   
 
Group Medicating Scale 
1. Suckling - Do you use group feed medication? 1 2 3 4 
2. Suckling - Do you use group water medication?  1 2 3 4 
3. Suckling - Do you use group injectable medication? 1 2 3 4 
4. Nursery - Do you use group feed medication? 1 2 3 4 
5. Nursery - Do you use group water medication?  1 2 3 4 
6. Nursery - Do you use group injectable medication? 1 2 3 4 
7. Grow-finish - Do you use group feed medication? 1 2 3 4 
8. Grow-finish - Do you use group water medication?  1 2 3 4 
9. Grow-finish - Do you use group injectable medication? 1 2 3 4 
10. Replacement gilts - Do you use group feed medication? 1 2 3 4 
11. Replacement gilts - Do you use group water medication?  1 2 3 4 
240 
241 
12. Replacement gilts - Do you use group injectable medication? 1 2 3 4 
13. Breeding herd - Do you use group feed medication? 1 2 3 4 
14. Breeding herd - Do you use group water medication?  1 2 3 4 
15. Breeding herd - Do you use group injectable medication? 1 2 3 4 
16. Boars - Do you use group feed medication? 1 2 3 4 
17. Boars - Do you use group water medication?  1 2 3 4 
18. Boars - Do you use group injectable medication? 1 2 3 4 
 
 
1 Never 
2 Yes 
3 Not applicable 
 
 
Individual Animal Treatment Scale 
19. Suckling - Do you use individual treatment? 1 2 3 
20.  Nursery - Do you use individual treatment?  1 2 3 
20. Grower - Do you use individual treatment? 1 2 3 
21. Finisher - Do you use individual treatment? 1 2 3 
22. Replacement gilts - Do you use individual treatment? 1 2 3 
23. Breeding Herd - Do you use individual treatment? 1 2 3 
24. Boars - Do you use individual treatment? 1 2 3 
 
25.  Who makes treatment decisions on the farm day to day?  
 a. Owner / manager 
 b. Herdsman 
 c. Veterinarian 
 d. Other 
 
26.  Does your farm have a written treatment protocol? _____________________ 
 
 a.  If yes, who wrote it? ___________________________________________ 
 b.  May we have a copy of it? ______________________________________ 
A.3 On-Farm In-Feed Antimicrobial Use 
Herd ID _____________ 
Stage of  
Production  
 
Product 
Name and 
Manufacturer 
Active 
Ingredient 
Name 
Dose (ppm) If not on label 
– intended 
dose above or 
below 
Reason for 
Use  
Preventive or 
treatment:  
Enteric, 
Respiratory 
or Other 
Duration 
(days 
administered)  
-may not be 
consecutive 
In the last 
year, did ALL 
pigs for this 
stage receive 
the 
treatment? 
Yes or no 
If no, number 
of animals 
that received 
treatment. 
         
         
         
         
242 
 
 
 A.4 On-Farm Water Soluble Antimicrobial Use 
Herd ID _______________ 
 
Stage of  
Production  
 
Product Name 
and 
Manufacturer 
Active 
Ingredient 
Name 
Intended dose 
and units 
If not on label 
– intended 
dose above or 
below 
Reason for 
Use;  
Preventive or 
Treatment 
and Enteric, 
Respiratory 
or Other 
Duration 
(days 
administered)  
-may not be 
consecutive 
In the last 
year, did ALL 
pigs for this 
stage receive 
the 
treatment? 
Yes or no 
If no, number 
of animals 
that received 
treatment. 
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A.5 On-Farm Parenteral Antimicrobial Use 
Herd ID___________________ 
 
Production Phase: __________________________________________________ 
 
To be used on farms without individual animal treatment records. Please fill out this form for 
every phase that does not have individual animal treatment records available. 
 
1. Do you inject pigs with an antibiotic to prevent disease?  Yes No 
i. If yes 
i. What % of the pigs are treated _____________________________ 
ii. What antibiotic is used ___________________________________ 
iii. What dose (cc/kg or mg/kg) _______________________________ 
iv. Number of times per pig _________________________________ 
 
2. Do you treat (inject) pigs that are sick?  Yes  No 
- If  yes: 
       i.  Who makes daily treatment decisions on the farm? ____________ 
 
3. Over the last year, what has been the most common disease in this production phase? 
i. Can you estimate how many pigs are typically treated for this problem? Any of 
the below “units” are fine. 
i. Treatments per day & average pigs at risk / day _____________ 
ii. Treatments per week & average pigs at risk / day ____________ 
iii. Treatments per batch or room (average pig/batch) _____________ 
ii. What antibiotic do you most commonly use to treat this? ______________ 
iii. What dose do you most commonly use? _____________cc / Kg or mg/ kg 
iv. How many days do you treat for? ________________________________ 
v. If the drug is not effective, what is your second choice of antibiotic? 
____________________________________________________________ 
vi. What dose do you most commonly use? _______________cc/kg or mg/kg 
vii. How many days do you treat with the second drug for?  _______________ 
 
4. Over the last year, what has been the second most common disease in this production 
phase? __________________________________________________ 
i. Can you estimate how many pigs are typically treated for this problem? Any of 
the below “units” are fine. 
i. Treatments per day (get avg. # @ risk/ day) __________________ 
ii. Treatments per week(get avg. # @ risk/ day) _________________ 
iii. Treatments per batch or room (get avg. # @ risk) ______________ 
ii. What antibiotic do you most commonly use to treat this? ______________ 
iii. What dose do you most commonly use? _____________cc / Kg or mg/ kg 
iv. How many days do you treat for? ________________________________ 
v. If the drug is not effective, what is your second choice of antibiotic? 
____________________________________________________________ 
vi. What dose do you most commonly use? _______________cc/kg or mg/kg 
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vii. How many days do you treat with the second drug for?  _______________ 
 
5. In an average week, day, or batch, how many piglets are treated with antibiotics?  
(& average number of pigs at risk)     
______________________________________________Units ____________ 
6. What is the most commonly used antibiotic in this production phase? 
_______________________________________________________________ 
7. What is the second most commonly used antibiotic in this production phase? 
_______________________________________________________________ 
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A.6 Animal Inventory  
Herd ID _____________________ 
 
Breeding Stock 
• Sow inventory May 2003      __________ 
• Sow inventory May 2004      __________ 
• Current number sows in barn      __________ 
• Gilt inventory May 2003       __________ 
• Gilt inventory May 2004      __________ 
• Current number of gilts in barn     __________ 
 
• Boar ( including V-boar) inventory May 2003   __________ 
• Boar ( including v-boar) inventory May 2004   __________ 
• Current number boars in barn      __________ 
 
Suckling piglets 
• Number of animals born alive May 2003 to May 2004  __________ 
• Number of animals weaned May 2003 to May 2004   __________ 
• Current number of suckling animals     __________ 
 
Nursery 
• Number of animals exiting nursery May 2003 to May 2004  __________ 
• Current number of nursery animals     __________ 
• For farms that iso-wean – indicate number of days for each   
     group in nursery and the % or number of animals in each group __________  
          __________ 
__________ 
          __________ 
 
 
Grow – finish inventory 
• Number of animals produced May 2003 to May 2004  __________ 
• Current number of grow-finish animals    __________ 
 
Breeding Companies 
• Boars – number sold between May 2003 and May 2004  __________ 
• Average number of days in barn beyond when would typically 
      have been sent for slaughter      __________ 
 
• Gilts - number sold between May 2003 and May 2004  __________ 
• Average number of days in barn beyond when would typically  __________         
have been sent for slaughter 
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A.7 Pig Characteristics by Production Phase 
 
Production Phase Days in phase  Age out Weight out 
 Farrowing (weaning age)      
 Nursery      
 Grow-Finish      
 
